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Summary 
 
Virtually all colon cancers have mutations in the Wnt signalling pathway which result 
in the constitutive activation of the pathway. This activation leads to stabilization of β-catenin. 
β-catenin enters the nucleus and activates its target genes through interaction with the TCF 
transcription factor.  Selectively replicating adenoviruses are promising novel agents that can 
destroy the tumour but not the surrounding normal tissue. In vitro, adenoviruses with TCF 
binding sites in the early viral promoters show selectivity and activity in a broad panel of 
viruses but in vivo they are less effective due to the lack of expression of the Coxsackie-
Adenovirus receptor (CAR). 
The aim of my thesis was to modify the major capsid protein of the adenovirus, fibre, 
to increase the infection of colon tumours. Fibre of adenovirus is responsible for the binding 
to cells and for the viral uptake. I inserted an RGD binding peptide into the HI loop of fibre 
that selectively targets the virus to integrins that are overexpressed on tumour cells and on 
tumour endothelium. The retargeted virus, vKH6, showed increased activity in all colon cancer 
cell lines while selectivity was maintained. 
 In vivo, vKH6 is superior to a matched virus with a wild type capsid in delaying tumour  
growth. vKH6 replicates and gradually spreads within the tumour as shown by in situ 
hybridization and Q-PCR. The virus alone can delay the growth of SW620 xenografts by 2 
weeks but due to uninfected tumour regions the tumour cannot be cured. Although 
combination with conventional chemotherapeutics is of potential interest, almost all of them 
interfere with the viral replication. Growing evidence supports that anti-angiogenic drugs are 
effective and promising anti-tumour agents. These drugs interfere less with the viral life cycle. 
RAD001 is a rapamycin derivative and it blocks mTOR, a protein kinase in the PI3K pathway. 
RAD001 inhibits cell growth and has strong anti-angiogenic and immunosuppressive effects. 
RAD001 in vitro does not affect viral gene expression and viral burst size. In vivo vKH6 and 
RAD001 have an additive effect in delaying tumour growth, but tumour growth is still not 
completely inhibited. 
To further increase tumour infection new tumour specific targeting peptides are 
needed. I created an adenovirus display library that will allow the selection of targeting 
peptides. This system may also facilitate the production of fibre modified viruses.  
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Résumé 
 
 
Pratiquement tous les cancers du colon contiennent des mutations dans la voie de signalisation de Wnt 
qui active constitutivement cette voie. Cette activation mène à la stabilisation de la β-catenine. La β-
catenin est transportée dans le noyau ou elle active des gènes cible en interagissant avec le facteur de 
transcription de TCF/LEF. Des adénovirus qui peuvent sélectivement se répliquer dans les cellules 
tumorales sont les agents qui peuvent permettre la déstruction de la tumeur mais pas le tissu normal. In 
vitro, les adénovirus avec des sites d’attachement du facteur de transcription TCF dans les promoteurs de 
l’adénovirus montrent une sélectivité et  une activité dans une large sélection de lignées cellulaires de 
cancer du colon. Au contraire, in vivo, quand les adénovirus modifiés sont injectés dans la circulation, ils 
sont moins efficaces à cause de leur fixation par le foie et à cause de l’absence d'expression du récepteur 
du Coxsackie-Adénovirus (CAR).   
 
Le but de ma thèse était  de modifier la protéine principale de capside de l'adénovirus, fibre, pour 
augmenter l'infection des tumeurs du cancer du colon. La fibre de l'adénovirus est responsable de 
l'attachement aux cellules et de l’entrée virale. J'ai inséré un peptide RGD dans la boucle HI de la fibre 
qui dirige sélectivement le virus aux récepteurs des integrines. Les integrines sont surexprimées par les 
cellules du cancer du colon et l'endothélium des vesseaux de la tumeur.  Le virus re-ciblé, vKH6, a 
montré une activité accrue dans toutes les lignées cellulaires de cancer du colon, tandis que la sélectivité 
était maintenue. In vivo, vKH6 était supérieur au virus avec une capside de type sauvage en retardant la 
croissance de la tumeur. Le virus s’est répliqué plus vite et dispersé graduellement dans la tumeur. Cet 
effet a été montré par hybridation in situ et par PCR quantitative. Cependant, la monothérapie avec le 
virus n’a pu retarder la croissance des cellules tumorales SW620 greffées que de 2 semaines, mais à cause 
des régions non infectées la tumeur n’a pas pu être éliminée. Bien que la combinaison avec les 
chimiothérapies conventionnelles soit d'intérêt potentiel, presque toutes interfèrent avec la réplication 
virale. Les drogues anti-angiogéniques sont des agents anti-tumoraux efficaces et prometteurs. Ces 
drogues n’interfèrent pas avec le cycle de vie de l’adénovirus. RAD001 est un dérivé de la rapamycine et il 
inhibe mTOR, une protéine kinase de la voie de PI3K. RAD001 empêche la croissance des cellules et il a 
aussi des effets anti-angiogénique et immunosuppressifs. RAD001 in vitro n'affecte pas l'expression des 
gènes viraux et la production virale. La combinaison de VKH6 et RAD001 in vivo a un effet additif en 
retardant la croissance de la tumeur.  
 
Des nouveaux peptides plus efficaces dans le ciblage de l’adénovirus sont néccésaires pour augmenter 
l’infection des tumeurs.  J’ai créé un système de recombinaison qui permettra la sélection de nouveaux 
peptides dans le contexte du génome de l’adénovirus.   
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1. Introduction 
 
1.1 Cancer gene therapy 
 
Cancer is a chronic systemic disease. Chemo and radiation therapy of cancer is 
constantly advancing but even with current therapy most cancers eventually spread to become 
a systemic disease which leads to death of the patient. The major problem with current 
cytotoxic therapies is their low therapeutic index: many conventional drugs display a lack of 
selectivity for malignant cells leading to dose limiting toxicity. Using viruses that find and 
selectively destroy the tumour is a promising modality since they have a much wider 
therapeutic index. The earliest report of using viruses to treat cancer was published 100 
years ago.4 However, it is only recently that advances in molecular biology, virology, and 
cancer biology have provided us with the tools necessary to develop oncolytic viruses for 
cancer therapy. Early in the development of gene therapy for cancer, non-replicating viruses 
were used to transfer suicide genes into the tumour but these methods failed to show efficacy 
in vivo. Replicating viruses are more promising since they can reach high local concentrations 
during replication in the tumour and destroy the tumour more efficiently.   
Many types of viruses have been tested for cancer gene therapy. Some of them are in 
advanced stages of evaluation while others are just entering preclinical testing. 
Table1. Viruses used for cancer gene therapy 
Virus Type Tumour 
specificity 
Stage of 
development 
Name 
Adenovirus dsDNA  TRE promoter 
complementation 
phaseI/II CV706;dl1520; 
CG5757 
Herpes simplex dsDNA complementation phaseI/II G207; 
OncoVex 
Vaccinia dsDNA complementation phaseI DryVax 
Reovirus dsRNA Ras pathway 
activation 
phaseI Reolysin 
Newcastle 
disease virus 
- ssRNA   phaseI/II PV701;       OV 
001 
Measles virus -ssRNA  INFγ preclinical  
Vesiculo 
stomatitis virus 
- ssRNA INFγ preclinical  
Parvovirus - ssDNA TRE promoter preclinical  
Coxsackie + ssRNA    
TRE: Transcriptional regulatory elements; INF: Lack of Intereferon-γ response in tumour 
cells.  
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1.2 Adenovirus 
 During my thesis I tried to exploit adenovirus for cancer gene therapy. First I will describe  
adenovirus biology and then different methods to target tumour cells. 
Adenoviruses are the most widely used gene therapy vectors. Adenoviruses are non 
enveloped double stranded DNA viruses. In clinical practice adenovirus is a mild pathogen. It 
can cause upper respiratory tract infections, gastroenteritis and epidemic conjunctivitis. It can 
cause encephalitis in immunosuppressed patients but can not pass the blood brain barrier in 
healthy individuals. Almost 99% of the human population develop neutralising antibodies 
against common serotypes before the age of 14. The 50 human adenoviruses can be 
subdivided into 6 serotype groups: A, B, C, D, E and F based on sequence comparisons and 
haemagglutination properties. Many non-human species of adenovirus exist. The group C 
adenovirus Adenovirus 5 is one of the most well studied viruses. The following chapters will 
discuss this virus. 
  The viral life cycle of Ad5 lasts for 48-72 hours and consists of two phases.  In the 
early phase upon adenovirus infection the virus binds to its receptor, the Coxsackie 
Adenovirus Receptor (CAR). After CAR binding the virus induces receptor mediated 
endocytosis through the interaction of penton with integrins. The virus enters the cell through 
lysosomes or by micropinocytosis.  In the low pH environment of the endosome the viral 
capsid is partially disassembled. It loses fibre. The change in the viral capsid allows disruption 
of the early endosome and release into the cytoplasm where the viral capsid travels to the 
nuclear membrane using microtubules. At the nuclear membrane the viral DNA is released 
into the nucleus5.  
In the nucleus expression of the early viral genes creates a favourable environment for 
viral replication by inducing S phase and blocking apoptosis. The early viral transcripts 
promote the replication of viral genomes.  
The transition from the early to late phases is marked by the onset of DNA replication. 
The replication of the viral DNA requires viral DNA as a template, terminal protein, pTP, 
DNA polymerase encoded by the virus, topoisomerase I and dNTPs. The viral genome 
consists of a single 36 Kb double stranded DNA. The viral DNA is flanked by 103 bp long 
inverted repeats (ITRs) that are essential for viral replication.  A 170 bp long packaging signal 
is located adjacent to the left ITR. It promotes encapsidation of the viral genome with the help 
of viral proteins. 
In the late phase viral structural proteins are produced from the major late promoter of 
the virus, the viral capsid is assembled and the virus is released, destroying the host cell.  
Transcripts encoded by the viral genes can be also divided into early and late 
transcripts. The viral genome carries 5 early transcription units (E1A, E1B, E2, E3 and E4), 
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two intermediate units (IVa2 and IX) and a major late unit with 5 distinct cassettes (L1, L2, L3, 
L4 and L5). There are two other late transcripts including from the late E2 promoter (E2L) 
and the E3 coding sequences that are spliced from the major late promoter. The virus also 
expresses two PolIII dependent RNAs (VAI and VAII RNAs). Expression of VA RNAs is 
increased during infection. VA RNAs are responsible for inhibition of the interferon pathway 
by binding and inhibiting PKR. 
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 A 
 
B 
Figure 1. A; Schematic representation of the structure of adenovirus B; Proteins of the 
icosahedral viral capsid.2 
A 
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1.2.1 Early gene expression  
 
Early viral gene expression has three functions: 1, to drive the cell to S phase, 2, to protect the 
virus from cellular antiviral responses and 3, to produce transcripts responsible for viral DNA 
replication.  
 
A 
B 
Figure 2. A, Schematic representation of the viral genome. The genome size is shown in 
kilobases, starting from the left ITR of the virus in front of the E1A gene. B, General 
description of the adenoviral life cycle.1 
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E1A proteins 
 
The first transcripts to be expressed are from the E1A gene. The E1A promoter is 
constitutively active6 and it has been shown that the viral pIX protein can transactivate the 
E1A promoter.7 E1A expression occurs rapidly after infection. The E1A RNA is spliced to 
give 12S and 13S mRNAs that give rise to 243R and 289R proteins, respectively. The role of 
E1A proteins is to push the cells to enter the cell cycle. E1A proteins of different serotypes 
contain four conserved regions (CR1 to CR4).8 These regions interact with a wide range of 
different cellular proteins involved in chromatin remodelling and transcription (pRB, 
p300/CBP, CtBP, ATF). The most important role of E1A is to promote entry of the cell into 
S phase. E1A binds to pRB, the product of the retinoblastoma gene. pRB in quiescent cells 
binds to and inhibits the E2F transcription factors that are responsible for the activation of 
genes involved in multiple actions that drive cells through S phase. E1A binding to pRB blocks 
the inhibition of E2F and allows S phase entry.9,10  
The other important role of the E1A proteins is to transactivate viral promoters. E1A 
activates the E2F and E4F transcription factors that activate the E2 and E4 promoters, 
respectively.10 E1A also activates these promoters and the E3 promoter by interacting with 
ATF.11  
 
E1B proteins 
 
The E1B gene encodes the E1B19K and E1B55K proteins. One major role of these 
proteins is to prevent E1A-induced apoptosis. E1B19K is similar to the anti-apoptotic protein 
Bcl-2 and prevents procaspase-9 activation.12 E1B55K binds to p53 and can function as a 
transcriptional repressor.13 E1B55K, together with E4orf6, also inhibits p53-dependent 
apoptosis by promoting p53 degradation.14 E1B55K binds to viral RNA15 and is involved, 
together with E4orf6, in the preferential transport and stabilisation of the transcripts of the 
major late unit.16 Finally DNA concatamer formation by the RAD50/MRE11/NBS1 complex 
is prevented by E1B55K/E4orf6.  E1B55K/E4orf6 and E4orf3 targets MRE11/RAD50 to 
proteasome-mediated degradation and excludes the complex from the viral replication centers.  
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E2 proteins 
 
 The E2 region encodes viral replication proteins. It can be subdivided into two regions, the 
 E2A and E2B region. E2A encodes the single-stranded DNA binding protein (DBP), which 
is required to coat single-stranded DNA during adenoviral DNA replication.17 DBP was also 
shown to activate a variety of viral promoters18 but other reports showed that DBP has an 
inhibitory effect on early promoters.19 E2B encodes the adenoviral polymerase (Pol) and the 
precursor of the terminal protein (pTP). pTP is cleaved to TP, which is covalently linked to the 
termini of the viral genome, mediates its association with the proteins of the nuclear matrix, 
and serves as a primer for viral DNA replication.20 
 
E3 proteins 
 
The E3 proteins are involved in the immune modulation of the host. They play various roles, 
such as inhibition of antigen presentation, inhibition cell death induced by TNFα, Fas, and 
Trail. In animal models the E3 region expressed as a transgene has also demonstrated its 
efficacy in the prevention of autoimmune diabetes21 and in facilitating allogenic 
transplantation.22   Seven proteins are produced from the E3 region23:  
• E3-gp19k is a transmembrane protein that binds to the MHC class I heavy chain and 
retains it in the endoplasmic reticulum, thus preventing antigen presentation.24  
• A heterotrimer of E3-10.4kD and E3-14.5kD (RIDα&β) inhibits TNFα and Fas 
ligand-induced cell death by internalizing their receptors and promoting their 
degradation in lysosomes.25  
• E3-14.7k inhibits TNFα-mediated apoptosis by enhancing IKKγ phosphorylation of 
IKγ, thus stabilising NF-κB.23 
• The function of E3-12.5kD is unknown. 
• E3-6.7kD functions in the specific modulation of the two death receptors for tumour 
necrosis factor-related apoptosis-inducing ligand (TRAIL). The 6.7K protein is 
expressed on the cell surface and forms a complex with the 10.4K and 14.5K proteins, 
and this complex is sufficient to induce down-modulation of TRAIL receptor-1 and -2 
from the cell surface and to reverse the sensitivity of infected cells to TRAIL-mediated 
apoptosis.26 
• The E3-11.6K protein (adenoviral death protein, or ADP) is a glycosylated 
transmembrane protein required at late stages of infection to accelerate lysis and 
induce virus release from the host cell.27 Although originally described as an early 
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protein, ADP is expressed late during infection from the MLP and is therefore 
primarily a late protein.27  
•  
E4 proteins 
 
The E4 region encodes six distinct polypeptides defined as E4orf1 to E4orf6/7 
according to the arrangement of their open reading frames. These proteins have a wide range 
of functions, but are mainly involved in the facilitation of viral mRNA metabolism and in the 
protection of the viral DNA ends. They also interact with the PI3K pathway promoting 
cellular growth, proliferation and survival.   
E4orf3 and E4orf6 are associated with E1B55K.28 E4orf3 reorganises components of 
nuclear bodies or PML oncogenic domains (PODs).  
E4orf6 plays a role, with E1B55K, in the preferential cytoplasmic accumulation of 
viral late mRNAs and in the degradation of p53. In the cytoplasm, E1B55K and E4orf6 were 
found in a complex with proteins involved in the ubiquitin/proteasome pathway such as 
Cullin-5, Rbx1 and Elongins.14 Based on these findings, a model was proposed according to 
which E1B55K and E4orf6 replace MDM2, a protein responsible for targeting p53 to the 
proteasome pathway. E4orf3 and E4orf6 also enhance viral replication, reorganise the PODs 
and target the double-strand break repair machinery to prevent concatenation of viral 
genomes. E4orf3 redistributes the double-stranded break repair complex Mre11-Rad50-NBS1 
and E4orf6 targets it for degradation.29 E4orf3 also binds to the DNA-dependent protein 
kinase (DNA PK) and protects the ends of the viral chromosome from non-homologous end 
joining.30 
E4orf6/7 transactivates the E2 promoter by binding to free E2F and inducing its 
dimerisation.31 The E2F dimer binds with an increased stability to the two inverted E2F-
binding sites in the Ad5 E2 early promoter32 and in the cellular E2F-1 promoter.33 E4orf6/7 is 
sufficient to displace pRb and the related protein p107 from E2F complexes and activate E2 
expression.32 
E4orf1 and E4orf6 have partial transforming activities that are able to stimulate 
transformation by E1. E4orf1 is related to dUTP pyrophosphatases and interacts with PDZ 
domain-containing cellular proteins.34 This leads to PDZ protein-dependent activation of 
PI3K, which contributes to the transforming potential of E4orf1.35 E4orf1 was shown to 
promote Akt activation that was independent from growth factor signalling and from PI3K.  
 E4orf4 interacts with PP2A13736 and downregulates AP-1 activity through 
hypophosphorylation of both c-Fos and E1A.37 E4orf4 inactivates SR-mediated splicing in L1, 
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probably through dephosphorylation of the SR proteins. E4orf4 was shown to block yeast and 
mammalian cells in G2/M phase of cell cycle.38 
Finally E4orf4 has been implicated in the activation of the PI3K pathway through 
direct interaction with the mTOR protein. E4orf4 deleted mutant adenovirus failed to activate 
mTOR or induce phosphorylation of p70S6K and 4EBP1.39  
1.2.2 Late transcripts 
 
Late gene expression takes place after the onset of viral DNA replication. The 
adenovirus major late transcription unit (MLTU) is differentially spliced and polyadenylated. 
The resulting mRNAs are grouped into five families from L1 to L5. This unit is under the 
control of the major late promoter (MLP), whose activation depends on viral DNA 
replication40, on IVa241 and on pIX expression.7  
Functionally three types of genes are encoded by the MLTU. Proteins of the capsid: 
fibre (IV), penton (III), hexon (II), cement proteins (pVIII, IIIa, VI) and non-structural 
proteins. Non-structural proteins have various functions in viral capsid assembly and 
encapsidation. L1 52/55 Kd protein together with IVa2 and pVII binds to the packaging 
sequence of the viral chromosome and is essential for encapsidation of the viral genome.42,43 
 As earlier mentioned E1B-55K and E4orf6 proteins regulate the selective transport of 
these late viral transcripts into the cytoplasm44 while the host cell transcripts are blocked 
resulting in host cell shut off. Further selective expression of viral proteins is achieved by 
inhibition of the cap-dependent RNA helicase complex eIF4F. eIF4F consists of three 
polypeptides: the cap-binding protein, eIF4E; an ATP-dependent RNA helicase, eIF4A; and a 
scaffold protein eIF4G (eIF4GI and eIF4GII). Mnk1 binds to and phosphorylates eIF4E, 
which is necessary for the initiation of the cap dependent translation. eIF4G functions as a 
scaffold protein to allow eIF4E phosphorylation. During the late phase of infection Mnk1 is 
replaced by 100K in an RNA-independent fashion and blocks cap-dependent translation.45 
Viral mRNAs transcribed from the MLP have a common 5’ sequence called the tripartite 
leader. This sequence helps late mRNAs to bypass the requirement for eIF4F by a mechanism 
called ribosome shunting.46,47  
Once the capsid is assembled, the viral DNA packaging signal directs the 
encapsidation of the viral DNA. The L3-encoded protease cleaves at least four viral 
polypeptides to generate the mature VI, VII, VIII, and TP proteins. The release of the progeny 
virus is helped by the E3 adenovirus death protein (ADP)27 and by cytokeratin cleavage.48  
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1.3 Adenovirus cancer gene therapy 
 
Cancer gene therapy with adenoviruses is based on the assumption that a virus that selectively 
replicates in the tumour will destroy only the tumour cells while the surrounding normal tissue 
will be spared.  Different approaches have been taken to allow selective replication, which are 
discussed in this chapter. 
   
1.3.1 Complementary defect approach  
 
Cancer arises from uncontrolled cell proliferation and reduced apoptosis. Viruses 
promote cell proliferation and block apoptosis. Therefore deleting the viral genes involved in 
the S phase entry or in blocking apoptosis would allow replication of the virus only in tumour 
cells. The most well studied adenovirus so far is dl1520 (Onyx-015) which is deleted for the 
E1B55K gene.49 E1B55K together with E4orf6 blocks p53 induced apoptosis. Therefore, in 
non-tumour cells, where p53 is functional, though E1A will induce the cell to enter S phase, 
p53 will be activated and it will promote apoptosis which will abort viral replication and 
spread. In more than 50% of tumour cells p53 is mutated. Lack of p53 will allow selective viral 
replication and destruction of tumour cells. dl1520 entered phase I and II clinical trials.50,51 In 
phase I trials the virus has been used both in local and systemic therapy and has shown safety. 
However, the in vitro activity of the virus was not reflected in vivo.52 The virus failed to show 
major efficacy in phase II trials involving patients with liver metastases53-55 and clinical 
development was discontinued in the US and Europe.  
Later it was shown that replication of dl1520 is not p53-dependent.56 E1B55K together 
with E4orf6 also regulates the preferential export of late viral mRNAs. It has been suggested 
that tumour cells are permissive for the export of late viral transcripts even in the absence of 
E1B55k. Reduced export of viral mRNAs in normal cell may explain the tumour selectivity of 
E1B55K deleted viuses .57  
Mutations in the E1A protein that delete the pRB binding site can also render 
adenoviruses selective for cancer cells.58 The pRB pathway is mutated in many types of cancer. 
Mutations in E1A that abolish pRB binding will prevent the inhibition of pRB by E1A. In 
quiescent cells infected with E1A-mutant virus, pRB will still block E2F proteins and S phase 
entry.  In contrast,  in pRB-mutant or cycling cells there is no pRB inhibition.59 
Other mutations that can be complemented by defects in tumour cells have been 
shown in the VA RNAs60 and in E4orf1 and orf4.39  
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1.3.2.  Tumour selective promoters 
 
Tumour selectivity can be achieved by placing viral promoters under the regulation of 
tissue or tumour specific promoters. Most of these modifications have been introduced into 
the E1A, E1B and E4 promoters. PSA is a clinical marker that is transcriptionally activated in 
prostate cancer. The E1A promoter of adenovirus has been replaced by the PSA promoter.61 
This virus showed selective replication in PSA-positive prostate cancer. It has been further 
modified by using the prostate-specific probasin promoter.62 
 The E2F-1 promoter is active in tumours and also in cycling normal cells. The E1A promoter  
of adenovirus has been replaced with the E2F-1 promoter. This virus was active in cancer cells 
but was inactive in regenerating liver showing that the level of E2F is only high enough to 
activate the promoter in cancer cells in vivo.63 The E4orf 6/7 gene of adenovirus activates E2F 
therefore the E4 region of the virus was also placed under the control of E2F-1 promoter and 
the orf7 splice acceptor was mutated.33 
 
1.3.3  Suicide gene therapy 
 
In vivo experiments with adenoviral vectors showed that adenovirus is not potent 
enough to eradicate most tumour tissue. It is possible to unconditionally express genes from 
adenovirus, like TNFα, that destroy the tumour but this raises safety problems.64  
 It is safer to express pro-drug activating enzymes which, when expressed, will transform an  
otherwise harmless prodrug into a cytotoxic compound. The most commonly used enzymes 
are: herpes simplex virus thymidine kinase (TK)65, yeast cytosine deaminase (CD)66 and the 
bacterial nitroreductase (NTR).67 CD and NTR have been expressed both as an early and as a 
late transcript. Late expression of the enzymes should reduce the effect of the activated drug 
on viral replication.68,69 
 
1.3.4  Capsid modifications 
 
Viral uptake into cells is dependent on the capsid proteins of the virus. Modifying 
these proteins can substantially change the viral tropism and activity. The viral capsid is formed 
by hexons. From each vertex of the icosahedral capsid a fibre protrudes. The fibre is 
connected to the hexons of the capsid through binding to penton.  The fibre monomers form 
a trimer. The fibre can be divided into two parts: the C-terminal knob domain and the shaft 
domain (Figure 4). The knob domain has a trimerization surface, where it interacts with the 
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other two monomers, and an outer surface which binds to receptors. Adenovirus serotype A, 
C, E and F use the Coxsackie-Adenovirus Receptor (CAR) while B group adenoviruses (Ad7, 
11, 35, and 37)70,71 use CD46 for initial attachment to cells.  Group F viruses (Ad40 and 41) 
evolved a short and a long fibre both of which are expressed from the L5 transcript. The long 
fibre binds to CAR, whereas the receptor for the short fibre is unknown. Ad40 and 41 only 
infect the intestinal tract and it is hypothesized that the two fibres evolved to help survival in a 
low pH environment and to allow specific infection of the intestinal epithelium.    
Three loops are formed on the outer surface of the knob domain: the AB, DG and HI 
loops.  The AB loop is the most important in the CAR-fibre interaction72,73 but some residues 
in the DG loop74 also influence  
 
Figure 3. The two-step model of viral entry.  First fiber binds to CAR. Then the penton binds 
to αv intergrins which induce endocytosis and entry of the virus. 
 
 
 
 
Figure 4. The crystal structure of the adenovirus fibre. The fibre is formed as a trimer and can 
be divided into a long shaft and a globular knob domain. The shaft domain binds to HSPGs 
HSPG 
binding 
CAR 
binding 
AB 
loop 
HI 
loop 
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and the knob domain binds to CAR. The knob contains a trimerization surface and an outer 
surface with loops. AB loop is the major interacting partner of CAR.  
 
receptor binding. The HI loop is the most heterogeneous part of the fibre of different 
serotypes and has no known function.75  
After CAR binding, the penton base binds to αvβ3 and αvβ5 integrins. The penton base contains  
an RGD76 sequence that is essential for integrin binding.77 Adenovirus fibre is flexible. This 
flexibility allows the fibre to bend after binding to CAR.78 Rigid fibres reduce the infectivity of 
the virus.79 It has been shown that fibre also binds to heparin sulfate proteoglycans (HSPG).80 
HSPGs are abundant proteoglycans in human and present on cell surfaces. HSPGs bind 
positively-charged amino acid residues like lysine (K). A KKTK sequence has been described 
in the lower third of the shaft after the first hinge region.81 Mutation of this motif to GAGA 
greatly reduces viral infection. However, no clear evidence proves that this change is due to 
reduced HSPG binding. Others have suggested that HSPG binding sites are present in the 
knob domain (Transgene, ESGT 2002 and unpublished data).   
 After i.v. injection of an adenovirus serotype 5 (Ad5) with wild type capsid, 99% of the virus is 
 taken up by the liver. The virus is trapped by liver macrophages, liver sinusoidal endothelial 
cells and hepatocytes. The capsid is responsible for the neutralizing antibody response82 and 
for interaction with different blood components. The fibre binds to blood clotting factor IX. 
Factor IX deficient mice have reduced liver transduction. The virus binds to platelets and also 
to red blood cells.83 Red blood cell binding cannot be detected in mouse but it was shown in 
rats. Finally the fibre binds to different components of the complement system: C3a and 
C4BP.84 
 Deletions in penton and fibre have already been constructed to reduce liver transduction.  
Liver infection with CAR and integrin binding ablated viruses is not reduced.77,85 Deletion of 
the KKTK motif reduces the liver infection but results in a non-functional fibre.81 The KKTK 
deletion might have reduced the bending of fibre and increased rigidity. Liver infection can 
also be reduced by shortening the fibre shaft or by replacing the fibre shaft with shorter shafts 
of other serotypes.86,87 
         Tumour cells downregulate CAR.88,89 CAR is a part of the tight junction complex in  
epithelial cells. CAR transcription is repressed during tumour progression. In colon cancer, 
progression free survival and CAR expression are positively correlated.90 Several methods have 
been use to target viral capsid proteins to tumour cells. These methods are summarised in 
figure. 5. 
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 Introduction of targeting ligands to different capsid proteins is the most promising 
method.  Almost all capsid proteins have been modified including fibre, penton, pIX and 
hexon.  
 The first efforts to retarget Ad transduction by expanding its tropism beyond the natural  
receptors focused on the incorporation of peptide ligands into the C-terminus of the fibre 
protein. The addition of a polylysine motif to the C-terminus of the Ad fibre protein91,92 
increases transduction efficiency by retargeting Ad transduction to heparin sulfate residues on 
the surface of multiple cells. However this method was too general due to the abundant 
expression of HSPGs. The addition of an RGD motif, targeting αvβ3 and αvβ5 integrins, to the 
C-terminus of the Ad fibre protein can overcome low CAR expression on target cells, thereby 
enhancing transduction.93 Other peptide sequences used for retargeting have included the 
terminal decapeptide of the gastrin-releasing peptide (GRP). More recently, the attachment of 
a 12-amino-acid transferrin like peptide to the C-terminus of the fibre protein was used to 
Figure 5. Selective retargeting of adenoviral vectors. Adenoviral particles can be 
transductionally retargeted to tumour cells by the genetic incorporation of targeting 
ligands into capsid proteins. Adenoviral particles can also be retargeted to tumour 
cells by the genetic incorporation of fiber/knob chimeras in which the adenovirus 
fiber knob is replaced by another adenovirus knob, or in which the entire adenovirus 
fiber is replaced with an artificial fiber and knob. Finally adenoviral particles can be 
retargeted using heterologous targeting ligands that are bispecific in binding to the 
fiber knob domain and to a tumor-associated antigen.3 
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retarget viruses to the transferrin receptor.94 However, a major limitation to the addition of 
peptide sequences to the C-terminal end of the fibre is that peptides of 27 aminoacids or more 
inhibited trimer formation95, although this limitation may be dependent upon the specific 
sequence involved. 
 A second place for the incorporation of peptides was identified by X-ray crystallography: the  
HI loop is exposed on the fibre knob, and can incorporate up to 83 amino acids without 
deleterious effects on viral replication.96 In vitro, Ad vectors containing RGD peptide 
sequences in the HI loop of the fibre knob showed a higher level of gene transfer than vectors 
containing RGD peptides at the C-terminus of the fibre knob.97,98 Incorporation of the RGD 
motif in the HI loop was successful in retargeting viruses to a number of tumour cells 
normally resistant to adenovirus infection, including ovarian 99,100, pancreatic101, meningioma102, 
rhabdomyosarcoma89, glioma103 and colon tumours.104 Other sequences identified by phage 
display libraries such as, SIGYPLP or NGR, showed increased infection of tumour associated 
endothelium. Finally, it was hypothesized that dual modification of the C-terminus and the HI-
loop with peptide additions could additively improve gene transfer efficiency. An Ad vector 
containing an RGD motif in the HI loop and a pK7 (polylysine) motif at the C-terminus of the 
fibre demonstrated an increased infectivity in both CAR-positive and negative cells97,98 
compared to individual modifications. There are clear limits to the size of heterologous 
proteins that can be incorporated into the fibre 75,96,134,135,136,137, which effectively limit the 
repertoire of motifs to small peptides. 
  Capsid protein IX (pIX) is a small polypeptide of 140 residues (14.7 kD) that acts as a cement  
protein to stabilize hexon–hexon interactions and therefore the capsid structure itself.105 Four 
trimers of pIX interact with a group of nine hexons (GON) in each facet of the icosahedron106, 
resulting in 240 copies of the protein per virion.107 In addition, pIX serves as a transcriptional 
activator of several viral and cellular TATA-containing promoters, including adenoviral E1a, 
E4, and major late promoter.7 Based on the realisation that the pIX C-terminus is surface 
exposed108, pIX has been exploited to incorporate heterologous peptides (lysine octapeptide 
and polylysine) into its C-terminus for targeting purposes.109 The RGD motif was also 
successfully fused to pIX and assembled into virions.110 Retargeting via pIX modification still 
needs to be demonstrated, and may require a contribution from fibre to be successful.  
Hexon is the largest and most abundant of the structural proteins in the adenovirus 
capsid. The 720 hexon monomers present in each virion form 240 hexon homotrimers, which 
in turn form 20 capsid facets, each consisting of 12 hexon homotrimers.111 As the most 
abundant capsid protein, modification to the hexon protein is particularly attractive. However, 
genetic modification of hexon often results in non-viable viruses. Oligonucleotides encoding 
six histidine residues (His6) were incorporated into different hyper variable regions (HVRs) of 
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the hexon, which are non-conserved among hexons of different serotypes.112 Successful rescue 
of the modified viruses provides the potential for transductional retargeting involving hexon 
modification.  
The pentons located at the 12 vertices of the adenovirus icosahedral capsid are 
composed of homopentameric proteins which are non-covalently linked to the fibre by the 
penton base. Subsequent to fibre knob binding to CAR, interaction of RGD sequence motifs 
in the penton base with integrins induces endocytosis; deletion of the RGD motif significantly 
reduces the rate of virus internalization. Although little work has been carried out on 
incorporation of ligands, it has been demonstrated that high affinity targeting ligands can 
function following insertion into the penton base. 
 
1.3.5 Fibre pseudotyping 
 
 A total of 50 distinct serotypes of human adenoviruses have been identified. These serotypes  
have been classified into six subgroups (A–F) based on sequence comparisons, each subgroup 
with different tropisms. Subgroup A adenoviruses include serotypes 12, 18, and 31. Subgroup 
B adenoviruses can be divided into subgroup B1 (serotypes 3, 7, 16, 21, and 50) and B2 
adenoviruses (serotypes 11, 14, 34, and 35). These viruses display different organ tropisms, 
suggesting a difference in receptor usage. CD46 was suggested to be a receptor for Ad 
serotypes 11 and 35, both members of subgroup B2.70 However, discrepancies in CD46 
binding between subgroups B1 and B2 suggested the use of an alternative receptor. Blocking 
experiments confirmed that B2 adenoviruses utilize a different receptor than B1 
adenoviruses.113 The identity of the receptor for Ad serotype 3 remains disputed. CD80 (B7.1) 
and CD86 (B7.2) have been shown to be the main cellular attachment receptors for serotype 
3.114 However Ad3 can also use CD46 as a receptor.115  
 Adenovirus serotype 5, the most commonly used serotype for gene therapy applications, is  
classified as subgroup C, which also includes serotypes 1, 2, and 6. 
 The subgroup D adenoviruses include the largest number of serotypes (serotypes 8–10,  
13–20, 22–25, 27–30, 32, 33, 36–39, and 42–49). Serotype 37 uses sialic acid residues as a 
receptor, rather than CAR116, and an Ad5 vector with an Ad 37 knob can also use sialic acid as 
a cellular receptor.117,118 However, other studies have demonstrated that wild-type Ad37 may 
use a 50-kDa protein for binding to human conjunctival and cervical carcinoma cells.119,120 
 Ad4 is unusual among adenoviruses, because it is the single known serotype of subgroup E.  
However, the Ad4 fibre gene has close phylogenetic relationship to subgroup C fibre genes.121 
 Subgroup F adenoviruses (serotypes 40 and 41) are associated with gastrointestinal disease.  
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Uniquely, Ad40 and 41 contains two distinct long and short fibres. The short fibre is unable to 
recognize CAR, while the long fibre binds to CAR. 
 
Fibre pseudotyping by either switching the complete fibre between serotypes, or parts 
of the fibre between serotypes, can retarget the virus to tumour cells and detarget it from some 
cell types in the liver. 
 
Subgroup B pseudotyping 
  
 Replacement of the Ad5fiber knob domain with that of Ad3 fibre in an oncolytic virus  
resulted in a cytopathic effect at least four orders of magnitude higher than wild-type Ad5 on 
primary melanoma cells122 and in ovarian, renal and squamous cell carcinoma cell lines. The 
Ad5/3 knob chimera was further modified by insertion of the RGD peptide into the HI loop 
and at the C terminus. This combination of modifications has been referred to as the complex 
mosaic approach and showed increased efficiency.123    
 Pseudotyping with the Ad35 fibre, that binds to CD46 but not CAR, resulted in increased  
tumour infection124 and reduced liver infection.125 CD46 is  overexpressed by different tumour 
cells including ovarian cancer, prostate cancer, sarcomas71 and also in malignant myeloid and B 
lymphoid cell lines. Biodistribution studies of Ad35 pseudotyped virus showed extremely low 
levels of uptake in liver, lung, spleen and bone marrow.  
 
Subgroup D pseudotyping 
 
 It has been demonstrated that Ad5 vector containing Ad19p or Ad37 fibre substitutions  
produced significantly less viral infectivity and transgene expression in liver.126 A vector 
construct in which the Ad17 fibre replaced the Ad2 fibre showed an increase in the binding 
and efficiency of gene transfer to well-differentiated human airway epithelia compared to a 
wild-type Ad2 construct.127 
 
Subgroup F pseudotyping 
 
 Ad5-based vector constructs with chimeric Ad40-derived fibres, composed of either long  
or short shafts, were tested both in vivo end on vitro. The results show that the high 
transduction efficiency observed in the liver and spleen following intravenous administration 
of adenovirus vectors is dramatically reduced by the use of the Ad40 short fibre shaft.128 These 
results also demonstrate that the natural tropism of adenovirus in vivo is influenced not only 
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by fibre–CAR interactions but also by fibre shaft length. An Ad5 vector pseudotyped with the 
short fibre from Ad 41 also mediated very low transduction of rat liver in vivo.83 
 Replacing Ad5 fibre with a structurally related bacteriophage protein, the T4 phage fibritin,  
resulted in a functional “fibre”.129 Targeting the fibre-fibritin chimera to integrins allowed high 
levels of infection.130 
 
1.3.6 Heterologous retargeting ligands 
   
The least attractive of the three methods is the use of bifunctional adaptor proteins. 
This method requires the separate production of both the adaptor protein and the virus which 
is undesirable for production of GMP grade vectors. Bifunctional adaptor fusion proteins, 
such as scFV and Fab shown in figure 5, target both the adenoviral fibre and a surface 
receptor. They have been extensively used and can potentially retarget the virus to any receptor 
of interest.  
The 59 amino-acid-long Fc-binding (C-domain) of Staphylococcus aureus protein A 
was genetically incorporated into the Ad5 fibre protein at the C-terminus or in the HI-loop.131 
The resulting viral vectors were capable of associating with the Fc domain of immunoglobulin 
(Ig). Genetically fusing the Ig Fc domain to an anti-CD40 targeting scFv or to the CD40L 
ligand, allow targeting to CD40 positive cells. The fusion proteins form stable complexes with 
the protein A-modified Ad vectors. The virus-protein complexes show significant 
augmentation of gene delivery to CD40-positive target cells.132 A similar approach was taken 
by an other group.133 They inserted a 33 amino-acid domain, corresponding to the 
immunoglobulin G (IgG)-binding domain (Z33) from S. aureus protein A, into the adenovirus 
fibre protein. The virus was incubated with an EGFR-specific mAb and was successfully 
retargeted to EGFR-expressing cells.  
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1.4 The Wnt signalling pathway 
 
The Wnt signalling pathway is conserved from nematodes to vertebrates. The pathway 
is active during embryogenesis, where it has been shown to regulate many patterning events, 
like the formation of the rostrocaudal axis in the developing vertebrate embryo. In the human 
adult body the Wnt pathway is active in stem cells in the bone marrow, in hair follicles, in 
crypts of the intestine and also in the subventricular zone (SVZ) of the brain.138 The role of 
Wnt signalling in stem cells is not completely understood: it might regulate the maintenance of 
the stem cell compartment or the amplification of transient amplifying (TA) cells. In the 
intestinal crypts, activation of the Wnt pathway leads to expression of c-myc, which blocks the 
transcription of the cell-cycle kinase inhibitor (CKI) p21. This enables the cells to progress 
through the cell cycle.139 The role of the Wnt signalling pathway is to provide information 
about the extracellular environment. Depending on the identity of the cell the signal is 
interpreted as an instruction to proliferate, as in TA cells or to differentiate, as in Paneth cells.  
Wnt ligands can activate several pathways: the canonical Wnt pathway, the planar cell 
polarity pathway, and the Wnt/Ca2+ pathway. The canonical Wnt pathway was shown to be 
mutated in many cancers. Binding of Wnt ligands to their receptors induces a cascade of 
events that leads to the stabilisation of β-catenin and its translocation into the nucleus. There, 
it functions as a cofactor for transcription factors of the T-cell factor/lymphoid enhancing 
factor (Tcf/Lef) family to turn on expression of target genes such as c-myc, cyclin D1, and 
conductin/axin2. β-catenin is also involved in the formation of adherent junctions and 
connects E-cadherin to γ-catenin/p120, which in turn binds to the actin cytoskeleton. β-
catenin is distributed among three main cellular pools: membrane-bound, cytoplasmic and 
nuclear.  
 
1.4.1 Regulation of the Wnt signalling pathway 
 
The main regulation of the canonical Wnt signalling pathway involves the control of 
the β-catenin protein level. In the absence of Wnt ligand, β-catenin is part of a multiprotein 
cytoplasmic complex, called the “destruction complex”, that contains APC, axin, CKI and 
GSK3β. APC is a large protein that interacts with many proteins including β-catenin, axin, 
EB-1 and DLG. Axin acts as a scaffold protein that brings together GSK3β, APC, β-catenin 
and diversin. This complex stimulates a two-step 
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Once primed by CKIα, β-catenin is phosphorylated on the remaining N-terminal sites by 
GSK3β. Axin can be also be phosphorylated by GSK3β to increase the stability of brings 
together GSK3β, APC, β-catenin and diversin. This complex stimulates a two-step 
Figure 6. Schematic representation of the Wnt signaling pathway. A; In the absence of Wnt ligand β-
catenin is bound by the destruction complex and tagged by GSK3β phosphorylation for degradation by 
the 26S proteosome. B; in presence of Wnt signal β-catenin is no longer phosphorylated. It is 
transported to the nucleus where together with TCF/LEF transcription factors it activates its target 
genes. 
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phosphorylation of β-catenin. First, Casein Kinase 1 α (CK1α) binds to diversin and 
phosphorylates β-catenin at Ser-45.140,141 
 Once primed by CK1α, β-catenin is phosphorylated in the remaining N-terminal sites by  
GSK3β. Axin can be also phosphorylated by GSK3β to increase the stability of the 
destruction complex. Finally, GSK3β phosphorylates APC after phosphorylating β-catenin. 
APC phosphorylation competes β-catenin away from the Axin binding site while β-catenin is 
still bound by APC. This step allows the binding of a new unphosphorylated β-catenin by 
Axin. Finally β-catenin is released from APC by the PP2A phosphatase 142,143. 
Polyphosphorylated β-catenin is then recognised by the F-box protein β-TrCP, an E3 
ubiquitin ligase, and degraded by the 16S proteosome.   
Canonical Wnt signalling is initiated upon binding of a Wnt ligand to a member of the 
Frizzled (Fz) family of receptors and a co-receptor, LRP–5/6.144 Upon Wnt binding, the 
intracellular domain of LRP-5/6 interacts with axin and targets it to the cell membrane, 
destabilising the scaffolding protein complex. In parallel, Wnt binding to Fz leads to 
phosphorylation of Dishevelled (Dsh), which is followed by dissociation of GSK3β from 
axin. Once the destruction complex is destabilised, phosphorylation of β-catenin is stopped 
and the protein accumulates and translocates to the nucleus. 
  Once in the nucleus, β-catenin binds to Lef/Tcf transcription factors and to additional  
proteins implicated in histone acetylation and remodelling such as CBP/p300.145 β-catenin 
activation is also regulated by BCL9 and Pygopus.146 Active β-catenin Tcf complexes drive 
transcription of target genes such as c-Myc147, Cyclin D148,  PPARγ149  and axin2/conductin.150 
 
 β-catenin is at the crossroads of many signalling pathways connecting cell adhesion with Wnt  
signalling, cellular growth and replication.  β-catenin activity is regulated at least at three 
different levels: at the cell membrane, at the nuclear membrane and at the promoter of its 
target genes. The C-terminal armadillo repeats of β-catenin bind to E-cadherin 151 and the N-
terminal armadillo repeats bind to α-catenin/p120, which interacts with the actin cytoskeleton 
network.152 The E-cadherin binding is regulated by c-src. C-src phosphorylates β-catenin 
(Y654), which dissociates it from E-cadherin.153 C-src phosporylated β-catenin, however, 
requires further phosporylation at the N terminal armadillo repeats (Y142) by fer, Fyn or Met 
oncogenes.154,155 Y142 phosphorylation not  
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Figure. 7. The complex regulation of the Wnt pathway/β-catenin. I. β-catenin interacts with 
E-cadherin and with α-catenin/p120 to connect tight junctions with the actin cytoskeleton. β-
catenin is regulated by tyrosine phosporylation of N-and C-terminal armadillo repeats. These 
modifications switch β-catenin to its transcriptionally active form. II.  β-catenin nuclear 
transport is regulated by APC, BCL9 and RanBP3. III. Repressor and activator transcription 
factors fine tune target gene expression. 
 
only inhibits the β-catenin/α-catenin interaction but is also necessary for BCL9-2 binding and 
to convert β-catenin into a transcriptionally active form.156 It has also been shown that β-
catenin exists in distinct molecular forms: in adhesive and transcriptional complexes.157 
 During development of carcinomas, cells undergo epithelial to mesenchymal transition  
(EMT). The hallmark of EMT is the loss of expression of E-cadherin and dissociation of the 
E-cadherin/β-catenin/α-catenin complexes at the membrane. Loss of E-cadherin mediated 
cell adhesion correlates with increased β-catenin-dependent transcription.158,159  
 Recent studies suggest that β-catenin can also be activated through G-protein coupled  
receptors. APCmin (multiple intestinal neoplasia) mice treated with COX-2 inhibitors develop 
fewer adenomas and have a prolonged life span. COX-2 produces prostaglandins in the 
intestine and it has been shown that prostaglandin E2 can induce nuclear β-catenin 
accumulation through activation of the Gα subunit that is regulated by the EP2 receptors.160 
The Gα subunit can bind to the RGS motif of Axin thus displacing it from the APC/β-
catenin/Axin/GSK3β destruction complex. The Gβ and γ subunits released by the 
dissociation of the G protein complex can activate Akt/PKB which in turn phosprorylates and 
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inactivates GSK3β. This dual effect can produce an increase in the amount of  
transcriptionally active β-catenin. 
  
 Nuclear transport of β-catenin is also tightly regulated. Both APC and BCL9 can influence  
β-catenin nuclear shuttling.161,162 APC contains several putative nuclear localisation signals 
(NLS) and export signals (NES). BCL9 (legless) also has an NLS. APC can both import and 
export β-catenin using the CRM1 export receptor. BCL9 imports β-catenin into the nucleus 
and promotes Wnt target gene transcription.  Finally Ran binding protein 3, RanBP3, can 
export β-catenin in a RanGTP-stimulated but CRM1-independent manner.163 Interestingly, 
other Wnt signaling proteins like Axin, GSK3B and βTrCP show regulated and specific 
nuclear transport. 
 
 In the nucleus β-catenin binds to TCF to activate transcription of Wnt target genes. BCL9,  
BCL9-2 and Pygopus are essential components of the β-catenin/TCF transcriptional 
complex.146 β-catenin also interacts with chromatin remodelling and histone modification 
proteins such as Brg1 (Brahma related gene 1)164, CBP (CREB binding protein)/p300145, 
TRRAP/TIP60165 and mixed-lineage-leukaemia (MLL1/MLL2) SET1-type chromatin 
modifying complexes.166 In the absence of Wnt signal, TCF proteins occupy and repress 
promoters of their target genes by recruiting Groucho167, CtBP (COOH-terminal binding 
protein)168 and histone deacetylases.  Furthermore, ICAT (inhibitor of β-catenin and TCF4), 
Chibby and Kaiso are identified as nuclear proteins that repress Wnt signalling by competing 
with TCF for binding to β-catenin.169,170 Interestingly, inhibition by Kaiso is relieved by the 
binding of Kaiso to p120-catenin suggesting an alternative and parallel signalling pathway from 
the membrane.171      
 
1.4.2 Colorectal Cancer and the Wnt pathway 
 
Colorectal cancer (CRC) is a leading cause of mortality with about 300’000 new cases 
and 200’000 deaths in Europe and in the USA each year. Most colorectal cancers arise from 
sporadic pre-existing adenomatous polyps, a common lesion whose incidence increases with 
age. Studies have shown a prevalence of about 35% in Europe and USA. About 5% of 
adenomatous polyps are estimated to become malignant, a process that takes 5 to 10 years.172 
The risk of developing colorectal cancer is determined by both genetic predisposition and 
environmental factors. Hereditary forms of CRC are familial adenomatous polyposis (FAP) 
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and hereditary nonpolyposis colorectal cancer (HNPCC). FAP patients have a mutant APC 
gene, whereas HNPCC patients have mutations in genes involved in DNA mismatch repair. 
Each cell must undergo multiple mutations for malignant transformation to occur. Vogelstein 
and colleagues have proposed a model where multistep genetic events favour the progression 
of sporadic CRC. These events involve oncogenes like K-Ras and myc and tumour suppressor 
genes like APC and p53.173 Virtually all CRCs have activating mutations of the canonical Wnt 
signalling pathway, leading to stabilization and nuclear accumulation of β-catenin. The vast 
majority of sporadic colon cancers (85%) have truncated APC proteins. Both alleles of APC 
need to be mutated for loss of growth-suppressing activity. The remaining 10% of CRC 
tumours have mutations that affect the phosphorylation sites of β-catenin or the scaffolding 
function of axin. APC and β-catenin mutations are mutually exclusive, consistent with their 
participation in the same signalling pathway. 
1.5 The PI3K pathway 
 
 The PI3K pathway is an important regulator of cell proliferation and cell survival, most 
notably in cells that are responding to growth-factor-receptor engagement. Originally, PI3K 
was identified as a kinase regulating insulin signalling. However, the PI3K pathway regulates 
many other aspects of cellular growth, survival, metabolism, energy production and 
differentiation. PI3K is an oncogene. It phosporylates the 3 position of the inositol ring to 
produce phosphoinositide-3,4,5-triphosphate (PIP3). One of the most important downstream 
targets of PI3K is Akt. The interaction of PIP3 with the Pleckstrin homology domain of Akt 
promotes the translocation of Akt to the plasma membrane, where it undergoes 
phosphorylation on two sites, one in the activation loop (Thr308) and the other at the 
carboxy-terminus (Ser473). Phosphorylation at Ser473 precedes and facilitates phosphorylation 
at Thr308 (Sarbassov et al., 2005 and references therein). The kinase that phosphorylates Akt 
at Thr308 is PI3K-dependent kinase 1 (PDK1)174. The kinase that phosphorylates Akt at 
Ser473 (PDK2) had been elusive for many years. Recent studies revealed that in 293T cells and 
several carcinoma cell lines, Akt phosphorylation at this site depends on a complex that 
contains the mammalian target of rapamycin (mTOR), GβL, and Rictor175. Earlier studies had 
shown that several additional kinases, including ILK-1, PDK1, Akt itself, and perhaps other 
members of the AGC kinase family, as well as DNA-PK, may have the potential to 
phosphorylate Akt at this site174,176. Although the role of the Rictor–mTOR complex in the 
phosphorylation of Akt at Ser473 is beyond doubt, the potential involvement of these kinases 
in this process in some cells responding to specific signals has not been excluded today. 
Phosphorylated Akt may translocate from the plasma membrane to the cytosol or the nucleus. 
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Activated Akt ultimately undergoes dephosphorylation by phosphatases and returns to the 
inactive state.177  
 PI3K activity is balanced by PTEN (phosphatase with tensin homology) activity. Somatic  
deletions or mutations of PTEN have been identified in a large fraction (12-60%) of 
tumours.178 PTEN is a phosphatase whose main in vivo substrate is PIP3. 
179
 The levels of PIP3 
are very low in quiescent cells, but rapidly increase upon stimulation of the cells by growth 
factors. 
Activated Akt, in turn, phosphorylates an ever-growing list of target proteins, thus regulating key  
processes such as proliferation, survival, cell size and mRNA translation. Briefly, Akt 
phosphorylation activates IKK and MDM2, and blocks GSK3β, BAD, caspase 9, FOXO3A, 
p21/WAF1 and tuberin (TSC2).  
Tuberin (TSC2) together with hamartin (TSC1) and RHEB form a multiprotein complex called  
the tuberous sclerosis complex.180,181  It has been shown that Akt/PKB directly phosporylates 
tuberin on two residues, S939 and T1462. Tuberin contains a highly conserved GTPase 
activating (GAP) domain. RHEB, a member of the Ras super-family, is the specific GTPase 
downstream of tuberin. The tuberous sclerosis complex is not only regulated by Akt but by 
many other important proteins including GSK3β, AMPK and Erk. 182,183 
 RHEB has a dual role: it activates mTOR and inactivates B-Raf.184,185 mTOR forms  
distinct protein complexes: one with raptor, one with Rictor. The mTOR/raptor complex 
regulates protein translation through direct phosphorylation of p70S6K and 4E-BP1.186 S6 
kinase (p70/S6K) regulates ribosomal protein translation and ribosomal biogenesis. 4E- 
binding protein 1 (4E-BP1) binds to  
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Figure 8.  Schematic representation of the PI3K pathway. 
 
 
 
eukaryotic initiation factor 4E (eIF4E) and blocks cap dependent translation.187 mTOR 
phosphorylation blocks 4EBP1 binding thus releasing eIF4E to bind to eIF4G and initiate 
translation.     
The mTOR/Rictor complex activates Akt/PKB and may thus participate in a positive feedback 
 loop within the PI3K pathway promoting cell survival and proliferation.175  
 RAF proteins (A, B, C-RAF) are part of a conserved signalling module that transduces signals  
from the cell surface to the nucleus. This module consists of the RAS family of small G 
proteins, which are the upstream regulators of the RAF proteins.188 Binding of extracellular 
ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates 
RAS and this initiates RAF activation. This leads to activation of the dual-specificity protein 
kinases MEK1 and MEK2 (Mitogen-activated protein kinase and extracellular signal-regulated 
kinase kinase) and subsequently the MAPK/ERK proteins ERK1 and ERK2. B-RAF has 
been shown to be the main activator of MEK1/2.189 B-RAF also activates NF-κB directly or 
indirectly through activating C-RAF.190 B-RAF is mutated at high frequency in human cancers. 
Accurate regulation of ERK is crucial to the balance of biological responses that a cell can 
make. All three RAF isoforms can trigger either proliferation or cell cycle arrest depending on 
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the signal intensity.  Scaffold proteins like kinase suppressor of RAS (KSR, a pseudo-kinase) 
the multidomain protein connector-enhancer of KSR (CNK) and the leucine rich-repeat 
protein suppressor of Ras mutations 8 (SUR8) regulate the efficiency of signalling.191 Inhibition 
of B-RAF by RHEB may counter-balance the activation of mTOR by RHEB, naturally 
limiting RHEB’s ability to induce tumour growth in cells expressing B-RAF, and contributing 
to the fact that the vast majority of tumours in tuberous sclerosis patients are benign.   
 
1.6 Systemic therapy with adenoviral vectors 
 
 Previously cancer gene therapy treatments have solely focused on local delivery of viral and  
non-viral agents by intratumoral injection. However, cancer, especially late stage metastatic 
cancer, is a systemic disease and therefore it requires systemic therapy. When adenovirus 
vectors are used systemically two major problems arise: first, the virus infects the liver and 
interacts with the innate immune system; second, the tumour itself is hardly infected.  
 
1.6.1 Adenovirus and liver infection 
 
The half life of the virus in blood is approximately 2 minutes.192 Almost 95% of an intravenously 
 injected dose of adenovirus is cleared by the liver. Most of the remaining virus is cleared by 
the lungs and the spleen. (Fig 9.) In the liver, adenovirus is taken up first by Kupffer cells193. 
Kupffer cells are liver-resident macrophages and form the first line of defence in the innate 
immune response. Kupffer cells scavenge viruses and other particles from the blood. They not 
only remove viral particles but also activate the innate and acquired immune system by 
releasing chemokines (RANTES, IL-6, IL-4, MIP-2, TNFα)194,195. Furthermore they behave as 
antigen presenting cells (APCs) and migrate into lymph nodes to activate humoral and cellular 
immune responses196,197.  Kupffer cell uptake is, however, saturable. The maximum dose that 
the mouse liver can efficiently remove from the blood stream is 2.5x1010 viral particles. When 
more virus was injected the amount of viral particles in blood and the amount of virus injected 
correlated linearly198. (Fig 9.) 
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Figure 9. A shows the half life of the virus in the blood measured by plaque assay. Triangles: 
injection of 1011 viral particles. Full circles: injection of 1011 viral particles after pre-treatment 
with gadolinium chloride. Full squares: 1011 injection of 1011 viral particles of adenovirus 
deleted for CAR binding.; Panel B shows the correlation between dose of virus and transgene 
expression (hINF-β) in the liver. 192 
 
 After a saturating dose of virus is injected, Kupffer cells disappear from the liver. The  
disappearance is still not fully understood. It is suggested that Kupffer cells die because of 
apoptosis or actively migrate away to become antigen presenting cells198. The Kupffer cells 
start to repopulate the liver after 4 days and the liver is fully repopulated within 2 weeks. 
Adenoviral vectors also infect sinusoidal endothelial cells and hepatocytes in the liver. This 
infection, however, happens through receptor-mediated endocytosis and it depends on 
integrins, the CAR receptor and HSPGs.  Immediately after vector injection a significant drop 
in blood pressure was measured that most probably was caused by the systemic activation of 
endothelial cells by nitrate released by Kupffer cells199.  The barriers to infection of tumour 
cells with adenovirus are summarized in Fig. 10.  
   
 
 
 
 
 
 
 
 
A 
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Figure 10.  Biological and chemical barriers that hamper adenovirus infection of tumours. 
The virus is injected into the hepatic artery and finds the nest of metastatic tumour.  1. 
Kupffer cells, hepatocytes and sinusoidal endothelial cells remove the virus and activate the 
innate immune response. 2. the tumour vessels are not properly formed. 3. The tumour 
microenvironement maintains high interstitial fluid pressure (IFP), hypoxia and acidosis 
created by tumour metabolism. NO, Nitric oxid.  
 
 Adenoviruses are classified according to differences in their ability to agglutinate red blood  
cells from different species. For example, subgroup B agglutinates only monkey erythrocytes. 
Subgroup D is classified into three groups: DI agglutinates rat and human erythrocytes, DII 
agglutinates only rat erythrocytes, and DIII shows no or only weak agglutination of rat 
erythrocytes.200 Agglutination is mediated by fibre. Domains in the fibre of subgroups B and D 
that are responsible for these interactions have been identified.201 From these studies, sites 
important for the hemagglutination in human and rat erythrocytes were localised. 
Hemagglutination in rats appeared to be mediated by at least two domains, one in the GH 
loop and one at the junction of the C β-strand an CD loop. However, domains important for 
the agglutination of human erythrocytes are located in the CD and HI loops of subgroup DI 
viruses.201 The hemagglutination domain of viruses from subgroup B2 has also been localized 
to the GH and HI loop.202 These residues define important regions of the γ-determinant, 
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which has been proposed to consist of at least 17 amino acid residues within the surface loops 
of the Ad fibre knob domain.203 The γ-determinant together with the ε-antigen of the hexon 
determines the serotype of an adenovirus. 
  Ex vivo agglutination of red blood cells has also been assessed with mutant Ad 5 vectors.83 
Interestingly, although the KKTK and penton base mutants produced no differences 
compared to wild-type Ad 5 (positive for agglutination of human and rat erythrocytes, but 
negative for mouse), vectors containing the CAR-ablating mutation did not agglutinate human 
or rat red blood cells, indicating the importance of residues in this region of the knob for 
mediating these effects. 
 Recent evidence highlights the importance of serum factors in the hepatic tropism of  
adenoviruses.84,204 Zinn et al.204 compared the efficiency of hepatic transduction using real-time 
bioluminescence imaging in either wild type or complement component C3 knockout mice. 
Systemic delivery of 2.3 x109 viral particles produced 99-fold lower transgene expression levels 
at 3 days in C3 knockout mice compared to wild type. Preincubation of the virus with C1q-
deficient or factor B-deficient mouse sera enhanced hepatic transgene expression in C3 
knockout mice. However, in this study the authors were not able to identify the receptor that 
Ad was utilizing ro infect the liver cells. Shayakhmetov et al.84 devised an in situ perfusion 
technique in which liver transduction by Ad could be analyzed in the presence or absence of 
blood. In this study the authors demonstrated the existence of a non-CAR pathway for liver 
transduction, which could be utilized by CAR-binding-ablated Ad 5 and by non-CAR-
interacting adenoviruses, such as Ad 35. In the liver perfusion model, liver transduction in the 
presence of blood was shown to be equivalent for Ad5, an Ad5 containing the Y477A 
mutation (to ablate CAR binding), and Ad 5/35. However, when the liver was transduced in 
the absence of blood the level of transduction from non-CAR-interacting Ads was 2–3 logs 
lower than for parental Ad 5. To identify receptors involved in this phenomenon the authors 
then co-injected potential competing ligands and identified lactoferrin, a ligand for both the 
low density lipoprotein-related protein (LRP) and HSPG. As LRP deletion is lethal the authors 
focused on the role of HSPGs and demonstrated that heparinase pretreatment of mice 
significantly reduced non-CAR-interacting Ad transduction. Slot-blot assays with recombinant 
Ad 5 fibre knobs revealed that the knob was able to bind to factor IX and the complement 
component C4BP and that these factors mediated CAR-independent transduction of hepatic 
cell lines and primary hepatocytes. Somewhat surprisingly, no differences in liver transduction 
occurred in factor IX knockout mice, possibly suggesting that multiple blood factors (including 
C4BP and factor X) may be involved in the host interaction with Ad 5, compensating for the 
lack of factor IX in this setting. An Ad 5 vector containing the Y477A mutation, the FG loop 
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TAYT deletion, and a 12-mer peptide inserted into the HI loop was generated in an attempt to 
block these multiple interactions in vivo and was shown to produce 50-fold lower hepatic 
transduction in mice compared to parental Ad 5. From previous studies it is clear that CAR 
ablation and HI loop peptide insertion alone do not affect liver transduction following 
systemic delivery 85,205 suggesting that the additional deletion of the TAYT may have influenced 
the tropism.  
 Recently, Baker at al. suggested (BSGT, March 2006) that pre-treatment with warfarin, a  
vitamin K antagonist can completely abolish liver infection by adenovirus. Vitamin K is 
necessary for blood clotting factor production by the liver.  
 
1.6.2  Infecting solid tumours 
 
 Solid tumours are not only formed of a homogeneous mass of tumour cells but also contain  
blood vessels, connective tissue and extracellular matrix (ECM). Sometimes these elements 
form structures that resemble the organ that gave rise to the tumour. In the case of colon 
cancer they may form pseudocrypts. These structural elements, however, hamper the infection 
of the tumour cells by adenovirus. Endothelial cells, pericytes, fibroblasts and macrophages 
create a physico-chemical barrier.206  
 Blood vessels in tumours arise from sprouting of local normal vessels. These vessels however  
fail to form functionally adequate vessels.207 They form chaotic, disorganised structures. The 
wall of the vessels is not properly formed: the tumour associated blood vessels contain large 
pores; the basal membrane is often not properly formed208 and the pericyte coverage is not 
sufficient.209 Colloid leakage creates high oncotic pressure within the tumour.210 This leads to 
high interstitial fluid pressure (IFP), which reduces the uptake of anti-cancer drugs. Even small 
molecules like doxorubicin fail to efficiently penetrate solid tumour structures.211 Adenovirus is 
approximately 87 nm in diameter.212 This size should allow the virus to extravasate easily. 
Despite the leaky vessels adenovirus fails to reach deep into the solid tumour, partly because of 
the raised IFP.213  
 Fibroblasts form layers between nests of tumour cells. It has been shown that in vivo the  
fibroblasts and the extracellular matrix efficiently block the spread of adenovirus vectors from 
one part of the tumour to another.214 Fibroblasts are also important in maintaining the high 
IFP level.210,211 It has been shown that after inhibition of PDGF receptors, fibroblasts collapse 
and IFP is reduced resulting in increased uptake of small molecules.  
 Rapidly growing tumours also create an unfavourable and hostile chemical environment  
for the virus. Tumour cells produce ATP mainly from glycolysis, a phenomenon called, the 
Warburg effect.215 Tumour cells use glucose and produce lactate instead of pyruvate. The 
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lactate is then used for the production of lipids or is excreted into the extracellular 
compartment resulting in a lower pH. It has been shown that the intratumoral pH of solid 
tumours is between 6 and 6.5, however, in extreme cases it can reach 5.5.206 Adenoviruses are 
sensitive to low pH.216 The viruses are usually stored at pH 8. At pH 6.5 the viral capsid first 
loses fibre and then disassembles.217 The low extracellular pH, therefore, might block the viral 
spread in solid tumour. 
 Large regions of solid tumours are hypoxic. These hypoxic cells respond by expressing  
HIF1α218 which activates VEGF production and in turn the induction of neo-angiogenesis. 
However, it has been shown that in hypoxic conditions the translation of the early adenoviral 
transcripts is reduced219,220 and consequently the viral burst size is also attenuated. Hypoxia 
induces PERK221 kinase which blocks eIF2α222, a factor necessary for translation of early viral 
transcripts.223 
             
 
 
 
 
 
 
 
 
 
 
 
2. Results 
 
2.1  Tcf adenoviruses 
Previously adenoviruses with TCF binding sites in the early promoters of adenovirus 
were generated in the Iggo Lab. In the first generation of these viruses, TCF sites were inserted 
in the E2 and E1B promoters (Fig. 11.)224 These viruses were selective for colon cancer but 
their activity was reduced compared to wild type virus. The second generation viruses were 
created by inserting TCF sites in the E1A and E4 promoters with or without the previous 
modifications of the E2 and the E1B promoter.225 vCF11, with E1A and E4 promoter 
modifications (Fig. 12) showed excellent selectivity and activity. However, the virus which had 
all the promoters modified, vCF22, was active only in a very limited number of colon cancer 
cell lines, though it was inactive in non colon cancer cell lines. To produce an optimal 
backbone for the capsid retargeted adenoviruses I introduced TCF sites in the E1B promoter 
of vCF11. The E2 promoter of the virus remained wild type. This virus, vKH1, was compared 
to wild type adenovirus and to vCF11 (Fig. 12). In most of the colon cancer cell lines vKH1 
was as active as vCF11. In SW480 vKH1 was 10-fold less active but this activity was still 
comparable to that of wild type adenovirus. vKH1 was 10-fold less active than vCF11 in a 
non-colon cancer cell line (Hela) confirming the more stringent regulation by the E1B 
promoter regulation. Therefore, vKH1 was considered as an optimal backbone for further 
capsid modifications.   
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Figure 11. Representation and short abbreviation of the 3 generations of viruses. TCF 
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Figure 12. CPE assay with vKH1, vCF11 and wt type Ad5 virus on SW480 and HT29 colon 
cancer cell lines and in Wnt negative cervical cancer cell line, Hela. Cells were infected with 
serial dilutions of virus for 4 hours at 37 °C. Cells were stained with crystal violet 8 days after 
infection.  
 
2.2  Capsid modifications 
 
2.2.1 Rationale 
 
Systemic adenovirus therapy results in the infection of liver cells: Kupffer cells (KC), 
sinusoidal endothelial cells and hepatocytes. Most of the side effects are the results of the 
infection of these cells. Similar to other tumours, the CAR receptor for adenovirus is 
downregulated in colon cancer. Therefore, modification of the fibre protein, that is responsible 
for the viral uptake, is necessary to increase the amount of virus that is taken up by colon 
tumours.  
 
2.2.2.  Results 
αvβ3 and αvβ5 integrins are overexpressed on tumour cells and on newly formed 
vessels. I inserted an αvβ3 integrin targeting peptide, RGD4C, into the HI loop of the fibre 
knob of all the viruses shown in Table 2. The CAR receptor binding site was also deleted, with 
SW480 HT29 Hela 
Ad5 Ad5 Ad5 vCF11 vCF11 vCF11 vKH1 vKH1 vKH1 
MOI 10  
 1  
 0.1  
 0.01  
 0.001  
MOCK  
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or without modification of the HSPG binding site in the shaft. Three viral genomes were 
cloned with the following combinations of mutations (Table 2): 
 
Virus CAR binding HSPG RGD 
vKH1 
vKH3 
vKH4 
vKH6 
+ 
- 
- 
+ 
+ 
+ 
- 
+ 
- 
+ 
+ 
+ 
 
Table 2. The combination of capsid modifications  
 
 vKH3 contains a deletion of the CAR binding site (“CAR deletion”) and insertion of the  
RGD peptide in the HI loop. vKH4 contains the CAR deletion, the HSPG binding site 
mutation and RGD insertion in the HI loop. vKH6 contains only the RGD peptide in the HI 
loop. Only the production of vKH3 and vKH6 was successful. vKH4 was severely attenuated 
and I could not produce the virus. Transfection of the viral genome into a fibre 
complementing cell line (211B) did not rescue the virus either. The mutation of the KKTK 
sequence to GAGA, in the fibre shaft has been shown to reduce cellular uptake81. It can be 
hypothesised that this mutation results in a non-functional fibre. The KKTK motif is situated 
in the first hinge region of the fibre shaft, which connects two repeats of the fibre.83 After 
binding to the CAR receptor by the fibre knob, the fibre bends to allow the binding of the 
RGD motif of the penton base to integrins. Mutating this hinge region might reduce the 
flexibility of fibre and prevent bending of the fibre. The lack of flexibility and/or bending 
could also be the reason for the reduced infectivity of short-shafted fibres. Pseudotyping with 
short shafted fibres (Ad7, 40, 41) and deletion of some of the N-terminal repeats of the shaft 
were shown to result in a substantial reduction of viral infectivity.83,226 
 
2.2.3    vKH3 and vKH6 in vitro 
 
Both viruses have been evaluated on a panel of cancer cell lines in comparison with 
vKH1. The particle to plaque-forming unit (pfu) ratio of vKH1, vKH3 and vKH6 was: 50, 
830 and 30, respectively. The pfu titre was based on infection of HER911 cells, which are 
permissive for the Tcf viruses because of transcomplementation of the regulated promoters. 
The particle to pfu ratio was much higher for vKH3 than for the other viruses, indicating that 
CAR plays a major role in HER911 infection. To avoid infecting cells with units of virus 
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defined according to misleading criteria, particle counts rather than pfu were used to calculate 
the viral titer for the experiments described below. Western blotting for the E1A, DBP, and 
fibre proteins was done to test whether the new Tcf viruses are able to infect colon cancer cells 
efficiently and retain selectivity. Three colon cancer cell lines were tested with strong Tcf 
activity, SW480, SW620, and LS174T, and two colon cancer cell lines with weak Tcf activity, 
HT29 and Hct116.161 A cervical cancer cell line without activation of the Wnt pathway, HeLa, 
was used as a negative control. Viral protein expression by the Tcf viruses was reduced or 
absent in HeLa cells, confirming the previous results with Tcf-regulated viruses and showing 
that fibre modification does not compromise promoter selectivity (Fig. 13A). The RGD 
viruses were at least as good as vKH1 in all of the colon cancer cell lines, and gave 
substantially higher viral protein expression in LS174T, indicating that integrin binding plays an 
important role in infection of LS174T cells. To determine whether addition of the RGD 
peptide changes the in vitro efficacy of the viruses, cytopathic effect assays were done (Fig. 
13B). At low multiplicities of infection, virus must undergo multiple rounds of productive 
infection to kill all the cells. Thus, the assay measures the ability of the virus both to infect cells 
and to replicate. Insertion of the RGD peptide into the fibre increased the efficacy of the Tcf-
regulated viruses on colon cells by a factor of 10 to 100. vKH3, in which the CAR-binding site 
in the fibre has been deleted, showed intermediate cytopathic effect in LS174T and Hct116, 
indicating that both CAR and integrins are used by vKH6 to infect these cells. The efficacy of 
vKH6 was comparable with, or greater than, that of wild-type Ad5 in all of the colon cancer 
cell lines tested except HT29, which has the lowest Tcf activity. vKH1 and vKH3 were 10,000-
fold less cytopathic than wild-type virus on the HeLa cells. vKH6 was 10-fold more cytopathic 
than the other Tcf-regulated viruses on HeLa cells, showing that integrins and CAR both 
contribute to HeLa infection. The perfect control for vKH6 would be a virus with wild-type 
promoters and RGD insertion in the fibre, but this virus was not constructed for biosafety 
reasons. The increase in cytopathic effect of vKH6 on HeLa cells probably reflects a large 
increase in the effective multiplicity of infection (number of viral genomes entering the cell) 
caused by the RGD modification, rather than any change in the Tcf regulation of the viral 
promoters. Therefore, the viruses with modified fibre genes retain selectivity for colon cancer 
cells and show similar or greater cytopathic effect than the parental virus. This is consistent 
with previous reports on the behaviour of RGD modified adenoviruses.227 
 44 
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
E1A
DBP
Fiber
E1A
DBP
Fiber
E1A
DBP
Fiber
SW
48
0
H
ct
11
6
H
el
a
Ad5wt vKH1 vKH3 vKH6
E1A
DBP
FiberSW
62
0
H
T2
9
LS
17
4T
A Ad5wt vKH1 vKH3 vKH6
E1A
DBP
Fiber
E1A
DBP
Fiber
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
4h 8h 12
h
24
h
48
h
 
Part/cell
Mock
1000
100
10
1
0.1
B SW620 LS174TSW480 HT29 Hct116 Hela
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
A
d5
v
K
H
1
v
K
H
3
v
K
H
6
 
 
2.2.4    vKH3 and vKH6 in vivo 
 
To determine whether addition of the RGD peptide alters the pattern of Tcf virus  
 
Figure 13. In vitro characterization of Tcf-regulated adenoviruses. A; Western blot for E1A, DBP, and fiber 
protein expression. SW620, SW480, HT29, Hct116, and LS174T cells were infected at a moi of 100. HeLa cells 
were infected at a moi of 1,000. Samples were collected at the indicated time points. B; cytopathic effect assay 
on colon cancer cell lines (SW620, SW480, LS174T, HT29, and Hct116) and HeLa cells. Cultures were infected 
with 10-fold dilutions of virus starting at a moi of 1,000, and stained with crystal violet on day 6 for SW620 and 
day 8 for the rest. 
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infection in vivo, the virus was injected into the tail vein of nude mice with s.c. SW620 
xenografts. The virus was injected in four aliquots at 4 hourly intervals. This schedule was used 
to prolong the circulation time of the virus in the blood and hence the probability of 
infection228: the first dose is rapidly cleared by Kupffer cells, which are themselves eliminated 
in the process. Fluorescence in situ hybridization (FISH) to viral DNA was used to identify 
sites of virus replication; single viral genomes were below the detection limit of the assay. Nine 
days after injection, vKH1 produced compact islands of infected cells, whereas vKH6 
produced a more diffuse pattern, suggesting that vKH6 may spread better through tumour 
tissue (Fig. 14A). To determine whether the spectrum of organs infected was altered by 
insertion of the RGD peptide, which can bind to multiple different integrins, the 
biodistribution was tested (Fig. 14B). 
Virus was injected into the tail vein as described above and organs were harvested for 
quantitative PCR 24 hours later. Compared to other organs, there was less viral DNA than 
expected in liver after injection of the virus with native tropism (vKH1). This may be related to 
the fractionated dosing schedule, which leads to clearance of Kupffer cells. The amount of 
viral DNA was 10 to 100 times higher in the tumours infected with the RGD viruses, 
consistent with the in vitro data showing that SW620 is more susceptible to infection with 
vKH6 than vKH1. The amount of viral DNA was similar for the viruses with native or 
modified tropism in all mouse organs except liver, where the amount was increased 50-fold for 
vKH3 and vKH6. Wild type adenovirus is lethal after i.v. injection of 1010 particles (Fig. 14C). 
This is caused by virus replication in the liver and fulminant hepatic necrosis229. None of the 
mice treated with the Tcf viruses developed fatal liver necrosis after injection of 10 times the 
lethal dose of wild-type virus (Fig. 14C). Consistent with the increased liver infection seen by 
quantitation of viral DNA, there was an inflammatory infiltrate in the region around the 
central veins of the mice 3 days after receiving vKH6 (Fig. 14C, arrows). The inflammatory 
infiltrates resolved completely and were undetectable 20 days after the last virus injection. The 
lack of overt signs of illness in the mice receiving the Tcf viruses indicates that the increased 
ability of the RGD viruses to infect the liver is more than offset by the reduction in toxicity 
caused by Tcf regulation of the early promoters.  
To test whether the increased ability of vKH6 to infect SW620 cells in vitro leads to 
increased efficacy in vivo, xenograft growth was analyzed after i.v. injection of virus. Two 
regimens were compared: injection on a single day (total 1011 particles injected) and injection 
on 3 days at weekly intervals (total 3x1011 particles injected). In both cases, the virus was 
fractionated on the day of injection to circumvent Kupffer cell clearance. Three courses of 
injection at weekly intervals (Fig. 15A, open symbols) were more effective than injection on a 
single day (closed symbols). The RGD modified virus, vKH6 (triangles), was more effective 
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than vKH1 (circles). Even in the best case, however, most of the tumours eventually relapsed. 
Quantitative PCR showed that there was a large amount of viral DNA present in the tumours 
at the time of relapse (data not shown). To understand why the virus had failed to control 
tumour growth, tumours were examined for viral DNA by FISH at different time points. 
Three days after infection, virus was found in isolated clusters of cells, corresponding to the 
cells infected with the injected virus and its progeny after one cycle of replication. At later time 
points, the infected regions expanded to form confluent areas of infection in some parts of the 
tumour (Fig. 15B). Relapse can be explained by uncontrolled growth of tumour regions that 
are devoid of virus. This is consistent with theoretical models showing that tumour cell spread 
generally outpaces virus spread.230 
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Figure 14. In vivo characterization of Tcf-regulated adenoviruses. A; FISH for viral DNA in SW620 xenografts 5 days after i.v. 
injection of 1011 particles of vKH1 and vKH6. Red, viral DNA (FISH); blue, cell nuclei (DAPI). Bar, 200 µm. B; biodistribution 
of vKH1, vKH3, and vKH6 24 hours after i.v. injection of 1011 particles of virus. Each column represents three individual 
experiments. Viral DNA was measured by quantitative PCR. C; liver histology 3 days after i.v. injection of virus. Wild-type Ad5, 
1010 particles; vKH1 and vKH6, 1011 particles. Arrows show inflammatory infiltrates around the central vein with vKH6. Bar, 
100 µm. 
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Figure 15. Xenograft infection with virus alone. A; growth curves of s.c. SW620 xenografts in nude mice (five 
mice per group). Viral treatment started when tumors reached 100 mm3. Circles, vKH1. Triangles, vKH6. Closed 
symbols, 1011 particles of virus i.v. on day 0. Open symbols, 1011 particles of virus i.v. on days 0, 7, and 14. × 
control (buffer injection). B; FISH for viral DNA in tumors 9 days after i.v. injection of 1011 particles of virus. 
The whole tumor is shown to demonstrate the patchy distribution of virus. Red, viral DNA. Scale bar:  1mm. 
(FISH); blue, cell nuclei (DAPI). Bar, 500 Am. The red fluorescence at the 
tumour margin (arrow) is caused by autofluorescence of erythrocytes not 
Days 
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2.3.  Combination therapy with cytotoxic compounds 
 
To improve the therapeutic effect of adenoviruses several groups have suggested to 
combine adenovirus with cytotoxic agents.52,231,232 The current chemotherapy of colon cancer 
consists of combination therapy with three compounds233: 5-fluoro-uracil/leucovorin, 
irinotecan and oxaliplatin. These drugs influence the cellular DNA at different levels.  
• 5-fluoro-uracil acts in several ways: it inhibits thymidilate synthase, alters DNA 
stability, induces single and double stranded breaks, and reduces RNA 
stability.234  
• Irinotecan is a DNA topoisomerase I inhibitor235 and it promotes the 
formation of double stranded breaks.  
• Oxaliplatin causes adduct formation between DNA and protein.236 Protein-
DNA adducts block DNA synthesis and induce DNA strand breaks.  
 I tested the combination of 5 fluoro-uracil and irinotecan with vKH1. In CPE assays  
irinotecan shows no increase in viral cytopathic effect on SW480 cells (Fig. 16A) nor on other 
cell lines. 5-Fluoro-uracil helped vKH1 on SW480 but not on other cell lines. In vivo these 
drugs are very toxic and administration to mice resulted in 30% to 50% weight loss. Hence in 
vivo experiments were discontinued. 
Taxol is an inhibitor of microtubule disassembly237. Taxol is not used in the therapy of 
colon cancer. However, it was shown that blocking microtubule disassembly can help viral 
entry and trafficking due to the increased viral transport to the nuclei of the tumour cells.238,239  
A PSA promoter-regulated virus, CV787, was shown to synergise with taxol both in vitro in 
prostate cancer cell lines and in vivo in xenografts.240 Colon cancer cell lines show variable 
sensitivity to taxol (data not shown), Co115 being the most sensitive. Taxol reduces the E1A 
expression in all the cell lines tested 24 hours after infection by vKH1 (Fig 9.B). In an MTT 
assay in SW620 cells taxol has no effect or slightly helps vKH1 at high MOIs.  
In conclusion, conventional chemotherapy drugs have little or no effect on viral cell 
killing by adenovirus. These compounds may influence viral DNA replication. Careful timing 
might be necessary to avoid inhibition of viral replication. The addition of cytotoxic 
compounds before or after the virus infection may have an effect on the viral cytopathic 
effect. 
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2.4       RAD001 and TCF viruses in vitro 
Figure 16. Combination of cytotoxic compounds with adenovirus A; CPE assays for the combination of 1 
and 0.1 MOI/cell adenovirus infection with either Irinotecan or 5FU. Cells were infected for 4 hours and then 
the medium was changed containing increasing amounts of the compounds. B; Western blot for E1A protein. 
Cells were infected with 1 MOI/cell and co-treated with 2.5 nM taxol. M: Mock; V: virus alone; VT virus plus 
taxol C; MTT assay for cellular death on SW620 cells. Cells were infected with serial dilutions of adenovirus 
and co-treated with 2.5 nM taxol. MTT reagent was added 6 days after infection 
Irinot  
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2.4 Combination therapy with RAD001 
2.4.1    Rationale 
 
 The initial rate and distribution of the tumour infection does not allow adenovirus to control  
the tumour growth. Combination of adenovirus with cytotoxic compounds is not attractive 
because of possible interference with viral replication. Combination of new therapeutic agents, 
like angiogenesis inhibitors, with viral therapy is of interest since these compounds will slow 
down the tumour growth without influencing viral replication.  RAD001 is a rapamycin 
derivative which blocks mTOR in the PI3K pathway.241 RAD001 is a strong inhibitor of 
cellular growth and mRNA translation. RAD001 also blocks angiogenesis242 and it is an 
immunosuppressant.243 Rapid induction of a humoral immune response limits the therapeutic 
response upon readministration of the virus. 244  
 
  
2.4.2     RAD001 and virus in vitro 
 
RAD001 is an mTOR inhibitor that inhibits tumour cell growth directly, blocks 
angiogenesis, and suppresses the immune response. To determine whether RAD001 interferes 
with translation of adenoviral proteins, a Western blot was done in the presence or absence of 
RAD001. There was no evidence of inhibition of viral protein expression (Fig. 17A). 
Quantitation of viral DNA 48 hours after infection showed only a small effect of RAD001 (in 
most cell lines, there was a slight increase in replication in the presence of the drug; Fig. 17B). 
In vitro efficacy was tested in cytopathic effect and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide assays (Fig. 17C). Both showed either no effect or a 5- to 10-fold 
increase in efficacy in the presence of the drug.   
Recently O’Shea et al.39 published that the replication of adenovirus requires active 
PI3K signalling. It was also shown that two E4 transcripts, E4orf4 and E4orf1 are responsible 
for activation of the pathway in infected confluent primary epithelial cells (small airway 
epithelial cells, SAECs).  E4orf1 activates the PI3 kinase which phosporylates Akt/PKB. 
E4orf4 activates the downstream member of the pathway mTOR. O’Shea also showed that 
virus deleted for E4orf1 and E4orf4 was unable to replicate in cells lacking activation of the 
PI3K pathway and suggested that these viruses will preferentially replicate in tumour cells.  
   Based on these data RAD001 should inhibit viral replication both in normal cells and in  
tumour cells but I have shown that the virus is not inhibited by RAD001 and in some cell lines 
it slightly helps viral replication. To investigate the interaction of RAD001 and viral replication, 
western blotting was performed to test the phosphorylation of Akt on S473. (Fig. 17D). S473 
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phosphorylation is essential for the full activation of Akt. S473 boosts subsequent 
phosphorylation by PDK1 on T308. Two different cell lines were tested: SW480 and HT29. In 
SW480 the virus and RAD001 show an additive effect in a CPE assay. In HT29, no further 
increase in CPE by RAD001 was detected. In SW480, RAD001 alone did not induce 
phosporylation of Akt on S473. Virus alone caused a pronounced Akt phosphorylation which 
was partially blocked by the PI3K inhibitor, LY290041. This result confirms that adenovirus 
activates Akt partly by activating PI3K. Surprisingly, rather than inhibiting Akt 
phosphorylation in SW480, RAD001 actually increased it.  
 HT29 is PTEN mutant and Akt is constitutively phosphorylated on S473. Infection by  
adenovirus further increased Akt phosphorylation but virus induced phosphorylation was not 
affected by RAD001 or by LY290041. Since PI3K is already fully active in HT29 adenovirus 
may activate Akt by another kinase than PI3K. The result in SW480 was unexpected. New 
studies have shown175,245 that inhibition of mTOR, in certain cell lines, can increase Akt 
phosphorylation.246 Rapamycin binds FKBP12 which in turn binds to mTORC1 (mTOR 
Complex1: mTOR/Raptor). This binding dissociates mTOR from Raptor and promotes 
mTOR binding to Rictor, and forms mTORC2 (mTOR Complex 2). The mTOR/Rictor 
complex then can phosphorylate Akt. Adenovirus therefore might act distinctively from the 
mTOR-Raptor complex and viral proteins might influence the mTOR-Rictor complex. To test 
this hypothesis I made a lentivirus expressing microRNA against Rictor. I am currently testing 
whether silencing Rictor can affect the viral replication. 
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Figure 17. Effect of RAD001 on vKH6 virus infection in vitro. A; Western blot for E1A and DBP protein 
expression 24 and 48 hours after infection. B; viral DNA replication was analyzed by quantitative PCR for 
viral DNA 48 hours after infection. Cells were infected at a moi of 1. RAD001 was added 4 hours after 
infection. C; cytopathic effect assay in the presence (+) or absence (-) or RAD001. Cells were infected with 
10-fold dilutions of virus starting at a moi of 1,000 and stained with crystal violet on day 6. D; Western blot 
for P-Akt. Cells were infected at 1 pfu/cell with vKH1 or mock infected. RAD001 (3.6 nM) or LY294002 
(50 µM) was added 4 hours after infection.  
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2.4.3.    RAD001 and virus in vivo 
 
To test whether RAD001 inhibits replication in vivo, an SW620 xenograft was infected 
by the i.v. route as above, and the amount and distribution of viral DNA in the tumour were 
examined after prolonged treatment of the mice with RAD001. Quantitative PCR showed that 
a large amount of viral DNA was present in tumours even after treatment with RAD001 for 6 
weeks (Fig. 18A). Widespread areas of the tumour were also positive by FISH for viral DNA 
after RAD001 treatment for 6 weeks (Fig.18B). Some of the FISH signal comes from cell 
debris in areas of necrosis, but the strongest signals are from the nuclei of living cells that are 
undergoing productive viral infection. Therefore, RAD001 does not inhibit virus growth in 
tumour cells in vitro or in vivo. 
 In addition to its effect on mTOR in the tumour, RAD001 is known to suppress the 
immune response by inhibiting mTOR in lymphocytes. The induction of a neutralizing 
antibody response is thought to limit the efficacy of oncolytic adenoviruses in vivo. To 
confirm that RAD001 can prevent induction of a primary antibody response against 
adenovirus, immunocompetent mice were treated with RAD001 and then immunized with 
adenovirus. As expected, RAD001 was able completely to block the primary antibody 
response to virus247(Fig. 18C). 
 The efficacy of combination therapy in vivo was tested by giving i.v. virus followed by 
daily oral RAD001. The virus was given according to the same schedules as in Fig. 15A. 
RAD001 was withheld the day before and on the day of virus injection, on the grounds that 
antivascular effects of the drug might limit access of the virus to the tumour. Mice treated with 
placebo (gavage with the vehicle used for the RAD001) all had to be sacrificed because of 
uncontrolled tumour growth by day 20 (Fig. 19A). This reflects the rapid growth of SW620 
xenografts once the tumours reach 100 mm3. The start of the experiment was delayed until the 
tumours reached 80 to 150 mm3 to ensure that they had developed a vascular tree that could 
be called on to deliver the virus after i.v. injection. Consistent with the known low toxicity of 
RAD001, there was no weight loss in RAD001-treated mice after 20 days of treatment. 
RAD001 alone was more effective than virus alone in slowing growth of the tumours, but by 
40 days most mice still had to be sacrificed because of progressive tumour growth (Fig. 19B). 
Tumours treated with the combination showed markedly better responses: only one mouse in 
each vKH1 plus RAD001 group had to be sacrificed, and no mice in either vKH6 plus 
RAD001 group had to be sacrificed before the end of the experiment 40 days after the first 
virus injection (Fig. 19B). The difference between the survival of the control and virus + 
RAD001 groups was significant in every case (P < 0.01). The smallest difference in survival 
was between that of the RAD001 alone and virus + RAD001 groups: it achieved significance 
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(P < 0.05) for the 1× vKH1, 1×  vKH6, and 3×  vKH6 groups but not the 3×  vKH1 group. 
The failure of the 3× vKH1 + RAD001 versus RAD001 alone survival difference to reach 
significance is explained by the small number of animals. Analysis of the growth curves (Fig. 
19A) showed that at the time the first mouse was sacrificed in the RAD001 alone group (day 
28), there was a significant difference in tumour size in the 3×  vKH1 + RAD001 versus 
RAD001 alone groups (P < 0.05). The mechanism for the interaction between oncolytic virus 
and RAD001 is unlikely to be related to the immunosuppressant effect of the drug because the 
mice were immunodeficient to allow xenografting. It could be partially explained by a direct 
inhibitory effect on the tumour cells, given that the drug slightly increased the cytopathic effect 
of the virus in vitro (Fig. 17C). Histologic examination of the tumours showed that RAD001-
treated tumours had the typical appearance of poorly vascularized tumours, with a rim of 
viable cells and a large central necrotic core, in contrast with the untreated tumours, which 
contained uniform sheets of viable cells with only patchy necrosis (Fig. 18D). It is likely that 
this antivascular effect contributed importantly to the interaction between virus and drug, 
substantially delaying the growth of the tumour while still allowing the virus to spread within it.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 56 
A
B
C
D
1x vKH1 3x vKH1 1x vKH6 3x vKH6 
0
1000
2000
3000
4000
5000
6000
7000
V
ira
l D
N
A 
co
pi
es
/ce
ll
vKH1 vKH1
+RAD
Control Virus
0
25
50
75
100
R
e
la
tiv
e 
u
n
it
Virus 
+ RAD
R
el
at
iv
e 
O
D
 
u
n
it
 
 
 
 
 
 
 
Figure 18. Effect of RAD001 in vivo. A; quantitative PCR for viral DNA in tumors 6 weeks after i.v. 
injection of vKH1 or vKH6. The mice received 1 or 3 days of treatment with 1011 particles of virus per day 
and daily RAD001. B; FISH for viral DNA in a tumor 6 weeks after i.v. injection of 1011 particles of vKH1 
and daily RAD001. Red, viral DNA (FISH); blue, cell nuclei (DAPI). Bar, 100 µm. C; ELISA for 
antiadenovirus antibody. Groups of four mice received RAD001 or placebo for 5 days followed by i.v. 
injection of 109 particles of vKH1. The titer of antiadenovirus antibodies in serum was measured by ELISA 
21 days after infection. D; histology of s.c. SW620 xenografts in mice treated with RAD001. Left, day 20 
after i.v. injection of vKH1 1011 particles; right, day 40 after i.v. injection of vKH1 1011 particles and daily 
RAD001. H&E staining. Bar, 100 µm. 
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2.4.4. Discussion 
 
 
Figure 19. Effect of RAD001 on tumor response in vivo. A; growth curves of s.c. SW620 xenografts in NMRI 
nu/nu mice. E, ▲ vKH6 and daily RAD001; ● vKH1 and daily RAD001; ■, daily RAD001 alone; ×, control. 
Virus injections are indicated by arrows. 1× virus injection: mice received 1011 particles of the virus i.v. on day 
0; 3× virus injection: mice received 1011 particles of the virus i.v. on days 0, 7, and 14. The control group 
received placebo (RAD001 vehicle) by daily gavage. B; Kaplan-Meier curves showing the fraction of mice with 
SW620 xenografts <1,000 mm3 [the corresponding growth curves are shown in Figs. 3A and (A)]. Each group 
contained five mice. Virus injections are indicated by arrows. V+R, virus plus RAD001; R, RAD001 alone; V, 
virus alone; C, control. 
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2.4.4 Discussion 
 
The major current limitation to the development of oncolytic viruses is the low 
efficacy of the viruses in vivo97. Virus plus RAD001 significantly slowed tumour growth 
and prolonged the survival of the treated animals. Combination therapy with RAD001 and 
RGD-modified viruses gave the best results. Although the ideal targeting ligand would lead 
to selective infection of cells in the tumour, no viruses selectively infecting tumour cells 
have yet shown high efficacy in vivo. The main concern is to preserve activity of the virus 
on tumour cells. The two approaches most widely used are to target heparan sulfate 
proteoglycans with poly-lysine or to target integrins with RGD. Neither change impairs the 
ability of the virus to infect cells through CAR. A virus using all three routes of infection 
has been produced and shows promise in ovarian cancer.248  
A potential drawback of this approach is that the viruses are not tumour specific, 
and side effects caused by infection of normal cells are potentially increased. Insertion of 
the RGD peptide into the Tcf-regulated viruses substantially enhanced its ability to infect 
tumour cells, and increased the amount of viral DNA that could be recovered from tumour 
and liver at 24 hours. The normal tissues where the Wnt pathway is likely to be active are 
stem cells in the skin, haematopoietic system and intestine, and neurons in the several 
regions of the brain, including the subventricular zone, cortex, and hippocampus.249 There 
was a small increase in the amount of viral DNA detectable in skin with vKH6, albeit to a 
very low level, and no change in the amount of viral DNA in brain or intestine. The liver 
was the major site of toxicity. The efficiency of infection depends on the relative 
expression of receptors on the cells and ligands on the viruses. It is likely that insertion of 
the RGD peptide alters the distribution of virus within the liver to take advantage of 
integrin expression by hepatocytes.195 Liver infection resulted in the formation of 
inflammatory infiltrates at early time points. In immunocompetent mice, the acute response 
is normally followed by T-cell infiltration and acquired immunity. In the immunodeficient 
mice used here, the inflammatory infiltrates completely resolved by 20 days. Inflammatory 
infiltrates around the central veins in the liver were accompanied by viral replication in 
occasional hepatocytes, which could be detected by FISH. Compared with infection by 
wild-type virus, which produced fulminant liver necrosis after injection of 1010 particles, 
the RGD viruses were very well tolerated by the mice after injection of 10 times more 
virus. This must reflect the decrease in expression of viral proteins caused by Tcf 
regulation of the early promoters. I have not constructed Ad5 with wild-type promoters and 
RGD in the fibre, but one might reasonably expect such a virus to produce liver necrosis at 
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lower doses than the wild-type virus. Compared to such a virus, Tcf-regulated viruses 
would probably be >100-fold less toxic to the liver.  
The other major toxicity that has been reported for systemically administered 
adenoviral vectors in mice is acute hypotension.199 About one third of the mice in the 
vKH6 group showed signs consistent with hypotension after the first injection of virus, but 
no mice died as a result. There were no overt clinical changes after subsequent injections, 
consistent with reports that the initial hypotension is caused by activation of Kupffer cells, 
which are then eliminated.199  
Many classic chemotherapeutic drugs have been tested in combination with 
oncolytic viruses.250 The combination of 5-fluoro uracil and irinotecan in patients with 
advanced malignancies failed to show any sign of additional effect.50,52,251 With the 
exception of taxanes, which act on microtubules, most of these drugs are expected to inhibit 
viral DNA replication. RAD001 has several attractive properties for combination therapy 
with oncolytic viruses. It has no known inhibitory effect on viral DNA replication, it 
inhibits tumour cell growth directly, it blocks tumour angiogenesis, and it specifically 
inhibits the immune response. A major advantage of RAD001 is its low toxicity compared 
with standard chemotherapeutic agents. RAD001 inhibits translation of cellular mRNAs 
with highly structured 5’-untranslated regions by blocking phosphorylation of 4E-BP1.252 
Early in adenovirus infections, there is an E1A-dependent increase in 4E-BP1 
phosphorylation, which can be blocked by rapamycin.253 Despite this potentially adverse 
interaction, there was a small increase in cytopathic effect and viral DNA replication in the 
presence of RAD001 in most of the tumour cell lines that were tested. One interpretation is 
that induction of 4E-BP1 phosphorylation by the virus is more important in quiescent 
normal cells than in tumour cells. Late in infection, the virus uses the L4 100 K protein to 
inhibit translation of capped cellular mRNAs by competing for Mnk1 binding to eIF4G.45 
The 100 K protein contains an RNA-binding domain that binds to the tripartite leader 
sequence in late mRNAs. This allows selective translation of late viral RNAs by ribosome 
shunting, a process that is independent of scanning by eIF4A.254 It can be speculated that 
this process is largely resistant to RAD001.  
RAD001 is an orally active derivative of rapamycin, a well characterized 
immunosuppressant that is used clinically in organ transplant recipients. Therapy with 
oncolytic adenoviruses induces a strong neutralizing antibody response in all patients.251 
This is a particular concern for treatment schedules involving multiple cycles of virus 
injection. Most viruses already manipulate the immune system in some way, but total 
suppression of the immune response by a virally encoded gene would raise obvious 
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biosafety concerns. Transient immune suppression by a drug avoids this problem. Several 
approaches have been tested to suppress the immune response, including the use of anti-
CD40 antibodies.255 RAD001 is more suitable for combination with viral therapy than 
cyclosporin, because cyclosporin stimulates the formation of tumour blood vessels.256 
RAD001 can suppress the primary immune response to adenovirus in mice, but most 
patients already have anti-Ad5 antibodies following Ad5 infection in childhood. This 
means that what is required is the ability to suppress a secondary immune response, which 
is a much more difficult task. One way to investigate this problem would be to use 
immunocompetent mouse tumour models, some of which may be permissive for Tcf-
regulated viruses.257  
Combination therapy with oncolytic viruses and RAD001 is more effective than 
treatment with either agent alone. Mathematical modeling suggests that seeding of virus to 
multiple sites in the tumour is essential to achieve rapid spread of the virus throughout the 
tumour mass, which is a prerequisite for cure of the disease.230 The main requirement is to 
deliver large amounts of virus to as many regions of the tumour as possible at the start of 
treatment. Tumour blood vessels are disorganized and leaky, which should favour escape 
of the virus from the circulation, but this is counterbalanced by high interstitial fluid 
pressure within the tumour and a thickened basement membrane, which are known to 
reduce delivery of macromolecules to the tumour.258 Antiangiogenic therapy, for example, 
with antibodies against vascular endothelial growth factor (VEGF, bevacizumab) or 
VEGFR2 (CD101), transiently normalizes the vasculature and lowers interstitial fluid 
pressure.259,260 This so-called ‘‘normalization window’’ is associated with pericyte 
recruitment and thinning of the basement membrane. Adenovirus is large (90 nm) 
compared with normal drugs, but smaller than the pores in tumour blood vessels (>200 
nm). The ideal solution would be to normalize the vessels to thin the basement membrane 
and then transiently increase vessel permeability at the time of virus injection. TNFα is 
known to increase the permeability of tumour blood vessels, but in preliminary experiments 
an increase in hepatotoxicity after low-dose TNFα therapy was observed. Systemic therapy 
with VEGF is unattractive because it increases permeability indiscriminately.261 
Rapamycin and RAD001 block VEGF induction.262 To exploit this fact a weekly dosing 
schedule was used in which RAD001 was withdrawn the day before giving the virus. This 
schedule might result in normalization of the vasculature during RAD001 treatment, 
followed by induction of vessel leakiness by a burst of VEGF secretion around the time of 
virus injection. Because the precise timing of the change in perfusion upon RAD001 
treatment is unclear, it is possible that other schedules would give even better results. There 
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are clearly many possible levels of interaction between antiangiogenic therapy and 
oncolytic viruses. The important conclusion is that oncolytic viruses are particularly well 
suited to combination with antiangiogenic therapy. 
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2.5 Systemic delivery of adenovirus 
 
2.5.1 Rationale 
 
 The rate of initial infection of tumor xenograft by adenovirus is low and uninfected regions 
 overgrow the virus infected regions despite viral spread and efficient replication. In the 
previous results section I discussed the possibility of slowing down tumour growth by using 
RAD001. Another way to increase the control of tumour growth by adenovirus gene therapy 
is to increase the initial rate of infection. The therapy is limited by the short half life of 
adenovirus in blood (less than 2 minutes)192 which is due to the rapid clearance of adenovirus 
by Kupffer cells (KC) and by other non-target cells. It has already been shown that depletion 
of KCs increases the efficacy of gene delivery by non-replicating adenoviral vectors to the 
liver.193 KCs can be inhibited and removed from the liver by using drugs that are scavenged 
from the circulation by KCs. Two compounds have been shown to achieve efficient Kupffer 
cell depletion are gadolinium chloride and clodronate-containing liposomes.  
 Gadolinium chloride is a contrast agent used clinically for magnetic resonance imaging (MRI)  
technology. It is a heavy metal. Kupffer cells scavenge gadolinium from the circulation. Four 
to eight hours after intravenous injection of gadolinium chloride, KCs disappear from the 
liver.195 It has been speculated that at neutral pH in the bloodstream gadolinium chloride forms 
a colloidal precipitate which is phagocytosed by KCs and dissolves in the acidic environment 
within the lysosomes, resulting in cell destruction. A single injection of gadolinium chloride 
blocks phagocytosis in more than 90% of KCs.263 Gadolinium was shown to increase the 
transgene expression of second and third generation (gutless) adenovirus vectors in the liver.193 
 Liposomes are widely used in medical therapy to allow slow release of compounds and to  
reduce side effects.193,264 Clodronate is a bis-phosphonate derivative. Bis-phosphonates were 
originally described and used for the therapy of hypercalcaemia in patients with bone derived 
malignancies or more often with cancer metastases to bone.265,266 Clodronate blocks the 
osteoclasts in bone.267 Osteoclasts are bone-associated macrophages and are tightly regulated 
by endocrine mechanisms. Osteoclasts remove Ca-phosphate from the bone and increase the 
blood Ca++ content. Clodronate therefore reduces the calcium level of blood.268 Other bis-
phosphonates (Zoledronate) recently have been implicated in TNFα-dependent inhibition of 
Focal Adhesion Kinase (FAK) and Akt/PKB in endothelial cells. This effect might contribute 
to the TNFα dependent death of endothelial cells and to the effect of bis-phosphonates on 
bone metastases.269  Clodronate liposomes similar to gadolinium chloride were shown to 
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eliminate KCs from the liver and to increase transgene expression from non-replicating 
adenoviral vectors in the liver.270  
 Finally, KCs can be blocked by adenoviral vectors.271 It has been shown that 2.5x1010 viral  
particles of a non-replicating gutless vector can block KCs and induce their disappearance 
from the liver.198 I used low dose adenovirus pre-treatment in the previous results section 
(Fig15A). The total virus dose was injected in four separate injections. Each dose contained 
2.5x1010 particles. The first dose probably removed Kupffer cells. It would have been possible 
to give the rest of the dose in one injection, however it was previously hypothesised that the 
tumour vessels are randomly perfused.272 Therefore, 4 hour spacing between the injections 
could allow a more even infection of the tumour. Gadolinium chloride and clodronate had not 
been tested previously in adenovirus cancer gene  
therapy models. 
 
2.5.2 Results with Gadolinium Chloride 
 
 Mice were pre-treated with gadolinium chloride (10mg/kg of body weight) 48 and 24 hours  
before virus injection. Gadolinium pre-treatment reduced the viral copy number of vKH3 in 
the liver. Three days after injection of vKH3, the number of viral genomes in the SW620 
xenograft was not increased by the gadolinium pre-treatment (Fig. 20A).  Six days after 
injection, virus replication increased the number of viral genomes in the control tumour by a 
factor of 10. Surprisingly, in the gadolinium treated mice the viral copy number in the tumour 
fell. FISH for viral DNA confirmed that in the liver the number of infected hepatocytes is 
lower after gadolinium treatment (Fig. 20C). In the gadolinium treated xenografts vKH3 failed 
to initiate viral replication foci (Fig. 20E). These results suggest that gadolinium can reduce the 
infection of liver, possibly by removing Kupffer cells and that hepatocyte infection might 
necessitate the presence of Kupffer cells. Gadolinium also blocked the infection of tumour 
cells by vKH3.  
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Figure 20. The effect of gadolinium chloride pre-treatment on viral distribution. A; Viral copy 
number measured by Q-PCR in liver and in tumour 3 days and 6 days after virus injection. B-
E; FISH for viral DNA in liver and in SW620 xenografts 3 days after injection of 1011 viral 
particles. Pink: replicating virus. Blue: DAPI. Yellow, red blood cells. 1011 viral particles of 
vKH3 was injected alone, (B: Liver; D: Tumour) or after gadolinium pre-treatment, (C: Liver; 
E: Tumour). Scale bar: B, D, E: 100 µM, C: 50 µM 
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Figure 21. Quantitative PCR for adenoviral genome 24 hours after i.v. injection of 1011 particles  
A: liver; B SW620 Xenograft. C, FISH for viral DNA in SW620 s.c. xenograft 3 days after virus 
injection and 5 days after Clodronate liposome treatment. Blue: DAPI, Pink: Viral DNA 
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Figure 22. HPMA coating of vKH1 and vKH6. vKH1 and vKH6 were incubated with 
different concentrations of HPMA for 8 hours at room temperature and then at 4ºC 
overnight. At 2.5 mg/ml HPMA the fibre of the viruses was partially coated as shown by 
western blotting for fibre.   
 
2.5.3 Results with Clodronate liposomes and HPMA coating 
 
Since no viral infection or replication was detected in tumours where mice were pre-treated with 
gadolinium chloride, I was interested in knowing if other KC depleting compounds show the 
same effect. Two mg/kg clodronate liposome was injected into the tail vein of a mouse, 2 days 
before the viral treatment. Similar to mice receiving gadolinium or virus pre-treatment, mice 
receiving clodoronate liposomes show signs of lethargy and skin flushing. The lethargy and 
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flushing can be interpreted as activation of the Kupffer cells. This activation results in the release 
of cytokines and nitrates199,273. Nitrates act on endothelial cells to induce hypotension. 
The clodronate liposomes reduced the copy number of vKH6 in the liver 24 hours after 
injection (Fig 21A). The viral uptake by the tumour was also reduced in the SW620 xenograft 
(Fig. 21B). The virus could infect the SW620 xenograft. The number of foci, however, was 
reduced indicating a reduced rate of infection. The size of the foci did not differ from that of the 
control group showing that the viral replication and spread were not hampered by clodronate 
liposomes (Fig. 21C). Despite reducing the level of liver infection clodronate liposomes could 
not increase the infection of tumour cells but did permit viral replication. 
Liver infection by adenovirus is also dependent on different components of the blood. Blood, 
however, not only promotes liver infection but also immobilizes adenovirus. The adenovirus 
capsid can bind to both red blood cells and platelets which therefore sequester adenovirus from 
the plasma and reduce the available adenovirus titer reaching the tumour274. In humans 
adenovirus infection is efficiently blocked by circulating neutralising antibodies.     
These interactions can be blocked by coating adenovirus with polymers. The first coating 
method proposed for adenovirus used poly-ethylene-glycol (PEG). It has been shown that PEG 
can efficiently reduce liver infection.275 N-(2-Hydroxypropyl) methacrylamide (HPMA) has also 
been used to coat adenovirus. HPMA shows remarkable effects: it can reduce liver infection and 
increase the half life of polymer-coated virus in the blood.276 HPMA coating can also reduce 
interaction of the virus with red blood cells and platelets of human and murine blood. Finally 
HPMA can avoid the induction of neutralising antibodies277. The main disadvantage of virus 
coating is that the virus has to be retargeted to the target tissue. Large proteins, like FGF and 
EGF, or antibodies, like Herceptin, have been successfully used in retargeting.277 Smaller 
peptides, like RGD and SYGPLIP, are also able to retarget the virus.278 These retargeting 
methods, however, require several additional manipulations after virus production.  
I hypothesised that the capsid-unmodified and the capsid-modified TCF viruses, vKH1 and 
vKH6, might behave differently when coated in the presence of low concentrations of HPMA. 
HPMA creates intermolecular bridges through covalently binding to lysines. The HPMA coating 
shields the virus with several layers of the polymer and more extensive coating produces a 
thicker shield. The CDCRGDCFC targeting sequence protrudes from the adenovirus fibre knob 
and therefore, could potentially avoid coating (Fig.23).  
HPMA coating inhibits the non-retargeted virus, vKH1, at 2.5 mg/ml concentration of HPMA, 
while vKH6 was only blocked at 20 mg/ml HPMA (Fig 22C). Western blotting of the HPMA 
treated virus for fibre shows that at 2.5 mg/ml both vKH1 and vKH6 fibres are almost 
completely shifted to higher molecular weights indicating almost complete HPMA coating. At 
higher concentration HPMA coating is complete. This indicates that the difference in viral CPE 
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(Fig. 22C) is not caused by a lack of crosslinking HPMA to the fibre and therefore might allow 
effective coating of the virus and retargeting through genetic modification of the capsid.  
In vivo, 5 mg/ml HPMA coating reduced the viral copy number of both vKH1 and vKH6 in 
the liver. Clodronate liposome pre-treatment cannot further reduce the liver infection by HPMA 
coated vKH6. In the xenograft model, as predicted, vKH1 is blocked by the 5 mg/ml HPMA 
coating. However, HPMA coated vKH6 is able to infect and replicate in the tumour but 
clodronate liposome pre-treatment cannot increase the viral infection by HPMA coated vKH6.   
 
2.5.4 Discussion 
  
Inhibition of Kupffer cell function is of great interest in adenoviral cancer gene therapy. 
Gadolinium is a well known contrast agent and it has been extensively studied and evaluated.279 
Gadolinium is very potent in removing Kupffer cells and reducing adenovirus sequestration 
from the blood by Kupffer cells. However, it might also block uptake of the virus into tumour 
cells. It is unknown how gadolinium would affect the uptake of the virus by tumour cells but it 
is possible that adenovirus interacts with gadolinium. Similar to blood factors gadolinium might 
“opsonise” adenovirus by forming virus-gadolinium complexes in the blood. In the tumour no 
viral infection was detected but a very strong pepper-like staining was present. The FISH 
detection method used here might not be able to detect a single copy of viral DNA but could 
detect deposits of ineffective viral particles. Another possibility is that gadolinium blocks tumour 
associated macrophages. It has been shown that tumour associated macrophages are important 
for the development and maintenance of the neo-angiogenic tumour vasculature.280 Clodronate 
liposomes can block tumour macrophages and angiogenesis and can delay the growth of tumour 
xenografts (R. Schwendener pers. communication). This effect however, was only seen after 
continuous treatment with clodronate liposomes. It can be speculated that gadolinium is a more 
potent inhibitor of macrophages than clodronate liposomes. Gadolinium might destroy the 
tumour associated macrophages which surround the blood vessels in the tumour while 
clodronate liposomes only affect Kupffer cells. After gadolinium chloride pre-treatment blood 
vessels might collapse and block the ability of the virus to exit from the vessels. 
The clodronate liposomes at 2 mg/kg of body weight concentration reduced the liver infection 
by vKH6 almost to the level of infection by vKH1. The infection of the SW620 xenograft by 
vKH6 was also reduced after clodronate liposome pre-treatment.  Clodronate liposomes, 
however did not block viral replication in the tumour suggesting a different effect from 
gadolinium chloride.  
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Figure 23. Schematic presentation of the differential coating method.  HPMA coating of a wild type 
virus will cover the knob of the fibre and also block the uptake of the virus into any cell type (Panel 
A). HPMA coating of an HI loop retargeted virus will be less sensitive to a low concentration 
HPMA coating because of the HI loop extension. The virus will be taken up depending on the 
selectivity of the targeting ligand. Extensive coating would block both viruses.  
 
 
Retargeted oncolytic adenoviruses can be differentially coated using low concentrations of HPMA. 
This coating still allows the HI loop modified virus to infect tumour cells and might retain some of 
the advantages given by the coating. More extensive coating would be necessary to ensure the 
maximum advantages offered by HPMA coating. More expanded coating, however would block the 
infection by the RGD peptide. Increasing the length of the HI loop of the knob domain of fibre, 
might permit more extensive coating. This method would also simplify the generation of other 
polymer-coated genetically retargeted vectors.       
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2.6 Ovarian cancer models 
 
2.6.1 Rationale 
 
Cancers from origins other than colon were shown to have active Wnt signalling (Table 2). Some of 
these cancers are extremely rare, like pilomatricoma that arises from hair follicles. Ovarian cancer 
and hepatocellular carcinoma are frequent and very aggressive malignancies. Ovarian cancer remains 
undetected for a long time and when discovered the tumour has usually already spread in the 
abdominal cavity from the primary tumour site and formed large untreatable peritoneal metastases.  
Cancer type Mutant (%) 
Colon 90 281 
Pilomatricoma 75 281 
Hepatoblastoma 50 
Hepatocellular carcinoma 30 282 
Pancreatic Solid-pseudopapillary neoplasm (SPN) 80 283 
AnaplasticThyroid 65 
Ovarian cancer 25 284 
Endometrial 45 285 
Wilms Tumour 15 
Desmoid 50 286 
Squamous cell  
Melanoma  
Medulloblastoma 80 
 
Table2. List of Wnt positive tumours. The right column shows the percentage of tumours 
mutant in the Wnt signalling pathway. 
 
 Ovarian cancer and hepatocellular carcinoma are, therefore, potential targets for the TCF  
regulated oncolytic adenoviruses.  
 
 
2.6.2 Results 
 
 Different ovarian cancer cell lines were tested with vKH1 and vKH6 (Fig. 24A). In the  
OVCAR3 cell line, vKH6 is as active as wild type Ad5 virus. vKH1 and vKH3 are 10-fold less 
active than wild type adenovirus. vKH3, with only the RGD peptide in the capsid, is less active 
than vKH6, with both RGD peptide and CAR binding present in the capsid. Therefore, the 
presence of both CAR and integrin binding through the HI loop is necessary for maximal viral 
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uptake by OVCAR3 cells. Wnt signalling allows efficient replication in OVCAR3 cells.  The 
other ovarian cell lines, OVMZ36, OVMZ37, OVMZ52 and SKOV3 are difficult to infect 
even with wild type adenovirus. However vKH6 is able to show cytopathic effect in the 
OVMZ36 cell line at MOI of 10 particles/cell.  
 Reporter assays, using TCF promoter driven firefly luciferase, confirmed that OVCAR3 has  
active Wnt signalling (Fig 24B). OVMZ36 shows lower Wnt activity. OVMZ6, OVMZ52, 
OVMZ37 and SKOV3 cell lines show low TCF activity. The CPE assay and the reporter assay 
confirm the selective replication of TCF viruses in cell lines with sufficiently active Wnt 
signalling.    
 To test whether the in vitro activity of vKH6 can be translated into in vivo efficacy I  
established an ovarian cancer model. Intraperitoneal tumours are more difficult to follow than 
subcutaneous xenografts since it is impossible to measure the tumour mass. Two main 
parameters are used to follow intraperitoneal tumour development: peritoneal ascites and 
survival. These markers limit the precise follow-up of ovarian cancer in mice. Therefore, I 
decided to use cancer cells marked with fluorescence to follow intraperitoneal tumour 
development. Luminescence would have been a better choice since luminescence can 
penetrate further through tissue than fluorescence. The lack of an optimal luminescent 
measurement system hampered the development of such a model. 
  Fluorescent cells can be detected when they are close to the body surface. This can allow the  
follow-up of cancer development on the peritoneum of nude mice. OVCAR3, OVMZ36, 
OVMZ37, OVMZ52 and SKOV3 cells were tested in a  
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Figure 24. A. CPE assay on ovarian cancer cell lines with 10 fold dilutions of virus. Cells were 
fixed and stained with crystal violet 8 days after infection. B. Luciferase assay on ovarian 
cancer cell lines. SW480 was used as a positive control and the U2OS osteosarcoma cell lines 
as a negative control. 
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Figure 25.  A., OVCAR3GFP subcutaneous xenografts in nude mice. B., GFP positive signal 
from the abdominal cavity of a nude mouse. The mouse was injected intraperitoneally with 107 
OVCAR3GFP cells. C., OVCAR3GFP peritoneal carcinomatosis in nude mice. D., tumour 
dissemination in the abdominal cavity. E., Enlarged lymph nodes that are also GFP positive 
(F.) 
 
lentivirus expressing EGFP from a CMV promoter. 107 cells were injected intraperitoneally 
into athymic nude mice. Only OVCAR3 and OVMZ36 developed peritoneal carcinomatosis. 
The earliest GFP signal from OVCAR3 cells and from OVMZ36 cells was detected 2 weeks 
after injection, using a fluorescence stereo microscope. A big tumour mass was detected on the 
D 
F 
A 
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left side of the abdominal cavity (Fig. 25B) The signal from the peritoneum was weaker than 
the GFP signal from a matched subcutaneous xenograft (Figure25A).  
 The peritoneal tumours progressed. A month after the initial injection, peritoneal  
carcinomatosis was detected in all animals. Consequently ascites was formed and the 
experiment was discontinued. Autopsy of the animals showed extensive carcinomatosis 
throughout the peritoneum (Fig. 25 C and D). Lymph nodes also showed the presence of 
fluorescent tumour cells (Fig. 25 E and F). In a pilot experiment animals were treated with 
vKH6. A single dose of 1011 virus particles was injected intraperitoneally. The animals were 
treated when the presence of peritoneal cancer was obvious, usually 2 weeks after 
intraperitoneal injection of cancer cells. In a small group of animals (2 animals/group) the 
development of visible ascites was delayed by 2 weeks.   
 
 
2.6.3 Discussion 
  
 The fraction of ovarian cancer that would be amenable for therapy with TCF-regulated  
adenoviruses is low because only 25% of tumours have activation of the Wnt pathway and of 
these many are difficult to infect. Nevertheless, TCF-regulated adenovirus therapy might be of 
interest since no therapy offers a survival benefit in disseminated ovarian cancer. Further 
studies are required to investigate whether the retargeted TCF adenoviruses can prolong or 
even cure ovarian cancer as a single agent or in combination with novel therapies, like 
RAD001. A higher percentage of hepatocellular carcinomas have active Wnt signalling and it 
will be interesting to test hepatocellular carcinoma cell lines for TCF virus activity in vitro and 
also in vivo.  
 The GFP marking of tumour cells can also be used for other cancer models such as colon  
cancer. It is relatively easy to follow the growth of subcutaneous xenografts of colon cancer. 
The subcutaneous cancer model, however, is artificial because colon cancers metastasise 
extremely rarely to the skin. A more relevant model of colon cancer would be intraperitoneal 
carcinomatosis or a liver metastasis model. These models, however, are not readily available 
for simple measurements. GFP or luciferase marked cells allow the detection of tumour cells 
within an animal. GFP marking is suitable for the peritoneal carcinomatosis model of colon 
cancer but the liver metastasis model requires the use of luminescence because of the thick 
parenchyma of the liver.  
 
2.7. Material and Methods 
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Chemicals. RAD001 (everolimus) was supplied by Novartis (Basel, Switzerland) as dry 
powder for in vitro use and microemulsion for oral use. The powder was dissolved in ethanol 
and stored as 10 mmol/L stock solution at -20°C. The microemulsion (2% RAD001) and 
placebo emulsion were aliquoted and stored at -20°C.  
Cell lines. The colon cancer cell lines SW620, HT29, and Hct116 were obtained from the 
American Type Culture Collection (ATCC, Manassas, VA). LS174T and SW480 cells were 
provided by Dr. B. Sordat (ISREC, Epalinges, Switzerland). HER911 cells 287were provided by 
Dr. P. Beard (ISREC, Epalinges, Switzerland). HeLa cells were provided by Dr. D. Lane 
(Department of Surgery, University of Dundee, Scotland). cR2 cells are derivatives of 
HEK293 cells that express a stable mutant of β-catenin, the viral polymerase and viral 
preterminal protein 288,289. All cells were cultured in DMEM (Invitrogen, Carlsbad, CA) with 
10% fetal bovine serum and 1% penicillin/streptomycin. RAD001 was used at final 
concentration of 3.6 Amol/L in vitro.  
Viruses. The E1B-Tcf integrating vector, pRDI-241, was described by Brunori et al.224. The 
KpnI/XbaI Ad5 fragment (nucleotides 30,470 to 33,598) containing the fiber region was 
cloned from Ad5 genomic DNA (ATCC VR5) into pUC19 to give pCF159. The 
CDCRGDCFC motif was inserted into the HI loop of the fiber by inverse PCR from pCF159 
using primers GGAGACTGTTTCTGCCCAAGTGCATACTCTATGTC (oKH11) and 
GCGGCAGTCACAAGTTGTGTCTCCTGTTTCCT (oKH12) to create pKH67. 
The Coxsackie-adenovirus receptor (CAR) binding site was mutated in the knob of the fiber 
by inverse PCR from pKH67 using primers 
GGTGGTGGAGATGCTAAACTCACTTTGGTC (oKH9) and 
ATTTAGACTACAGTTAGGAGATGGAGCTGG (oKH10) to create pKH68. The amino 
acid sequence of the modified fiber around the mutation is NCRLNAEKDAK in the wild-
type and NCSLNGGGDAK in the mutant 290.The KpnI/XbaI fragments of pKH67 and 
pKH68 were cloned into pRS406 291 to create pKH69 (RGD insertion) and pKH70 (RGD 
insertion and CAR deletion), the mutant fiber integrating 
vectors. The adenovirus genome was modified by two-step gene replacement as described by 
Gagnebin et al. 292.First, the Tcf-E1B sites were inserted into vpCF11 (Tcf-E1A and Tcf-
E4;225) using pRDI-241 to create vpKH1. Subsequently, the fiber mutations were inserted in 
vpKH1 using pKH69 and pKH70 to create vpKH3 and vpKH6, respectively. The vKH1, 
vKH3, and vKH6 viruses were produced by transfection of PacI digested vpKH1, vpKH3, 
and vpKH6 into cR2 cells288. The viruses were then plaque purified on SW480 cells, expanded 
on SW480 cells using Cell Factories (Nunc, Roskilde, Denmark), purified by double CsCl 
banding, buffer exchanged using HR400 columns (Amersham, Little Chalfont, United 
 76 
Kingdom) into 1 mol/L NaCl, 100 mmol/L Tris-HCl (pH 8.0), 10% glycerol, and stored 
frozen at   -70°C. The identity of each batch was checked by restriction digestion and 
automated fluorescent sequencing in the E1B (nucleotides 1,300 to 2,300) and fiber 
(nucleotides 30,470-33,598) regions using the following primers: E1B sense, 
TGTCTGAACCTGAGCCTGAG; fiber antisense, CTACTGTAATGGCACCTG; fiber 
sense, GCCATTAATGCAGGAGATG. Apart from the desired mutations, no differences 
were found between the sequences of VR5 and the Tcf viruses. Particle counts were based on 
the absorbance at 260 nm (A260) of virus in 0.1% SDS, using the formula 1 A260 = 1012 
particles/mL. 
Western blotting. Cells were infected with 100 particles/cell in DMEM. Two hours after 
infection, the medium was replaced with complete medium. Cells were harvested at the 
indicated times in SDS-PAGE sample buffer. E1A, DBP, and fiber were detected with the 
M73 (Santa Cruz Biotechnology, Santa Cruz, CA), B6 , and 53 4D2 (Research Diagnostics, 
Inc., Flanders, NJ) antibodies, respectively.  
Cytopathic effect assay. Cells in six-well plates were infected with 10-fold dilutions of virus 
in DMEM. Four hours after infection, the medium was replaced with complete medium 
containing RAD001. Four days after infection, fresh medium containing RAD001 was added. 
After 5 to 8 days, the cells were fixed with 4% formaldehyde in PBS and stained with crystal 
violet.  
Quantitative PCR assay. Cells were infected in vitro with one viral particle per cell in 
DMEM. The medium was replaced after 4 hours and cells were harvested after 48 hours. 
DNA was purified from tissue culture cells and mouse tissues using a DNeasy kit (Qiagen, 
Hilden, Germany) according to the manufacturer’s instructions. Quantitative PCR was done 
on a Light Cycler (Roche, Basel, Switzerland) using FastStart SYBR Green (Roche), 500 
nmol/L primers (Invitrogen), and 10 ng template DNA. Results were expressed relative to cell 
number assuming 6 pg DNA/cell. The primers used for quantitative PCR were hexon forward 
primer, CTTCGATGATGCCGCAGTG and hexon reverse primer, 
GGGCTCAGGTACTCCGAGG.  
Animal experiments.  Four-week-old female NMRI nu/nu mice were purchased from 
Elevage Janvier (Le Genest St Isle, France). S.c. SW620 flank xenografts were made by 
injecting 107 cells. Mice ( five per group) were injected with virus when tumors reached 80 to 
150 mm3 in size. A total of 1 x 1011 particles were injected into the tail vein per day, given as 
four shots of 2.5 x 1010 particles at four hour intervals. Two regimens were tested: virus 
injection on a single day at the start of the experiment (total dose per mouse 1 x1011 particles) 
or virus injection at weekly intervals for 3 weeks (total dose 3 x1011 particles). RAD001 
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microemulsion was diluted in water and 5 mg/kg/d was administered by daily gavage starting 
the day after virus injection. For mice receiving weekly injections of virus, RAD001 was 
omitted the day before and on the day of the injection; RAD001 administration continued 
daily thereafter to the end of the experiment. Tumor size was measured every 2 days. Tumor 
volume was calculated according to the formula, volume = length x width2 x 3.14/6. 
Differences in growth curves were calculated by two-tailed Student’s t test. Differences in 
survival curves were calculated by log-rank test in R.  
ELISA. Three weeks after i.v. injection of 109 viral particles of adenovirus (vKH1), 200 µL of 
blood was taken from each mouse. The serum titer of antibodies against adenoviral proteins 
was measured by ELISA using ELISA plates (Nunc) coated with Ad5 as described.  
Fluorescence in situ hybridization. Viral genomic DNA was labeled using the DIG DNA 
labeling kit (Roche). Tumor sections were fixed in 4% PFA, digested for 30 minutes with 
proteinase-K, acetylated with TEA for 10 minutes, and blocked with hybridization buffer 
without probe for 2 hours. Labeled probe was added and slides were hybridized overnight at 
50°C. After washing in SSC, slides were incubated overnight with anti-DIG horseradish 
peroxidase at 4°C and label was detected with TSA Cy3 reagent kit (Perkin-Elmer, Boston, 
MA). 4,6-Diamidino-2-phenylindole (DAPI) was used to counterstain nuclei. 
HPMA coating. The adenovirus prep was first buffer exchanged from 2x storage buffer(1M 
NaCl, 100 mM TRIS pH8, 10 gylcerol)  into HPMA coating buffer (1xPBS, 50mM HEPES, 
pH7.8). The given concentration of HPMA was added in water. The virus/HPMA mixture 
was incubated for 8 hours at room temperature and than overnight at 4ºC. For animal 
experiments 5 mg/ml HPMA coating was used. The virus/HPMA mixture was not further 
purified.  
Ovarian cancer model. Ovarian cancer cell lines were infected with lentivirus vectors 
expressing GFP under the CMV promoter. The titer of lentivirus was 107 pfu/ml. 107 cells 
were injected intraperitoneally or subcutaneously into NMRI nude mice. GFP signal was 
detected 2 weeks after initial injection. In a preliminary experiment 1011 particles of vKH6 was 
injected in 100 µl. The mice were sacrificed when ascites developed.   
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2.8.     Adenovirus display Library- The AdLib system 
 
2.8.1    Rationale 
 
The use of RGD peptide in the HI loop of the fibre knob revealed that retargeting to 
cellular receptors using small peptides is possible in the context of adenoviral capsid proteins. 
However, the number of useful sequences is limited. RGD was identified by using phage 
display libraries.293,294 In phage display libraries random libraries of 3 to 9 amino-acid long are 
expressed at the tip of the IIIa protein of the λ phage (Fig. 26A). Other peptides, like NGR, 
were also discovered by this technique but most of them failed to allow tumour specific 
binding in the context of the adenovirus capsid.136 In the fibre knob peptides are inserted into 
an environment that structurally differs from the phage capsid IIIa protein. The secondary, 
tertiary and quaternary structure formation of fibre influences and potentially blocks the 
function of some of the targeting ligands. Therefore, new techniques that would allow the 
selection of tumour targeting peptides in the context of the adenoviral fibre are needed to 
further improve adenoviral cancer gene therapy.  
It was shown that fusion of the fibre knob or the HI loop to the λ phage IIIa protein 
can present a useful platform for peptide library display.295-297 The new targeting sequences 
generated by these methods also failed to show significant improvement of viral uptake when 
they were inserted into the fibre of adenovirus.  
It is relatively easy to generate a mutant fibre bank in plasmids and to reintroduce the 
mutant fibres into the viral backbone by homologous recombination in bacteria (Fig 26B). The 
critical step is the transfection of the library of viral genomes into packaging cells. Regardless 
of the method of transfection only a small fraction of the viral genomes will produce viral 
particles. The production of virus from “naked” DNA is inefficient because the virus needs 
terminal proteins that serve as primers for DNA polymerase and promote binding of the viral 
DNA replication machinery. 
Therefore, I propose a recombination system, the AdLib system, which would allow 
the generation of a complex peptide library in the context of the adenovirus (Fig. 27A). Such a 
viral library will contain a mutagenised fibre bank and will be injected into the tail vein of a 
tumour-bearing mouse. Viruses that can infect the tumour xenograft the best will be selected. 
The problem of transfection of viral genomes can be solved by using infection by 
adenovirus instead of transfection. The recombination would then take place in mammalian 
cells between the mutant plasmid fibre bank and viral genomes which already have TP bound 
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to the ITRs and are ready to replicate. Using a viral genome where TP is bound to the ITRs 
will increase the efficiency of virus production.  
A virus lacking only the fibre gene will, however, replicate and increase the background 
of non-recombined viruses. The background can be reduced by coupling the fibre gene with 
the adjacent E4 region of the virus. E4 transcripts are essential for viral replication298. A virus 
deleted for both fibre and E4 would not replicate. The pAdBack plasmid containing the fibre 
gene and E4 transcripts will be transfected into 293T cells. The plasmid will not express fibre 
or E4. After recombination fibre and E4 will be reintroduced into their genomic environment 
and will be expressed. Expression of fibre and E4 will allow the replication of the virus. 
Therefore, replication of the virus  will be dependent on the recombination between the 
plasmid and the adenovirus genome. The AdLib system necessitates the use of a virus which is 
deleted for fibre and for the E4 regions. The deletion would be flanked by loxP sites. This 
virus can be grown only in helper cell lines that express both fibre and E4.  
The Cre/loxP system offers efficient recombination in mammalian cells. It allows site 
specific recombination between a plasmid and a viral genome. The Cre/loxP bacterial 
recombination system has its limitations. I planned to use two loxP sites in the plasmid and 
two in the virus. Two identical loxP sites in the same genome would allow the possibility of 
intramolecular recombination. To favour intermolecular recombination between the plasmid 
and the viral genome two different loxP sites were used: a wild type loxP site and a mutant 
loxP site, loxP 511299 (Fig27 B). The loxP recombination site has two parts: a middle 9 
nucleotide sequence through which Cre recombinase initiates homologous recombination 
flanked by binding sites for the Cre recombinase. The loxP511 site has a point mutation in the 
middle part of the loxP site. Recombination is efficient between cognate loxP sites; 
recombination between the wild type loxP site and the mutant loxP site is reduced but not 
abolished. Other loxP sites, loxP66 and loxP77 were also considered as possible loxP sites.300 
These sites contain mutations in the Cre recombinase binding sites. It was shown that these 
mutant sites are mutually exclusive for recombination but they are also less accessible for the 
Cre recombinase. 
I will first discuss the production of the lox viruses and then show evidence for 
recombination between the pAdBack plasmid and the adenoviral genome. 
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Figure 26. A., Phage display library B., recombination of plasmid and viral genome in bacteria 
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Figure 27. A Schematic description of the AdLib system. The recombination takes place after both the 
Cre expressing plasmid and pAdBack plasmid have been transfected into 293T cells. After transfection, 
cells are infected with the loxP virus at approximately 1 MOI/cell. B. Intermolecular recombination 
between pAdBack plasmid and the loxP virus. Note that the two different loxP sites allow 
recombination only between the plasmid and virus and not within the virus or plasmid DNA.  
∆E4∆L5: vKH5 
fibreless genome 
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2.8.2 Results 
 
 I first constructed loxP virus in a wild type adenovirus backbone to show that a 
mutant virus lacking both fibre and the E4 transcripts can be rescued and propagated. The 
resulting virus is called vKH5. Cell lines expressing E4 and fibre were not generated 
previously. E4 is toxic for cells. 293 cells expressing the E4 transcripts from a dexamethasone-
inducible MMTV promoter were previously created by Graham et al.301 The 293E4pIX cell 
line also expresses pIX, inducible by Zn+. 293E4pIX cells can express E4orf6 transcript after 
24 hours induction by 10-6 M dexamethasone (Fig 28A). To complement the lack of fibre 
expression in the virus I tried to express fibre from lentiviral vectors. Different lentiviral 
constructs were created (Fig. 26B):   
• without the tripartite leader (pKH9),  
• with the full tripartite leader (pKH21),  
• with a spacer between fibre and the tripartite leader (pKH36) 
• expressing from an EF1α promoter (pKH51)  
 
None of the lentiviral vectors that I constructed expressed fibre (Fig. 28C). Cell lines expressing  
fibre have been previously created.302,303  These cell lines, created by Daniel von Seggern, 
express fibre with a tripartite leader different from my constructs.  The full tripartite leader 
allowed fibre expression only when a partial deletion was made in Tpl1. The most pronounced 
expression was achieved when fibre was expressed after a tripartite leader containing the I/II 
native intron from the virus. I used this expression plasmid, pDV67, to express fibre in 
293E4pIX cells and created the cK1 cell line. Western blotting showed that in cK1 cells fibre 
expression is comparable to that seen after wild type adenovirus infection. cK1 cells can 
efficiently complement the replication of a fibre deleted adenovirus (Ad∆fibreGFP) (Fig. 
28D).  
 Bacterial DNA containing the vKH5 genome was transfected into cK1 cells. The replication  
of the virus was slower than the replication of the wild type virus. Propagation of the virus 
required infections at high multiplicity (MOI of 10-100). Finally, a preparation of pure 
adenoviral genomic DNA was made. PCR, sequencing  and digest of the viral genome 
confirmed that only the mutant virus was present in the viral stock (Fig. 29A,B and Fig. 30A).      
The recombination of plasmid with the adenoviral genome was tested by transfecting 
293T cells with the pAdBack plasmid, which contains the fibre and the E4 genes, and a 
separate plasmid containing the Cre recombinase. Four hours after transfection the medium 
was changed. After an additional four hours the cells were infected with vKH5. CPE should 
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only be seen if recombination occurs leading to production of viable, replication competent 
virus. Only the co-transfection of Cre and pAdBack plasmids resulted in virus production (Fig. 
30A). In the first generation of pAdBack (pKH53) plasmid the LoxP sites were flanked by 300 
bp viral sequence “overhangs”. Occasionally, I found Cre-independent recombination and 
production of virus in 293T cells (Fig. 30A, middle panel) which later was able to infect non-
complementing SW480 colon cancer cells. I attribute this to the presence of the “overhangs” 
which was sufficient to allow homologous recombination without Cre recombinase. This Cre-
independent recombination was avoided by deleting the extra viral sequences (pKH110).  
Western blotting for fibre showed that fibre was only expressed when Cre and the 
modified pAdBack plasmid (pKH110) were co-transfected into 293T cells (Fig. 30C). It also 
confirmed that no recombination took place between virus and the plasmid without Cre. 
vKH5 did not express fibre which confirms that the preparation was free from contamination 
by wild type virus.  
  The virus produced by recombination was called vKH7. vKH7 was successfully propagated  
in the SW480 colon cancer cell line (Fig. 30D), suggesting that the presence of the loxP sites is 
compatible with viral replication. Digest of vKH7 shows that after recombination a 3.5 Kb 
NheI fragment, representing the fibre region, reappeared. Sequencing of the virus confirmed 
that the input virus recombined with the pAdBack plasmid and that only recombined viruses 
were growing in SW480 cells (Fig. 30B).  
The wild type viral backbone is not suitable for further fibre modifications because of 
biosafety issues. A new panel of viruses was generated in yeast using the gap-repair technology 
(Fig. 29C).292 vpKH8 (E1B55k deletion replaced with a CMV-EGFP cassette) and vpKH10 
(E1A deleted for pRb binding and TCF E1B promoter) have been transfected into cK1 cells. 
vKH10 was then further propagated and a caesium-chloride banded high titer stock was made. 
vKH10 was able to recombine with the pAdBack plasmid (pKH110) and also with the 
pAdBack plasmid containing RGD in the HI loop of the fibre (pKH73). These 
recombinations produced vKH13 and vKH14, respectively (Fig. 30D). I am currently testing 
the recombination efficiency of vKH10 and different pAdback plasmids containing, wild type 
fibre or fibre with RGD.  
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Figure 28. Production of the loxP virus A., Western blotting for E4 orf6 in the 293E4pIX cell 
line. Cells were incubated with or without Dexamethasone (10-6M) for 24 hours. Adenovirus 
infected SW480 cell extract served as positive control. B., Fibre constructs that were cloned 
into a lentiviral vector showing tri-partite leader sequences in the viral genome. C., Western 
blotting for fibre in lentivirus infected 293E4pIX cells and in 293E4pIX cells transfected with 
pDV67. D., CPE assay on cK1 cells infected with adenovirus deleted for fibre and expressing 
GFP.   
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Figure 29. Production of vKH5. A., PCR for the fibre E4 deletion. Primers flanking the 
deleted viral region were used to check the presence of viral genome in cK1 cell. Lane 1: 
Negative control, vKH3 genomic DNA. Lane 2.: positive control, pKH53, Lane 3. DNA 
extract from cK1 cells infected with vKH5. B., Genomic sequence of the virus. C., Schematic 
representation of viral genomes of loxP viruses.  
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293T 
Figure 30. A; 293T cells were transfected with 10 µg of pAdback and 10 µg of Cre plasmid. 4 
hours after infection medium was replaced. After further 4 hours cells were infected with vKH5 
cell lysate. The pictures were taken 6 days post infection. B., Digest of viral genomic DNA with 
HindIII and NheI enzymes. Lane 1: HindIII digest of vKH5, Lane 2: NheI digest of cKH5. 
Lane 3: HindIII digest of vKH7, Lane 4: NheI digest of vKH7 C; Western blot for fibre 
expression in 293T cells 24 hours after infection. Lane 1: negative control; Lane 2: cK1; Lane 3: 
Ad5; Lane 4: pAdBack; Lane 5: vKH10; Lane 6: vKH10 + pAdBack; Lane 7: Cre + vKH10 + 
pAdBack. Fibre was only expressed when both plasmids were transfected. D.; Crystal violet 
staining of SW480 cells. Cells were infected with 293T lysates and stained 6 days after infection.   
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2.8.3.     Discussion  
 
The adenoviral recombination system is intended to allow both the rapid production of mutant  
fibre viruses and the establishment of an adenoviral display library. The production of fibre 
mutant viruses can be reduced from months to weeks.  Despite the Cre dependent activation, 
the robustness of the system might not be sufficient to produce a high complexity library. The 
efficiency of the system still has to be tested. It would be possible to test the recombination 
efficiency by using two different plasmids in different dilutions. The threshold at which the 
recombination can still produce both mutant viruses would provide a measure of the efficiency 
of the AdLib system.   
 One of the main reasons why the AdLib recombination system might be inefficient is the  
Cre/LoxP system. Cre can efficiently delete sequences from DNA but Cre mediated insertion 
is a less efficient event.304 Other organisms evolved more robust integration systems. The 
phage ΦC31 integrase offers unidirectional recombination. The ΦC31 phage was identified in 
several Streptomyces species.305 The ΦC31 integrase is a member of the serine recombinases 
and is thought to use the mechanism of recombination similar to the well-studied resolvase-
invertase family.306 The attB and attP recombination sites used by ΦC31 are small, 39 and 34 
bp in size, respectively. The main advantage of the ΦC31 integrase is that the integration is 
unidirectional and irreversible. Recombination with Cre is reversible. 
  The peptide library can be built into the HI loop by site directed saturation mutagenesis. The 
 HI loop, as I previously showed, is suitable for the insertion of short peptides. The length of 
the peptide sequence is important in determining the specificity of the targeting. The longer 
the peptide the higher is the specificity. The phage display library system uses peptides from 
three to seven aminoacids. I planed to use an adenovirus containing a heptamer peptide 
random library.  The presentation of the targeting peptide may also neccessitate the use of 
disulfide bounds, as in the CDCRGDCFC sequence. These disulfide bonds would strengthen 
the structure of the HI loop and allow better targeting by the peptide.  It also has to be tested 
if the selection of the new peptides can take place in a wild type fibre knob and in a fibre 
detargeted from CAR. It is also possible to insert more than one new targeting peptide into the 
knob. As vKH6 showed the ability to bind both CAR and integrins permit a better targeting of 
cancer cells than targeting of only one receptor.  
 If the recombination efficiency is low it will not be possible to convert a high complexity  
plasmid library into a high complexity adenovirus library. The system, however, can be still 
used for the rapid production of viruses with individually modified fibres, where the 
modifications are known. The modifications that fibre can tolerate, could be detected and 
selected. Fibres of other serotypes can be also rapidly inserted into a replicating, promoter 
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modified adenovirus. This would allow a screen among different serotypes for the ideal colon 
targeting fibre. This fibre might be one of the fibres from Ad40 or Ad41 since these viruses are 
specialised in infecting the gastrointestinal tract.  
 Field isolates from patients can be also used to detect new potentially more potent fibres.  
   
2.8.4. Material and Methods 
 
Cell lines. 293E4pIX was obtained from Microbix (Toronto, ON, Canada). 293T and SW480 
cells were from ATCC. cK1 was made by transfecting pDV67 into 293E4pIX and selecting in 
Zeocin. E4 expression was induced by adding 10-6 M dexamethasone (Sigma) for 24 hours 
before infection.  
 
Virus construction. First, pMB2 was cut with Bgl1 and Cla1 and self ligated to create pKH1. 
pKH1 was digested by AflII, blunted by T4 polymerase and self ligated. This cloning created 
pKH5 with a unique NdeI site. A 9 kb fragment from wild type adenovirus was cloned by 
three-way ligation in pKH5 using the AflIII/PacI fragment from pCF8 and  NdeI/XbaI 
fragment from pCF159 as inserts into PacI/XbaI digested pKH5,  creating pKH6. Inverse 
PCR was done first with oKH29 and oKH30 to create new loxP 511 after E4orf2 and gave 
rise to pKH46. Then pKH47 was made by inverse PCR on pKH46 with NL and oKH28 
primers to create normal loxP site before fibre. HpaI BstEII fragment of pKH47 was cloned 
into pKH22 gap-repair vector to create pKH54. pKH54 was used for homologous 
recombination with SrfI digested wild type adenovirus genome in yeast that created vpKH5. 
vpKH5 has the wild type genome with E4 and fibre deletion flanked by LoxP and LoxP511 
sites in a YAC/BAC. Similar homologous recombination was done with SrfI digested LGM 
(dl1520, EGFP), vKH1 (E1A, E1B, E4 Tcf) and pCF23 (E1A, E1B, E4 Tcf, E1A∆24) that 
gave rise to vpKH8, vpKH9 and vpKH10 respectively. pAdBack was made by Inserting a 
BssHII fragment from pCF157 into pKH47 creating pKH52. Then a NdeI/PciI fragment of 
wild type adenovirus was cloned into pKH52 resulting in pKH53. pKH53 has 300 bp 
overhangs outside both loxP sites. pKH53 was subcloned into pBSSK- using PCR with loxrec 
upper and loxrec lower primers to create pKH110, the second generation pAdBack plasmid.   
 
Lentiviruses expressing fibre. pKH9 was made by inserting a PCR product created by 
oKH1 and oKH2 into pRDI267 (CMV hygro) by BamHI/EcoRI digest. pKH21 was cloned 
by first inserting TPL from RT-PCR products with oKH /oKH of infected adenovirus lysate 
into pKH4 by BamHI/AgeI creating pKH20. The BamHI/EcoRI fragment of pKH20 was 
cloned into pRDI267. pKH36 was created by first  inserting the RT-PCR product containing 
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TPL and the y leader into pKH4 BamHI/NdeI creating pKH35. The BamHI/EcoRI 
fragment of pKH35 was then cloned into pRDI267. pKH41 was created by cloning the 
BamHI/EcoRI fragment of pKH36 into pRDI291 (EF1α-hygro).     
 
Western blotting. Cells were infected with 100 particles/cell in DMEM. Two hours after 
infection, the medium was replaced with complete medium. Cells were harvested at the 
indicated times in SDS-PAGE sample buffer. E4 and fibre were detected with RSA3 and 53 
4D2 (Research Diagnostics, Inc., Flanders, NJ) antibodies, respectively. 
 
Cytopathic effect assay. Cells in six-well plates were infected with 10-fold dilutions of virus 
in DMEM. Four hours after infection, the medium was replaced with complete medium 
containing RAD001. Four days after infection, fresh medium containing RAD001 was added. 
After 5 to 8 days, the cells were fixed with 4% formaldehyde in PBS and stained with crystal 
violet.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Perspectives 
 
 I have constructed adenoviruses with capsid modifications that can increase the cytopathic  
effect of TCF regulated adenoviruses without loss in selectivity. The RGD peptide sequence in 
the HI loop of adenovirus can efficiently target tumour cells. Despite the superior in vitro 
efficacy of the RGD modified adenovirus, vKH6, the in vivo inhibition of tumour growth was 
still insufficient. Only systemic therapy has the potential to cure late stage colon cancer. 
Systemic therapy, as I have shown, demands an understanding of complex and still not fully 
understood interactions. Some of the undesirable interactions of adenovirus can be blocked by 
genetic modifications of the virus capsid but the list of modifications and interactions seems to 
be never ending. Therefore, the only easy way which can allow systemic therapy by 
adenoviruses is non-genetic detargeting of adenovirus by polymer coating. 
 Targeting the virus to tumour cells is a key component of adenovirus cancer gene therapy.  
But few targetable receptors and ligands are known. I have created a system, the AdLib system, 
which can serve as a basis for future screens. The setup of future screens will strongly 
determine the result. Both in vivo and in vitro selection could produce sequences that are 
useful for targeting of a polymer coated adenovirus. Maximum HPMA coating is necessary to 
optimize the benefits offered by HPMA. This will preclude the differential coating 
phenomenon. However, maximum coating may be possible if the tip of the fibre, the HI loop, 
is extended and the targeting sequence projects above the coat. It is difficult to create an 
optimal loop extension because no current bioinformatics technology can predict the effect of 
a long amino acid sequence within the fibre structure. Sequences with a defined secondary 
structure might allow extension of the HI loop without disturbing the structure but careful 
structural biology planning is necessary. 
 The AdLib system is also useful for the evaluation of new adenovirus modifications. In the  
Iggo lab, replicating adenoviruses expressing suicide genes (cytosine deaminase or 
nitroreductase) in the major late transcript were created. Two techniques were used for 
expression: an internal ribosomal entry site (IRES) or a splice acceptor from adenovirus 
serotype 41 cloned after the fibre gene.68 Evidence suggests that the IRES and the splice 
acceptor do not allow high levels of transgene expression.68,69   
 A new expression system is needed to increase the expression level of these prodrug  
converting enzymes. The 2A protease system is used by picornaviridae and by tetraviridae.307 
2A is a short peptide linker that allows multicistronic expression of transcripts. Insertion of a 
2A sequence after fibre might allow a higher level of transgene expression than did the IRES 
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or the splice acceptor site. The AdLib system can be used to evaluate which sequence would 
be the most suitable for adenovirus vectors. 
 Fibre is not the only capsid protein which can be exploited for prodrug activating enzyme  
expression. The pIX, penton and hexon loci can be also modified for expression.308 The 2A 
system leaves peptides of 18 to 49 aminoacids fused to the C-terminal end of the first 
protein.307 Fibre can tolerate the fusion of up to 23 amino acids.95 A short 2A linker therefore 
might be compatible with fibre function. Short 2A linker however can be less active. Longer 
peptides, up to 49 aminoacids, can be fused to pIX and penton without disturbing their 
functions.308  
 The 2A system can also allow the expression of proteins other than prodrug converting 
 enzymes. Viral spread is limited by the extra cellular matrix (ECM). If the matrix were to be 
degraded around infected tumour cells, that would increase the spread of the virus. Matrix 
metalloproteinases (MMP9, MMP7) can degrade the ECM.309 These proteins are however 
difficult to express from adenovirus because of their large size. Adenovirus can tolerate 
insertion of extra DNA up to 105% of the original size.310 Longer DNA sequences will reduce 
the efficiency of the packaging of viral DNA into capsid. Smaller proteins are more attractive. 
Bacteria, like Clostridia and Bacteroides, express ECM degrading enzymes. Bacteroides fragilis 
expresses a small protease, fragilysin which is only 20 kD.311 Fragilysin loosens cell-cell 
interactions by cleaving E-cadherin and destroying tight junctions.312 Fragilysin would not only 
facilitate viral spread but also could increase the intensity of Wnt signalling by blocking 
functional E-cadherin.  
 Finally the RGD modified adenovirus can target endothelial cells. TCF regulated  
adenoviruses, however, cannot replicate in neo-angiogenic endothelial cells. Therefore, use of 
promoters which can target endothelial cells and Wnt positive cells would increase the in vivo 
efficiency. Tumour endothelial cells are hypoxic and overexpress the transcription factor, 
HIF1α.313 Combination of HIF1α and TCF binding sites in the E1A promoter produces an 
adenovirus that is responsive to both signals (Christophe Fuerer, Alexandre Lukashev 
unpublished).  
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4. Contributions 
 
 The combination therapy with cytotoxic compounds was carried out together with  
Marta Salvado de Bobes. She was an undergraduate student during Summer 2003. She 
participated in the Taxol studies and she contributed to figure 16B and C.The in vivo results 
with RAD001 were performed in collaboration with a post–doctoral scientist, Alexander 
Lukashev who is an expert in large scale animal experimentation. He provided Figure 18A, B, 
D and Figure 19.  
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5. Appendix 
5. 1 Abbreviations 
 
4EBP1:           4E binding protein 1 
Ad:                 Adenovirus serotype  
ADP:             Adenovirus death protein 
APC:              Adenomatous polyposis coli gene 
Arm:              Armadillo 
BCL9:            B cell lymphoma 9 protein 
β-TrCP:         β-transducin repeats containing protein 
C3:                 Complement 3 
C4BP:            Complement 4 binding protein 
CAR:             Coxsackie-Adenovirus Receptor 
CK1:             Casein kinase 1 
CMV:            Cytomegalovirus 
COX-2:         Cyclo-oxygenase 2 
CPE:             Cytopathic effect 
CRC:             Colorectal cancer 
CtBP:            C terminal binding protein 
DBP:             DNA binding protein 
DNA PK:      DNA protein kinase 
Dsh:              Dishevelled 
E1A, E1B, E2, E3, E4: Early unit 1A, 1B, 2, 3, 4 
E2F:              E2 factor 
EGF:             Epithelial growth factor 
ERK:             Extracellular signal regulated kinase 
eIF2α:            Eukaryotic initiation factor 2α 
eIF4E:            Eukaryotic initiation factor 4E 
eIF4G:           Eukaryotic initiation factor 4G 
EMT:            Epithelial mesenchymal transition 
FAP:             Familial adenomatous polyposis  
Fz:                Frizzled 
GSK3β:        Glycogen synthase kinase 3 β 
GTP:            Guanosine tri-phosphate 
HAT:            Histone acetyltransferase 
HLF:             Human lung fibroblast 
HNPCC:       Hereditary non-polyposis colorectal cancer 
HSPG:          Heparan sulphate proteoglycan 
HVR:            Hyper variable region 
IFN:              Interferon 
ICAT:            Inhibitor of β-catenin 
IL-4, IL6:       Interleukin 4 and 6 
I.P.:                Intraperitoneal 
IRES:             Internal ribosomal entry site 
I.V.:               Intravenous 
ITR:               Inverted terminal repeat 
KKTK:          Lysine-Lysine-Tyrosine-Lysine 
L1 to L5:        Late unit 1 to5 
LRP:              Low density lipoprotein-related protein 
MAPK:          Mitogen activated protein kinase  
MIP-1:           Macrophage Inflammatory Protein 1 
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MLL1/2:        Mixed-lineage-leukaemia 
MLP:           Major late promoter 
MLTU:           Major late transcription unit 
MOI:           Multiplicity of infection 
mTOR:          Mammalian target of rapamycin 
NES:           Nuclear export signal  
NF-κB:          Nuclear Factor κB 
NGR:           Asparagine-Glycine-Arginine 
NLS:           Nuclear localisation signal 
NTR:           Nitroreductase 
PDK1,2:        PI3K dependent kinase 
PFU:          Plaque forming unit 
PI3K:            Phophatidylinositol 3 kinase 
PIP3:             Phosphatidylinositol 1,2,3 phosphate 
PKB:            Protein kinase B 
Pol:               Polymerase 
PSA:             Prostate specific antigen 
PTEN:         Phosphatase with tensin homology 
RAF:            Mitogen activated protein kinase kinase kinase (MAPKKK) 
RANTES:     Regulated upon activation, normal T cell expressed and secreted protein 
RGD:           Arginine-Glycine-Aspartic acid 
p300/CBP :  300kD protein/CREB binding protein 
PCR:            Polymerase chain reaction 
Q-PCR:        Quantitative real time PCR 
PKR:            Double stranded RNA activated protein kinase R 
PML:            Promyelocytic leukaemia protein 
POD:           PML oncogenic domain 
PP2A:           Protein phosphatase 2A 
pRb:              Retinoblastoma protein 
(p)TP:            (pre) Terminal protein 
Pygo:             Pygopus 
RID:              Receptor internalisation and degradation protein 
RGS:             Regulator of G-protein signalling 
SAEC:           small airway epithelial cells 
SCF:              Skp1/Cullin/F-box protein 
SWI/SNF:     DNA remodelling complex 
TAF:              TBP assiated factor 
TCF/LEF:     T cell factor/Lymphoid enhancer binding factor 
TFIIB:            Transcription initiation factor IIB 
TFIID:          Transcription initiation factor IID 
TNFα:           Tumour necrosis factor α 
TSC1/TSC2:  Tuberous sclerosis complex 1,2 
UTR:              Untranslated region 
VA RNA:       Virus associated RNA 
Wnt:               Wingless-Int 
Wt:                 wild type 
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5.2 Plasmid list 
 
Name______Origin________Resistance___Construction 
pKH1            pMB2                 Amp              ∆Bgl,Cla, Self ligation 
pKH2            pKH1                 Amp              Insert ∆ PacI, Spe I from vpCF10 (9 Kb)  
                                                                        to pKH1 PacI, Xba I 
pKH3            pLS114               Amp              Insert fibre with PCR oKH1&oKH2 with  
                                                                        5' BamHI and 3' EcoRI into pLS114 
pKH4            pKH3                 Amp              Back cloning fiber NdeI and Bgl II from 
                                                                        vpCF159 into pKH3 
pKH5            pKH1                 Amp              Delete AflII site to create NdeI site 
pKH6            pKH5                 Amp              Insert Afl III PacI from pCF8 and NdeI  
                                                                        Xba I from pCF159 
pKH7            pKH6                 Amp              Insert Normal LoxP site with PCR using  
                                                                       oKH and oKH before fibre 
pKH8            pKH6                 Amp              Insert LoxP511 site with iPCR using oKH  
                                                                        and oKH after E4orf1 
pKH9            pRDI267            Amp              Insert fibre PCR product with BamHI&EcoRI 
pKH10          pRDI267            Amp              Insert Cre from pHCCre with EcoRI 
pKH11          pKH8                 Amp              Second iPCR to create Normal LoxP 
pKH12          pKH6                 Amp              Backcloning XmaI&BglII fragment with        
pKH13          pKH12               Amp              SpeI&XBaI fragment from pCF157 to        
pKH14          pKH13               Amp              1.8 Kb XbaI DNA fragment from wt        
pKH15          pKH14               Amp              EcoRI,  Sal I Fragment containing left        
pKH16          pKH12               Amp              BssHII fragment from pCF159 to BssHII        
pKH17          pKH16               Amp              Nde I, Pci I fragment from pCF159 to        
pKH18          pHCCre             Amp               Partial deletion with Mlu I , and normal        
pKH19          pKH18               Amp              EcoRI fragment from pKH 18 to pRDI 276 
pKH20          pKH4                 Amp              Tpl PCR product with oKH& oKH. Digest with  
                                                                        BamHI and Age I and insert into pKH4    
                                                                        BamHI&AgeI 
pKH21          pKH20               Amp               BamHI, EcoRI fragment from pKH20 to pRDI276 
pKH22          pCF1                  Chlor              Pac I fragment from pKH 15 to pCF1 
pKH23          pCF153              Amp                iPCR with oKH5&6; penton deletion of RGD  
pKH24          pCF159              Amp                iPCR with oKH7 and oKH8(shaft KKTK to GAGA) 
pKH25          pCF159              Amp                iPCR with oKH9 and oKH10(AB loop) 
pKH26          pCF159              Amp                iPCR with oKH11 and 12(HI loop) 
pKH27          pBSSK-              Amp                Bluescript 
pKH28          pCF159              Amp                Backcloning NheI Age I fragment of pKH24 
pKH29          pMB31               Amp                Kpn I fragment from pKH23. Two step gene         
                                                                        replacement vector for RGD deleted penton 
pKH30          pKH27               Amp                EGFP PCR into pBluescript 
pKH31          pKH28               Amp                Three-way-ligation with inserts from pKH25 and 26 
pKH32          pMB31               Amp                XbaI&KpnI fragment from pKH31. Triple mutant  
                                                                         fibre in two-step gene replacement vector 
pKH33          pKH31               Amp                Three way ligation with triple mutant fiber and IRES    
                                                                         CD Sites used NcoI-MscI-MfeI 
pKH34          pCF330              Amp                SpeI XbaI fragment of pKH33 into pCF330 
pKH35          pKH4                Amp                 TPL+ y leader + fiber PCR into pKH4 used sites  
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                                                                         BamHI NdeI EcoRI 
pKH36          pRDI276           Amp                 BamHI EcoRI fragment of pKH35 into pRDI276 
                                                                         Insert contains TPL + y leader + fibre 
pKH37          pKH32              Amp                 Kpn I Hind III deletion in  pKH32 
pKH38          pKH32              Amp                 KpnI & MfeI deletion in pKH32 
pKH39          pKH35              Amp                 Backcloning fibre from pCF159 with NdeI&BglII into    
                                                                         pKH35 
pKH40          pRDI291            Amp                Cre from pKH19 into pRDI 291 with EcoRI  
                                                                         (EF1α, Hygro) 
pKH41          pRDI291            Amp      TPL Y leader fiber from pKH36 into PRDI291   
                                                                          BamHI&EcoRI 
pKH42          pKH17               Amp                 IRES cassette from pCF315 into pKH17 with   
                                                                         BstXI &MfeI 
pKH43          pKH17               Amp                IRES CD casette from pCF315 into pKH17 
pKH44          pKH42              Amp                 EGFP from pKH30 into pKH42 
pKH45          pKH6                Amp                 iPCR with NL and oKH28 to create new normal  loxp 
pKH46          pKH6                Amp                 iPCR with oKH29 and OKH30 to create new loxp 511 
pKH47          pKH46              Amp                 iPCR with NL and OKH28 to create NEW normal          
                                                                         loxp 
pKH48          pKH15              Amp                HpaI BsteII fragment from pKH47 to PKH15 
pKH49          pCF1                 Chlor                Pac I fragment from pKH48 to PCFI 
pKH50          pCF247             Amp                  NotI KpnI fragment from pCLF(Von Seggern)   
                                                                         containing partial TPL1 TPL2, 3, spacer and  fibre into   
                                                                         pCF247 EcoRI(blunt) 
pKH51          pCF247             Amp                 BamHI KpnI(blunt) fragment  containing humanized  
                                                                         Cre from 3950 (JH) into pCF247BamHI&EcoRI(blunt) 
PKH52          pKH47             Amp                  BssHII fragment from pCF157 into pKH47 
pKH53          pKH52             Amp                  NdeI Pci I fragment from Ad5 into pKH52 
pKH54          pKH22             Amp                  HpaI BstEII fragment from pKH47 into pKH22 
pKH55          pKH53             Amp                  KpnI HIndIII fragment containing Cre to pCIneo ScaI  
                                                                         NotI by Joerg Huelsken(JH3955) 
pKH56          pKH53             Amp                  MfeI BstXI fragment of pKH42 into pKH53 fiber  
                                                                         IRES Sal site created 
pKH57          pCF395             Chlor                ∆Fiber∆E4 Loxp fragment of pKH49 with partial  
                                                                         AvrII and SalI into pCF395 (gaprepair E1A, E1B,   
                                                                         E4old TCF sites)  
pKH58           pCF396            Chlor                 ∆Fiber∆E4 Loxp fragment of pKH49 with partial  
                                                                          AvrII and SalI into pCF396(gaprepair E1A, E1B,   
                                                                          NewE4 TCF sites) AvrII&SalI 
pKH59            pKH56            Amp                   Three way ligation to put GFP after fiber IRES  
                                                                           from pKH30. pKH30(PmlI&SpeI)  pKH56  
                                                                           NdeI&BfrBI and NdeI SpeI        
pKH60            pUC18             Amp                  SalI fragment of pWPI into pUC18 SalI 
pKH61            pKH56            Amp                   NdeI&SmaI fragment of pKH60 into pKH 56    
                                                                           PciI(Klenow blunt)&NdeI 
pKH62            pKH56            Amp                   Three way ligation to put dsRED after fibre IRES  
                                                                            from pKH30. pKH30  (PmlI&SpeI)  pKH56  
                                                                            NdeI&BfrBI and NdeI SpeI backbone)  
pKH63            pWPI               Amp                  Cre PCR Product(PmeI at the ends) from pKH55  
                                                                           into pWPI PmeI !! Double blunt.  
pKH64            pKH53            Amp                   iPCR with oKH32 and oKH33 to create NotI site  
                                                                           just after loxp normal 5' fiber. 
pKH65            pBSSK-            Amp                  BamHI casette from pSP161 into pBS- 
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pKH66            pKH64            Amp                   NotI &EcoRI fragment of pKH65 into  NotI            
                                                                           & MfeI of pKH64 
pKH67            pCF159           Amp                    iPCR with OKH 11 and oKH12 
pKH68            pKH67           Amp                     IPCR with oKH9 and oKH10 
pKH69            pRS406           Amp                    XbaI/KpnI fragment of pKH68 
pKH70            pRS406           Amp                    XbaI/KpnI fragment of pKH67 
pKH71             JH4152          Amp                     JH4152 EF 1alfa Cre PGK GFP cPPT  
pKH72             pWPI             Amp                     JH4153 cPPT (PGK CreERT, PGK GFP)  
pKH73             pKH69          Amp                    pKH53 BssHII&BspEI, pKH26   
                                                                           NdeI&BSSHII fragments in 3way ligation into  
                                                                           pKH69 NdeI&BSPEI. RGD into th addback   
                                                                           plasmid. 
pKH74             pKH70          Amp, Chlor         attP2 site from pSP24.1 ApoI BsaAI fragment to  
                                                                           pKH70 EcoRI SmaI 
pKH75             pKH69          Amp                   Create Pac I site after loxp with oligos oKH36 and  
                                                                           oKH35 in pKH69 
pKH76             pKH75          Amp                    Backcloning from pKH53 NdeI PciI to pKH75.  
                                                                           Fiber+ E4 backcloning. 
pKH77             pKH76          Amp                    pKH74 NotI EcoRI fragment to pKH76 NotI   
                                                                           MfeI 
pKH78             pKH77          Amp                    Short Ad41 fiber with oKH36 and oKH37 NotI 
                                                                            MfeI into pKH76 NotI MfeI 
pKH85             pKH70          Amp, Chlor         KpnI Nhe I fragment from pKH68 into KpnI SpeI  
                                                                           of pKH27 attR2 Cmr ccDB attR1 reverse orientation. 
pKH87             PDV67          Amp, Zeo            pDV67 pcDNA3.1 Zeomycin TPL fiber from D. von  
                                                                           Seggern 
pKH88             pBS               Amp                     pKH69 XmaI&HpaI fragment into AflIII blunt XmaI  
                                                                            fragment of pBS. Recepient for HI loop extension.  
                                                                            Knob only in pBS background. After iPCRs.   
                                                                            XmaI&EcoNI fragment can be cloned back   
                                                                            to pKH69 
pKH92             pSD3             Amp                     Deletion of GFP from the Naldini lentivector for insertion  
                                                                            of U6 mi30 Rictor miRNA from pKH91 and pKH91. It 
                                                                            still has CMV and WPRE. The new cassette has PGK  
                                                                             puro. pSD3 AgeI&SalI  T4 blunt. 
pKH93             pKH110        Amp                     pKH110 deletion from EcoRI to NheI that can serve  
                                                                             as PCR basis for PacI insertion. Check with   
                                                                            PvuI. Clone further with BamHI&NdeI. 
pKH96             pKH88          Amp                     HI loop extension inserting double alfa helix and  
                                                                            CDCRGDCFC. IPCR wit oKH45andoKH46   
                                                                             on pKH88. 
pKH97             pKH96          Amp                     HI loop extension inserting double alfa helix and  
                                                                            CDCRGDCFC. PCR with oKH48andoKH49  
                                                                             on iPCR product of pKH88 
pKH98             pKH97          Amp                     HI loop extension inserting double alfa helix and  
                                                                            CDCRGDCFC. PCR with oKH50 and  
                                                                            oKH51 on PCR product. 
pKH99             pKH98          Amp                     HI loop extension inserting double alfa helix and  
                                                                            CDCRGDCFC. PCR with oKH52 and   
                                                                            oKH53 on PCR product  
pKH100           pKH110        Amp                     Backcloning the fiber E4 region from  pKH53.  
                                                                            pKH110 NdeI BspEI as vector and NdeI   
                                                                            BspeI fragment(4 KB) from pKH53. 
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pKH101           pKH93          Amp                     Create Pac site before fiber. iPCR with oKH35&36  
pKH102           pKH101        Amp                      Delete SpeI site infront of LoxP wt. SpeI blunt self ligate 
pKH103           pKH100        Amp                      Helix loop into recombination plasmid. XmaI EcoNI 
                                                                            fragment from pKH99 into XmaI&EcoNI  
                                                                            backbone of pKH100 
pKH104           pKH110        Amp                      SpeI site after fiber. fiber SpeI from pCF263 into pKH110 
pKH105           pKH104        Amp                      PacI site from pKH101 into pKH104 
pKH106           pKH105        Amp, Chlor           AttR1-ccdB-AttR2 Strep containing Gateway cassette from 
                                                                            JH3894into adback plasmid. 
pKH110           pKH27          Amp                      BamHIand EcoRI digested PCR with loxrecupper and  
                                                                            loxreclower from pKH53 into pBSSK  
                                                                           BamHIand EcoRI 
     
 
 
 
 
 
 
 
5.3 Oligo list 
 
Name                Sequence 
 
oKH1                 5'-GCAGGATCCACCATGAAGCGCGCAAGAC-3' 
oKH2                 5'-CGGGAATTCTTATTCTTGGGCAATGTATGA-3'   
oKH4 upper       5’-CCAACCCTTTGATCTAGTCCTATATAATG-3’ 
oKH4lower        5’-AGGAAAGCAAAGTCAGTCACAATC-3’ 
oKH5                 5’-AGTCGGGCGGAGGAGAAGC-3’ 
oKH6                 5’-AGTATCGTTCATGTCCTCCACCG-3’ 
oKH7                 5’-GGCGCTTCAAACATAAACCTGGAA-3’ 
oKH8                 5’-GGCTCCGAGAGGTGGGCTCACAGT-3’ 
oKH9                 5’-GGTGGTGGAGATGCTAAACTCACTTTGGTC-3’ 
oKH10               5’-ATTTAGACTACAGTTAGGAGATGGAGCTGG-3’ 
oKH11               5’-GGAGACTGTTTCTGCCCAAGTGCATACTCTATGTC-3’ 
oKH12               5’-GCGGCAGTCACAAGTTGTGTCTCCTGTTTCCT-3’ 
oKH13               5’-TGAGCTCACGTGAGCAAGGGCGAGGAGCTG-3’ 
oKH14               5’-GGACTAGTTTATTACTTGTACAGCTCGTCCATGCCGAGAGT-3’ 
oKH15               5’-AAACAGTCTCCGCGGCAGTCA-3’ 
oKH16               5’-TAACCACTGTGAGCCCACCTCTCGGAGC-3’ 
oKH17               5’-GCAGAAACAGTCTCCGCGGCAGTCACA-3’ 
oKH18               5’-TCCTAACTGTAGTCTAAATGGTGGTGG-3’ 
oKH19               5’-CCAGTTGCTACGGTCAAAGTGTTTA-3’ 
oKH20               5’-GTGTATCCATATGACACGGAAACC-3’ 
oKH21               5’-GAGCCGGCGCTTCAAACAT-3’ 
oKH22               5’-AGCACCTCCTTGCCCTCCT-3’ 
oKH23               5’-TGCCCGCGACCATTAGAG-3’ 
oKH24               5’-TAACTGTAGTCTAAATGGTGGTGGA-3’ 
oKH25               5’-ACCGTGAGATTTTGGATAAGCTC-3’ 
oKH26               5’-TGGAACAGTTCAAAGTCCTCATCTTATT-3’ 
oKH27               5’-GAAACAGTCTCCGCGGCAGTC-3’ 
oKH28               5’-GTATAATGTATACTATACCAAGTTATTAA-3’ 
oKH29               5’-TATACGAAGTTATACCAGAGCTG-3’ 
oKH30               5’-GGTTTAAACATGGTGCCCAAGAAGA-3’ 
oKH31               5’-CGTTTAAACTCAGTCCCCATCCTCG-3’ 
oKH32               5’-AGGATCCGTATAACTTCGTATAA-3’ 
oKH33               5’-AGGATCCCAGAGCTGGGAGGAGG-3’ 
oKH34               5’-GCGGCCGCATAACTTCGTATAGCATACATTAT-3’ 
oKH35               5’-GCTGCAAACTTTCTCCACAATCTA-3’ 
oKH36               5’-TTAATTAAATAACTTCGTATAGCATACATTAT-3’ 
oKH37               5’-TACGGATCCGCCACCATGATTCGCTGCTTGA-3’ 
oKH38               5’-GACGAATTCTTATTCCAAAAGATTATCCA-3’ 
oKH39               5’-ACAGGAGACACAACTGGAGGTTTAGCAGCATTAGATGCAGAC-3’ 
oKH40               5’-AGAGTATGCACTTGGACCTCCTAAGGCTGCTTCTCC 
                               ACCTCT-3’ 
oKH41               5’-GCATTAGATGCAGACTTAGCTGCGCTAGACGCTCACGTC      
                               GCA-3’ 
oKH42               5’-TGCTTCTCGACCTCTAAGAGCAGCTTCTCTTCCTCTTAAGCC-3’ 
oKH43               5’-GACGCTGACGTCGGAGGTTGTGACTGCCGCGGTCAT-3’ 
oKH44               5’-TCTTCCTCTTAAGCCACCACAGCCGCA-3’ 
oKH45               5’-ATCTAATGCAGCTAATCCACCAGTTGTGTCTCCTGTTTC-3’ 
oKH46               5’-AGAGAAGCAGCTTTAGCAGGACCAAGTGCATACTCTAT-3’ 
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oKH47               5’-ATCAGCATCTAATGCAGCTAATCCACC-3’ 
oKH48               5’-AGAGGAAGAGAAGCAGCTTTAAGAGGAAGAGAAGCAGCTT  
                                TAGCAGGA-3’ 
oKH49               5’-TAAAGCAGCTAAATCAGCATCTAATGCAGCTAATCC-3’ 
oKH50               5’-GATTGTTTTTGTGGTGCAGGTAGAGGAAGAGAAG  
                               CAGCTTTAAGA-3’ 
oKH51               5’-ACCATCAGCATCTAAAGCAGCTAAATCAGC-3’ 
oKH52               5’-GATTGTTTTTGTGGTGCAGGT-3’ 
oKH53               5’-TCCTCTACAATCACAACCAGCACCATCAGCATCTAAAGC-3’ 
oKH54               5’-AGAGGAGATTGTTTTTGTGGTGCAG-3’ 
oKH55               5’-ACAATCACAACCAGCACCATC-3’ 
oKH56               5’-GTTAATTAAACCATGAAAAGAACCAGAATTGAAGAC-3’ 
oKH57               5’-GGACTAGTTTATTGTTCAGTTATGTAGCAA-3’ 
oKH58               5’-GTCTAGAGTCACCGAGTTGCTT-3’ 
oKH59               5’-TTGGGCCCAGGGTTGGACTCGAC-3’ 
oKH60               5’-CTACTAGTTTACTTGTACAGCTCGTCCATGC-3’ 
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5.4 Yeast strains 
 
yKH1: vpKH1, E1A, E1B, E4 promoter TCF sites, wt fibre 
yKH2: vpKH2 Loxp, ∆Fibre/E4, mutant LoxP 
yKH3: vpKH3, E1A, E1B, E4 promoter TCF sites;  ∆ CAR binding, RGD 
yKH4  vpKH4, E1A, E1B, E4 promoter TCF sites;  ∆ CAR; ∆ HSPG binding, RGD 
yKH5  vpKH5 Loxp, ∆Fibre/E4,  
yKH6  vpKH6, E1A, E1B, E4 promoter TCF sites;  RGD 
yKH8  vpKH8 Loxp, ∆Fibre/E4; dl1520, CMV EGFP cassette in olace of E1B55K 
yKH9  vpKH9 Loxp, ∆Fibre/E4; E1B TCF promoter 
yKH10 vpKH10 Loxp, ∆Fibre/E4; E1B TCF promoter; E1A ∆24 
yKH11 vpKH11 Loxp, ∆Fibre/E4; E1A E1B old E4 TCF promoter 
yKH12 vpKH12 Loxp, ∆Fibre/E4; E1A E1B new E4 TCF promoter 
yKH16 vpKH16 HRE, TCF E1A, TCF E1B, old TCF E4 promoters; RGD fibre 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
6. References 
 
1. Dimmock, N. J., Easton, A. J. & Leppard, K. Introduction to modern virology (Blackwell 
Science, Malden, MA, 2001). 
2. Russell, W. C. Update on adenovirus and its vectors. J Gen Virol 81, 2573-604 (2000). 
3. Mathis, J. M., Stoff-Khalili, M. A. & Curiel, D. T. Oncolytic adenoviruses - selective 
retargeting to tumor cells. Oncogene 24, 7775-91 (2005). 
4. Webb, H. E. & Smith, C. E. Viruses in the treatment of cancer. Lancet 1, 1206-8 (1970). 
5. Trotman, L. C., Mosberger, N., Fornerod, M., Stidwill, R. P. & Greber, U. F. Import 
of adenovirus DNA involves the nuclear pore complex receptor CAN/Nup214 and 
histone H1. Nat Cell Biol 3, 1092-100 (2001). 
6. Hearing, P. & Shenk, T. The adenovirus type 5 E1A transcriptional control region 
contains a duplicated enhancer element. Cell 33, 695-703 (1983). 
7. Lutz, P., Rosa-Calatrava, M. & Kedinger, C. The product of the adenovirus 
intermediate gene IX is a transcriptional activator. J Virol 71, 5102-9 (1997). 
8. Avvakumov, N., Wheeler, R., D'Halluin, J. C. & Mymryk, J. S. Comparative sequence 
analysis of the largest E1A proteins of human and simian adenoviruses. J Virol 76, 
7968-75 (2002). 
9. Chellappan, S. P., Hiebert, S., Mudryj, M., Horowitz, J. M. & Nevins, J. R. The E2F 
transcription factor is a cellular target for the RB protein. Cell 65, 1053-61 (1991). 
10. Nevins, J. R. et al. Transactivation by the adenovirus E1A gene. Biochem Cell Biol 66, 
578-83 (1988). 
11. Lee, K. A. et al. A cellular protein, activating transcription factor, activates 
transcription of multiple E1A-inducible adenovirus early promoters. Proc Natl Acad Sci 
U S A 84, 8355-9 (1987). 
12. Chiou, S. K., Tseng, C. C., Rao, L. & White, E. Functional complementation of the 
adenovirus E1B 19-kilodalton protein with Bcl-2 in the inhibition of apoptosis in 
infected cells. J Virol 68, 6553-66 (1994). 
13. Yew, P. R., Liu, X. & Berk, A. J. Adenovirus E1B oncoprotein tethers a transcriptional 
repression domain to p53. Genes Dev 8, 190-202 (1994). 
14. Harada, J. N., Shevchenko, A., Pallas, D. C. & Berk, A. J. Analysis of the adenovirus 
E1B-55K-anchored proteome reveals its link to ubiquitination machinery. J Virol 76, 
9194-206 (2002). 
15. Horridge, J. J. & Leppard, K. N. RNA-binding activity of the E1B 55-kilodalton 
protein from human adenovirus type 5. J Virol 72, 9374-9 (1998). 
16. Dobbelstein, M., Roth, J., Kimberly, W. T., Levine, A. J. & Shenk, T. Nuclear export 
of the E1B 55-kDa and E4 34-kDa adenoviral oncoproteins mediated by a rev-like 
signal sequence. Embo J 16, 4276-84 (1997). 
17. Friefeld, B. R., Krevolin, M. D. & Horwitz, M. S. Effects of the adenovirus H5ts125 
and H5ts107 DNA binding proteins on DNA replication in vitro. Virology 124, 380-9 
(1983). 
18. Chang, L. S. & Shenk, T. The adenovirus DNA-binding protein stimulates the rate of 
transcription directed by adenovirus and adeno-associated virus promoters. J Virol 64, 
2103-9 (1990). 
19. Carter, T. H. & Blanton, R. A. Possible role of the 72,000 dalton DNA-binding 
protein in regulation of adenovirus type 5 early gene expression. J Virol 25, 664-74 
(1978). 
20. Fredman, J. N. & Engler, J. A. Adenovirus precursor to terminal protein interacts with 
the nuclear matrix in vivo and in vitro. J Virol 67, 3384-95 (1993). 
21. Fessler, S. P., Delgado-Lopez, F. & Horwitz, M. S. Mechanisms of E3 modulation of 
immune and inflammatory responses. Curr Top Microbiol Immunol 273, 113-35 (2004). 
 103 
22. Efrat, S., Fejer, G., Brownlee, M. & Horwitz, M. S. Prolonged survival of pancreatic 
islet allografts mediated by adenovirus immunoregulatory transgenes. Proc Natl Acad Sci 
U S A 92, 6947-51 (1995). 
23. Horwitz, M. S. Adenovirus immunoregulatory genes and their cellular targets. Virology 
279, 1-8 (2001). 
24. Burgert, H. G. & Kvist, S. An adenovirus type 2 glycoprotein blocks cell surface 
expression of human histocompatibility class I antigens. Cell 41, 987-97 (1985). 
25. Wold, W. S. et al. Immune responses to adenoviruses: viral evasion mechanisms and 
their implications for the clinic. Curr Opin Immunol 11, 380-6 (1999). 
26. Benedict, C. A. et al. Three adenovirus E3 proteins cooperate to evade apoptosis by 
tumor necrosis factor-related apoptosis-inducing ligand receptor-1 and -2. J Biol Chem 
276, 3270-8 (2001). 
27. Tollefson, A. E. et al. The adenovirus death protein (E3-11.6K) is required at very late 
stages of infection for efficient cell lysis and release of adenovirus from infected cells. J 
Virol 70, 2296-306 (1996). 
28. Goodrum, F. D., Shenk, T. & Ornelles, D. A. Adenovirus early region 4 34-kilodalton 
protein directs the nuclear localization of the early region 1B 55-kilodalton protein in 
primate cells. J Virol 70, 6323-35 (1996). 
29. Stracker, T. H., Carson, C. T. & Weitzman, M. D. Adenovirus oncoproteins inactivate 
the Mre11-Rad50-NBS1 DNA repair complex. Nature 418, 348-52 (2002). 
30. Boyer, J., Rohleder, K. & Ketner, G. Adenovirus E4 34k and E4 11k inhibit double 
strand break repair and are physically associated with the cellular DNA-dependent 
protein kinase. Virology 263, 307-12 (1999). 
31. Obert, S., O'Connor, R. J., Schmid, S. & Hearing, P. The adenovirus E4-6/7 protein 
transactivates the E2 promoter by inducing dimerization of a heteromeric E2F 
complex. Mol Cell Biol 14, 1333-46 (1994). 
32. Hardy, S. & Shenk, T. E2F from adenovirus-infected cells binds cooperatively to 
DNA containing two properly oriented and spaced recognition sites. Mol Cell Biol 9, 
4495-506 (1989). 
33. Schaley, J., O'Connor, R. J., Taylor, L. J., Bar-Sagi, D. & Hearing, P. Induction of the 
cellular E2F-1 promoter by the adenovirus E4-6/7 protein. J Virol 74, 2084-93 (2000). 
34. Glaunsinger, B. A., Lee, S. S., Thomas, M., Banks, L. & Javier, R. Interactions of the 
PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 
oncoproteins. Oncogene 19, 5270-80 (2000). 
35. Frese, K. K. et al. Selective PDZ protein-dependent stimulation of 
phosphatidylinositol 3-kinase by the adenovirus E4-ORF1 oncoprotein. Oncogene 22, 
710-21 (2003). 
36. Kleinberger, T. & Shenk, T. Adenovirus E4orf4 protein binds to protein phosphatase 
2A, and the complex down regulates E1A-enhanced junB transcription. J Virol 67, 
7556-60 (1993). 
37. Muller, U., Kleinberger, T. & Shenk, T. Adenovirus E4orf4 protein reduces 
phosphorylation of c-Fos and E1A proteins while simultaneously reducing the level of 
AP-1. J Virol 66, 5867-78 (1992). 
38. Kornitzer, D., Sharf, R. & Kleinberger, T. Adenovirus E4orf4 protein induces PP2A-
dependent growth arrest in Saccharomyces cerevisiae and interacts with the anaphase-
promoting complex/cyclosome. J Cell Biol 154, 331-44 (2001). 
39. O'Shea, C. et al. Adenoviral proteins mimic nutrient/growth signals to activate the 
mTOR pathway for viral replication. Embo J 24, 1211-21 (2005). 
40. Toth, M., Doerfler, W. & Shenk, T. Adenovirus DNA replication facilitates binding of 
the MLTF/USF transcription factor to the viral major late promoter within infected 
cells. Nucleic Acids Res 20, 5143-8 (1992). 
 104 
41. Lutz, P. & Kedinger, C. Properties of the adenovirus IVa2 gene product, an effector of 
late-phase-dependent activation of the major late promoter. J Virol 70, 1396-405 
(1996). 
42. Perez-Romero, P., Gustin, K. E. & Imperiale, M. J. Dependence of the encapsidation 
function of the adenovirus L1 52/55-kilodalton protein on its ability to bind the 
packaging sequence. J Virol 80, 1965-71 (2006). 
43. Zhang, W. & Arcos, R. Interaction of the adenovirus major core protein precursor, 
pVII, with the viral DNA packaging machinery. Virology 334, 194-202 (2005). 
44. Chastain-Moore, A. M., Roberts, T., Trott, D. A., Newbold, R. F. & Ornelles, D. A. 
An activity associated with human chromosome 21 permits nuclear colocalization of 
the adenovirus E1B-55K and E4orf6 proteins and promotes viral late gene expression. 
J Virol 77, 8087-98 (2003). 
45. Cuesta, R., Xi, Q. & Schneider, R. J. Structural basis for competitive inhibition of 
eIF4G-Mnk1 interaction by the adenovirus 100-kilodalton protein. J Virol 78, 7707-16 
(2004). 
46. Cuesta, R., Xi, Q. & Schneider, R. J. Adenovirus-specific translation by displacement 
of kinase Mnk1 from cap-initiation complex eIF4F. Embo J 19, 3465-74 (2000). 
47. Yueh, A. & Schneider, R. J. Selective translation initiation by ribosome jumping in 
adenovirus-infected and heat-shocked cells. Genes Dev 10, 1557-67 (1996). 
48. Zhang, Y. & Schneider, R. J. Adenovirus inhibition of cell translation facilitates release 
of virus particles and enhances degradation of the cytokeratin network. J Virol 68, 
2544-55 (1994). 
49. Bischoff, J. R. et al. An adenovirus mutant that replicates selectively in p53-deficient 
human tumor cells. Science 274, 373-6 (1996). 
50. Nemunaitis, J. et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin 
to tumors of patients with non-small-cell lung cancer. J Clin Oncol 18, 609-22 (2000). 
51. Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a 
replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin 
Oncol 19, 289-98 (2001). 
52. Nemunaitis, J. et al. Pilot trial of intravenous infusion of a replication-selective 
adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in 
refractory cancer patients. Cancer Gene Ther 10, 341-52 (2003). 
53. Habib, N. et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for 
hepatocellular carcinoma. Cancer Gene Ther 9, 254-9 (2002). 
54. Reid, T. et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus 
(dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 62, 6070-9 
(2002). 
55. Reid, T. et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) 
in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther 8, 
1618-26 (2001). 
56. Rothmann, T., Hengstermann, A., Whitaker, N. J., Scheffner, M. & zur Hausen, H. 
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 
status in tumor cells. J Virol 72, 9470-8 (1998). 
57. O'Shea, C. C. et al. Late viral RNA export, rather than p53 inactivation, determines 
ONYX-015 tumor selectivity. Cancer Cell 6, 611-23 (2004). 
58. Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective 
systemic anti-tumoral efficacy. Nat Med 6, 1134-9 (2000). 
59. Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-
glioma effect in vivo. Oncogene 19, 2-12 (2000). 
60. Cascallo, M., Capella, G., Mazo, A. & Alemany, R. Ras-dependent oncolysis with an 
adenovirus VAI mutant. Cancer Res 63, 5544-50 (2003). 
 105 
61. Rodriguez, R. et al. Prostate attenuated replication competent adenovirus (ARCA) 
CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. 
Cancer Res 57, 2559-63 (1997). 
62. Yu, D. C., Sakamoto, G. T. & Henderson, D. R. Identification of the transcriptional 
regulatory sequences of human kallikrein 2 and their use in the construction of calydon 
virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. 
Cancer Res 59, 1498-504 (1999). 
63. Parr, M. J. et al. Tumor-selective transgene expression in vivo mediated by an E2F-
responsive adenoviral vector. Nat Med 3, 1145-9 (1997). 
64. Hu, S. X., Ji, W., Zhou, Y., Logothetis, C. & Xu, H. J. Development of an adenovirus 
vector with tetracycline-regulatable human tumor necrosis factor alpha gene 
expression. Cancer Res 57, 3339-43 (1997). 
65. Shewach, D. S. et al. Enhanced cytotoxicity of antiviral drugs mediated by adenovirus 
directed transfer of the herpes simplex virus thymidine kinase gene in rat glioma cells. 
Cancer Gene Ther 1, 107-12 (1994). 
66. Freytag, S. O. et al. Phase I study of replication-competent adenovirus-mediated 
double suicide gene therapy for the treatment of locally recurrent prostate cancer. 
Cancer Res 62, 4968-76 (2002). 
67. Weedon, S. J. et al. Sensitisation of human carcinoma cells to the prodrug CB1954 by 
adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 86, 848-54 
(2000). 
68. Fuerer, C. & Iggo, R. 5-Fluorocytosine increases the toxicity of Wnt-targeting 
replicating adenoviruses that express cytosine deaminase as a late gene. Gene Ther 11, 
142-51 (2004). 
69. Lukashev, A. N., Fuerer, C., Chen, M. J., Searle, P. & Iggo, R. Late Expression of 
Nitroreductase in an Oncolytic Adenovirus Sensitizes Colon Cancer Cells to the 
Prodrug CB1954. Hum Gene Ther (2005). 
70. Segerman, A. et al. Adenovirus type 11 uses CD46 as a cellular receptor. J Virol 77, 
9183-91 (2003). 
71. Gaggar, A., Shayakhmetov, D. M. & Lieber, A. CD46 is a cellular receptor for group B 
adenoviruses. Nat Med 9, 1408-12 (2003). 
72. Roelvink, P. W., Mi Lee, G., Einfeld, D. A., Kovesdi, I. & Wickham, T. J. 
Identification of a conserved receptor-binding site on the fiber proteins of CAR-
recognizing adenoviridae. Science 286, 1568-71 (1999). 
73. Kirby, I. et al. Identification of contact residues and definition of the CAR-binding site 
of adenovirus type 5 fiber protein. J Virol 74, 2804-13 (2000). 
74. Kirby, I. et al. Mutations in the DG loop of adenovirus type 5 fiber knob protein 
abolish high-affinity binding to its cellular receptor CAR. J Virol 73, 9508-14 (1999). 
75. Dmitriev, I. et al. An adenovirus vector with genetically modified fibers demonstrates 
expanded tropism via utilization of a coxsackievirus and adenovirus receptor-
independent cell entry mechanism. J Virol 72, 9706-13 (1998). 
76. Hong, S. S. & Boulanger, P. Protein ligands of the human adenovirus type 2 outer 
capsid identified by biopanning of a phage-displayed peptide library on separate 
domains of wild-type and mutant penton capsomers. Embo J 14, 4714-27 (1995). 
77. Mizuguchi, H. et al. CAR- or alphav integrin-binding ablated adenovirus vectors, but 
not fiber-modified vectors containing RGD peptide, do not change the systemic gene 
transfer properties in mice. Gene Ther 9, 769-76 (2002). 
78. Wu, E. et al. Flexibility of the adenovirus fiber is required for efficient receptor 
interaction. J Virol 77, 7225-35 (2003). 
79. Wu, E. & Nemerow, G. R. Virus yoga: the role of flexibility in virus host cell 
recognition. Trends Microbiol 12, 162-9 (2004). 
 106 
80. Dechecchi, M. C., Tamanini, A., Bonizzato, A. & Cabrini, G. Heparan sulfate 
glycosaminoglycans are involved in adenovirus type 5 and 2-host cell interactions. 
Virology 268, 382-90 (2000). 
81. Smith, T. A. et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in 
mice. Hum Gene Ther 14, 777-87 (2003). 
82. Willcox, N. & Mautner, V. Antigenic determinants of adenovirus capsids. II. 
Homogeneity of hexons, and accessibility of their determinants, in the virion. J Immunol 
116, 25-9 (1976). 
83. Nicol, C. G. et al. Effect of adenovirus serotype 5 fiber and penton modifications on 
in vivo tropism in rats. Mol Ther 10, 344-54 (2004). 
84. Shayakhmetov, D. M., Gaggar, A., Ni, S., Li, Z. Y. & Lieber, A. Adenovirus binding to 
blood factors results in liver cell infection and hepatotoxicity. J Virol 79, 7478-91 
(2005). 
85. Martin, K. et al. Simultaneous CAR- and alpha V integrin-binding ablation fails to 
reduce Ad5 liver tropism. Mol Ther 8, 485-94 (2003). 
86. Koizumi, N. et al. Reduction of natural adenovirus tropism to mouse liver by fiber-
shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J 
Virol 77, 13062-72 (2003). 
87. Breidenbach, M. et al. Genetic replacement of the adenovirus shaft fiber reduces liver 
tropism in ovarian cancer gene therapy. Hum Gene Ther 15, 509-18 (2004). 
88. Miller, C. R. et al. Differential susceptibility of primary and established human glioma 
cells to adenovirus infection: targeting via the epidermal growth factor receptor 
achieves fiber receptor-independent gene transfer. Cancer Res 58, 5738-48 (1998). 
89. Cripe, T. P. et al. Fiber knob modifications overcome low, heterogeneous expression 
of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and 
oncolysis for human rhabdomyosarcoma cells. Cancer Res 61, 2953-60 (2001). 
90. Yamamoto, H., Itoh, F., Hinoda, Y. & Imai, K. Inverse association of cell adhesion 
regulator messenger RNA expression with metastasis in human colorectal cancer. 
Cancer Res 56, 3605-9 (1996). 
91. Yoshida, Y. et al. Generation of fiber-mutant recombinant adenoviruses for gene 
therapy of malignant glioma. Hum Gene Ther 9, 2503-15 (1998). 
92. Shinoura, N. et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective 
adenovirus for gene therapy of gliomas. Cancer Res 59, 3411-6 (1999). 
93. Wickham, T. J. et al. Increased in vitro and in vivo gene transfer by adenovirus vectors 
containing chimeric fiber proteins. J Virol 71, 8221-9 (1997). 
94. Joung, I. et al. Improved gene delivery into neuroglial cells using a fiber-modified 
adenovirus vector. Biochem Biophys Res Commun 328, 1182-7 (2005). 
95. Hong, J. S. & Engler, J. A. Domains required for assembly of adenovirus type 2 fiber 
trimers. J Virol 70, 7071-8 (1996). 
96. Belousova, N., Krendelchtchikova, V., Curiel, D. T. & Krasnykh, V. Modulation of 
adenovirus vector tropism via incorporation of polypeptide ligands into the fiber 
protein. J Virol 76, 8621-31 (2002). 
97. Wu, H. et al. Double modification of adenovirus fiber with RGD and polylysine 
motifs improves coxsackievirus-adenovirus receptor-independent gene transfer 
efficiency. Hum Gene Ther 13, 1647-53 (2002). 
98. Koizumi, N., Mizuguchi, H., Utoguchi, N., Watanabe, Y. & Hayakawa, T. Generation 
of fiber-modified adenovirus vectors containing heterologous peptides in both the HI 
loop and C terminus of the fiber knob. J Gene Med 5, 267-76 (2003). 
99. Vanderkwaak, T. J. et al. An advanced generation of adenoviral vectors selectively 
enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol Oncol 74, 
227-34 (1999). 
 107 
100. Hemminki, A. et al. An adenovirus with enhanced infectivity mediates molecular 
chemotherapy of ovarian cancer cells and allows imaging of gene expression. Mol Ther 
4, 223-31 (2001). 
101. Wesseling, J. G. et al. Improved gene transfer efficiency to primary and established 
human pancreatic carcinoma target cells via epidermal growth factor receptor and 
integrin-targeted adenoviral vectors. Gene Ther 8, 969-76 (2001). 
102. Dirven, C. M. et al. Gene therapy for meningioma: improved gene delivery with 
targeted adenoviruses. J Neurosurg 97, 441-9 (2002). 
103. Grill, J. et al. Combined targeting of adenoviruses to integrins and epidermal growth 
factor receptors increases gene transfer into primary glioma cells and spheroids. Clin 
Cancer Res 7, 641-50 (2001). 
104. Homicsko, K., Lukashev, A. & Iggo, R. D. RAD001 (everolimus) improves the 
efficacy of replicating adenoviruses that target colon cancer. Cancer Res 65, 6882-90 
(2005). 
105. Colby, W. W. & Shenk, T. Adenovirus type 5 virions can be assembled in vivo in the 
absence of detectable polypeptide IX. J Virol 39, 977-80 (1981). 
106. Stewart, P. L., Burnett, R. M., Cyrklaff, M. & Fuller, S. D. Image reconstruction reveals 
the complex molecular organization of adenovirus. Cell 67, 145-54 (1991). 
107. Lehmberg, E. et al. Reversed-phase high-performance liquid chromatographic assay 
for the adenovirus type 5 proteome. J Chromatogr B Biomed Sci Appl 732, 411-23 (1999). 
108. Akalu, A., Liebermann, H., Bauer, U., Granzow, H. & Seidel, W. The subgenus-
specific C-terminal region of protein IX is located on the surface of the adenovirus 
capsid. J Virol 73, 6182-7 (1999). 
109. Dmitriev, I. P., Kashentseva, E. A. & Curiel, D. T. Engineering of adenovirus vectors 
containing heterologous peptide sequences in the C terminus of capsid protein IX. J 
Virol 76, 6893-9 (2002). 
110. Vellinga, J. et al. Spacers increase the accessibility of peptide ligands linked to the 
carboxyl terminus of adenovirus minor capsid protein IX. J Virol 78, 3470-9 (2004). 
111. Vellinga, J., Van der Heijdt, S. & Hoeben, R. C. The adenovirus capsid: major progress 
in minor proteins. J Gen Virol 86, 1581-8 (2005). 
112. Wu, H. et al. Identification of sites in adenovirus hexon for foreign peptide 
incorporation. J Virol 79, 3382-90 (2005). 
113. Segerman, A., Arnberg, N., Erikson, A., Lindman, K. & Wadell, G. There are two 
different species B adenovirus receptors: sBAR, common to species B1 and B2 
adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J Virol 77, 
1157-62 (2003). 
114. Short, J. J. et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as 
cellular attachment receptors. Virology 322, 349-59 (2004). 
115. Sirena, D. et al. The human membrane cofactor CD46 is a receptor for species B 
adenovirus serotype 3. J Virol 78, 4454-62 (2004). 
116. Arnberg, N., Pring-Akerblom, P. & Wadell, G. Adenovirus type 37 uses sialic acid as a 
cellular receptor on Chang C cells. J Virol 76, 8834-41 (2002). 
117. Arnberg, N., Edlund, K., Kidd, A. H. & Wadell, G. Adenovirus type 37 uses sialic acid 
as a cellular receptor. J Virol 74, 42-8 (2000). 
118. Cashman, S. M., Morris, D. J. & Kumar-Singh, R. Adenovirus type 5 pseudotyped with 
adenovirus type 37 fiber uses sialic acid as a cellular receptor. Virology 324, 129-39 
(2004). 
119. Wu, E. et al. A 50-kDa membrane protein mediates sialic acid-independent binding 
and infection of conjunctival cells by adenovirus type 37. Virology 279, 78-89 (2001). 
120. Wu, E. et al. Membrane cofactor protein is a receptor for adenoviruses associated with 
epidemic keratoconjunctivitis. J Virol 78, 3897-905 (2004). 
121. Gruber, W. C., Russell, D. J. & Tibbetts, C. Fiber gene and genomic origin of human 
adenovirus type 4. Virology 196, 603-11 (1993). 
 108 
122. Rivera, A. A. et al. Combining high selectivity of replication with fiber chimerism for 
effective adenoviral oncolysis of CAR-negative melanoma cells. Gene Ther 11, 1694-702 
(2004). 
123. Volk, A. L. et al. Enhanced adenovirus infection of melanoma cells by fiber-
modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther 2, 
511-5 (2003). 
124. Sova, P. et al. A tumor-targeted and conditionally replicating oncolytic adenovirus 
vector expressing TRAIL for treatment of liver metastases. Mol Ther 9, 496-509 (2004). 
125. Ni, S. et al. Evaluation of biodistribution and safety of adenovirus vectors containing 
group B fibers after intravenous injection into baboons. Hum Gene Ther 16, 664-77 
(2005). 
126. Denby, L. et al. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup 
D show modified tropism in vitro and in vivo. Hum Gene Ther 15, 1054-64 (2004). 
127. Zabner, J. et al. A chimeric type 2 adenovirus vector with a type 17 fiber enhances 
gene transfer to human airway epithelia. J Virol 73, 8689-95 (1999). 
128. Nakamura, T., Sato, K. & Hamada, H. Reduction of natural adenovirus tropism to the 
liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and 
use of replaceable short fiber. J Virol 77, 2512-21 (2003). 
129. Krasnykh, V., Belousova, N., Korokhov, N., Mikheeva, G. & Curiel, D. T. Genetic 
targeting of an adenovirus vector via replacement of the fiber protein with the phage 
T4 fibritin. J Virol 75, 4176-83 (2001). 
130. Hedley, S. J. et al. An adenovirus vector with a chimeric fiber incorporating stabilized 
single chain antibody achieves targeted gene delivery. Gene Ther 13, 88-94 (2006). 
131. Henning, P. et al. Genetic modification of adenovirus 5 tropism by a novel class of 
ligands based on a three-helix bundle scaffold derived from staphylococcal protein A. 
Hum Gene Ther 13, 1427-39 (2002). 
132. Korokhov, N. et al. Targeting of adenovirus via genetic modification of the viral capsid 
combined with a protein bridge. J Virol 77, 12931-40 (2003). 
133. Volpers, C. et al. Antibody-mediated targeting of an adenovirus vector modified to 
contain a synthetic immunoglobulin g-binding domain in the capsid. J Virol 77, 2093-
104 (2003). 
134. Krasnykh, V. et al. Characterization of an adenovirus vector containing a heterologous 
peptide epitope in the HI loop of the fiber knob. J Virol 72, 1844-52 (1998). 
135. Xia, H., Anderson, B., Mao, Q. & Davidson, B. L. Recombinant human adenovirus: 
targeting to the human transferrin receptor improves gene transfer to brain 
microcapillary endothelium. J Virol 74, 11359-66 (2000). 
136. Mizuguchi, H. et al. A simplified system for constructing recombinant adenoviral 
vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther 
8, 730-5 (2001). 
137. Nicklin, S. A. et al. Efficient and selective AAV2-mediated gene transfer directed to 
human vascular endothelial cells. Mol Ther 4, 174-81 (2001). 
138. Reya, T. & Clevers, H. Wnt signalling in stem cells and cancer. Nature 434, 843-50 
(2005). 
139. van de Wetering, M. et al. The beta-catenin/TCF-4 complex imposes a crypt 
progenitor phenotype on colorectal cancer cells. Cell 111, 241-50 (2002). 
140. Giles, R. H., van Es, J. H. & Clevers, H. Caught up in a Wnt storm: Wnt signaling in 
cancer. Biochim Biophys Acta 1653, 1-24 (2003). 
141. van Es, J. H., Giles, R. H. & Clevers, H. C. The many faces of the tumor suppressor 
gene APC. Exp Cell Res 264, 126-34 (2001). 
142. Xing, Y., Clements, W. K., Kimelman, D. & Xu, W. Crystal structure of a beta-
catenin/axin complex suggests a mechanism for the beta-catenin destruction complex. 
Genes Dev 17, 2753-64 (2003). 
 109 
143. Hsu, W., Zeng, L. & Costantini, F. Identification of a domain of Axin that binds to the 
serine/threonine protein phosphatase 2A and a self-binding domain. J Biol Chem 274, 
3439-45 (1999). 
144. Bhanot, P. et al. A new member of the frizzled family from Drosophila functions as a 
Wingless receptor. Nature 382, 225-30 (1996). 
145. Hecht, A., Vleminckx, K., Stemmler, M. P., van Roy, F. & Kemler, R. The p300/CBP 
acetyltransferases function as transcriptional coactivators of beta-catenin in vertebrates. 
Embo J 19, 1839-50 (2000). 
146. Kramps, T. et al. Wnt/wingless signaling requires BCL9/legless-mediated recruitment 
of pygopus to the nuclear beta-catenin-TCF complex. Cell 109, 47-60 (2002). 
147. He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 
1509-12 (1998). 
148. Tetsu, O. & McCormick, F. Beta-catenin regulates expression of cyclin D1 in colon 
carcinoma cells. Nature 398, 422-6 (1999). 
149. He, T. C., Chan, T. A., Vogelstein, B. & Kinzler, K. W. PPARdelta is an APC-
regulated target of nonsteroidal anti-inflammatory drugs. Cell 99, 335-45 (1999). 
150. Lustig, B. et al. Negative feedback loop of Wnt signaling through upregulation of 
conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 22, 1184-93 (2002). 
151. Orsulic, S., Huber, O., Aberle, H., Arnold, S. & Kemler, R. E-cadherin binding 
prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated 
transactivation. J Cell Sci 112 ( Pt 8), 1237-45 (1999). 
152. Aberle, H., Schwartz, H., Hoschuetzky, H. & Kemler, R. Single amino acid 
substitutions in proteins of the armadillo gene family abolish their binding to alpha-
catenin. J Biol Chem 271, 1520-6 (1996). 
153. Roura, S., Miravet, S., Piedra, J., Garcia de Herreros, A. & Dunach, M. Regulation of 
E-cadherin/Catenin association by tyrosine phosphorylation. J Biol Chem 274, 36734-
40 (1999). 
154. Piedra, J. et al. p120 Catenin-associated Fer and Fyn tyrosine kinases regulate beta-
catenin Tyr-142 phosphorylation and beta-catenin-alpha-catenin Interaction. Mol Cell 
Biol 23, 2287-97 (2003). 
155. Xu, G. et al. Continuous association of cadherin with beta-catenin requires the non-
receptor tyrosine-kinase Fer. J Cell Sci 117, 3207-19 (2004). 
156. Brembeck, F. H. et al. Essential role of BCL9-2 in the switch between beta-catenin's 
adhesive and transcriptional functions. Genes Dev 18, 2225-30 (2004). 
157. Gottardi, C. J. & Gumbiner, B. M. Distinct molecular forms of beta-catenin are 
targeted to adhesive or transcriptional complexes. J Cell Biol 167, 339-49 (2004). 
158. Vleminckx, K., Vakaet, L., Jr., Mareel, M., Fiers, W. & van Roy, F. Genetic 
manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion 
suppressor role. Cell 66, 107-19 (1991). 
159. Perl, A. K., Wilgenbus, P., Dahl, U., Semb, H. & Christofori, G. A causal role for E-
cadherin in the transition from adenoma to carcinoma. Nature 392, 190-3 (1998). 
160. Castellone, M. D., Teramoto, H., Williams, B. O., Druey, K. M. & Gutkind, J. S. 
Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin 
signaling axis. Science 310, 1504-10 (2005). 
161. Rosin-Arbesfeld, R., Cliffe, A., Brabletz, T. & Bienz, M. Nuclear export of the APC 
tumour suppressor controls beta-catenin function in transcription. Embo J 22, 1101-13 
(2003). 
162. Townsley, F. M., Cliffe, A. & Bienz, M. Pygopus and Legless target Armadillo/beta-
catenin to the nucleus to enable its transcriptional co-activator function. Nat Cell Biol 6, 
626-33 (2004). 
163. Hendriksen, J. et al. RanBP3 enhances nuclear export of active (beta)-catenin 
independently of CRM1. J Cell Biol 171, 785-97 (2005). 
 110 
164. Barker, N. et al. The chromatin remodelling factor Brg-1 interacts with beta-catenin to 
promote target gene activation. Embo J 20, 4935-43 (2001). 
165. Bauer, A. et al. Pontin52 and reptin52 function as antagonistic regulators of beta-
catenin signalling activity. Embo J 19, 6121-30 (2000). 
166. Sierra, J., Yoshida, T., Joazeiro, C. A. & Jones, K. A. The APC tumor suppressor 
counteracts beta-catenin activation and H3K4 methylation at Wnt target genes. Genes 
Dev 20, 586-600 (2006). 
167. Lepourcelet, M. & Shivdasani, R. A. Characterization of a novel mammalian Groucho 
isoform and its role in transcriptional regulation. J Biol Chem 277, 47732-40 (2002). 
168. Valenta, T., Lukas, J. & Korinek, V. HMG box transcription factor TCF-4's interaction 
with CtBP1 controls the expression of the Wnt target Axin2/Conductin in human 
embryonic kidney cells. Nucleic Acids Res 31, 2369-80 (2003). 
169. Gottardi, C. J. & Gumbiner, B. M. Role for ICAT in beta-catenin-dependent nuclear 
signaling and cadherin functions. Am J Physiol Cell Physiol 286, C747-56 (2004). 
170. Takemaru, K. et al. Chibby, a nuclear beta-catenin-associated antagonist of the 
Wnt/Wingless pathway. Nature 422, 905-9 (2003). 
171. Park, J. I. et al. Kaiso/p120-catenin and TCF/beta-catenin complexes coordinately 
regulate canonical Wnt gene targets. Dev Cell 8, 843-54 (2005). 
172. Nicum, S., Midgley, R. & Kerr, D. J. Colorectal cancer. Acta Oncol 42, 263-75 (2003). 
173. Fearon, E. R. & Vogelstein, B. A genetic model for colorectal tumorigenesis. Cell 61, 
759-67 (1990). 
174. Chan, T. O., Rittenhouse, S. E. & Tsichlis, P. N. AKT/PKB and other D3 
phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent 
phosphorylation. Annu Rev Biochem 68, 965-1014 (1999). 
175. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and 
regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-101 (2005). 
176. Kikani, C. K., Dong, L. Q. & Liu, F. "New"-clear functions of PDK1: beyond a 
master kinase? J Cell Biochem 96, 1157-62 (2005). 
177. Meier, R. & Hemmings, B. A. Regulation of protein kinase B. J Recept Signal Transduct 
Res 19, 121-8 (1999). 
178. Ng, H. K. & Lam, P. Y. The molecular genetics of central nervous system tumors. 
Pathology 30, 196-202 (1998). 
179. Maehama, T. & Dixon, J. E. The tumor suppressor, PTEN/MMAC1, 
dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. 
J Biol Chem 273, 13375-8 (1998). 
180. Zhang, Y. et al. Rheb is a direct target of the tuberous sclerosis tumour suppressor 
proteins. Nat Cell Biol 5, 578-81 (2003). 
181. Saucedo, L. J. et al. Rheb promotes cell growth as a component of the insulin/TOR 
signalling network. Nat Cell Biol 5, 566-71 (2003). 
182. Inoki, K., Zhu, T. & Guan, K. L. TSC2 mediates cellular energy response to control 
cell growth and survival. Cell 115, 577-90 (2003). 
183. Ma, L., Chen, Z., Erdjument-Bromage, H., Tempst, P. & Pandolfi, P. P. 
Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous 
sclerosis and cancer pathogenesis. Cell 121, 179-93 (2005). 
184. Garami, A. et al. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP 
signaling, is inhibited by TSC1 and 2. Mol Cell 11, 1457-66 (2003). 
185. Karbowniczek, M. et al. Regulation of B-Raf kinase activity by tuberin and Rheb is 
mammalian target of rapamycin (mTOR)-independent. J Biol Chem 279, 29930-7 
(2004). 
186. Kim, D. H. et al. mTOR interacts with raptor to form a nutrient-sensitive complex 
that signals to the cell growth machinery. Cell 110, 163-75 (2002). 
 111 
187. Fingar, D. C., Salama, S., Tsou, C., Harlow, E. & Blenis, J. Mammalian cell size is 
controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev 
16, 1472-87 (2002). 
188. Robbins, D. J. et al. MAP kinases ERK1 and ERK2: pleiotropic enzymes in a 
ubiquitous signaling network. Adv Cancer Res 63, 93-116 (1994). 
189. Lahlou, H. et al. sst2 Somatostatin receptor inhibits cell proliferation through Ras-, 
Rap1-, and B-Raf-dependent ERK2 activation. J Biol Chem 278, 39356-71 (2003). 
190. Finco, T. S. & Baldwin, A. S., Jr. Kappa B site-dependent induction of gene expression 
by diverse inducers of nuclear factor kappa B requires Raf-1. J Biol Chem 268, 17676-9 
(1993). 
191. Anselmo, A. N., Bumeister, R., Thomas, J. M. & White, M. A. Critical contribution of 
linker proteins to Raf kinase activation. J Biol Chem 277, 5940-3 (2002). 
192. Alemany, R., Suzuki, K. & Curiel, D. T. Blood clearance rates of adenovirus type 5 in 
mice. J Gen Virol 81, 2605-9 (2000). 
193. Lieber, A. et al. The role of Kupffer cell activation and viral gene expression in early 
liver toxicity after infusion of recombinant adenovirus vectors. J Virol 71, 8798-807 
(1997). 
194. Liu, Q. & Muruve, D. A. Molecular basis of the inflammatory response to adenovirus 
vectors. Gene Ther 10, 935-40 (2003). 
195. Liu, Q. et al. The role of capsid-endothelial interactions in the innate immune response 
to adenovirus vectors. Hum Gene Ther 14, 627-43 (2003). 
196. Roland, C. R., Walp, L., Stack, R. M. & Flye, M. W. Outcome of Kupffer cell antigen 
presentation to a cloned murine Th1 lymphocyte depends on the inducibility of nitric 
oxide synthase by IFN-gamma. J Immunol 153, 5453-64 (1994). 
197. Matsuno, K. & Ezaki, T. Dendritic cell dynamics in the liver and hepatic lymph. Int Rev 
Cytol 197, 83-136 (2000). 
198. Schiedner, G. et al. Selective depletion or blockade of Kupffer cells leads to enhanced 
and prolonged hepatic transgene expression using high-capacity adenoviral vectors. 
Mol Ther 7, 35-43 (2003). 
199. Schiedner, G. et al. A hemodynamic response to intravenous adenovirus vector 
particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. 
Hum Gene Ther 14, 1631-41 (2003). 
200. Norrby, E. Biological significance of structural adenovirus components. Curr Top 
Microbiol Immunol 43, 1-43 (1968). 
201. Pring-Akerblom, P., Heim, A. & Trijssenaar, F. E. Molecular characterization of 
hemagglutination domains on the fibers of subgenus D adenoviruses. J Virol 72, 2297-
304 (1998). 
202. Mei, Y. F. & Wadell, G. Epitopes and hemagglutination binding domain on subgenus 
B:2 adenovirus fibers. J Virol 70, 3688-97 (1996). 
203. Eiz, B. & Pring-Akerblom, P. Molecular characterization of the type-specific gamma-
determinant located on the adenovirus fiber. J Virol 71, 6576-81 (1997). 
204. Zinn, K. R., Szalai, A. J., Stargel, A., Krasnykh, V. & Chaudhuri, T. R. 
Bioluminescence imaging reveals a significant role for complement in liver 
transduction following intravenous delivery of adenovirus. Gene Ther 11, 1482-6 (2004). 
205. Smith, T. et al. In vivo hepatic adenoviral gene delivery occurs independently of the 
coxsackievirus-adenovirus receptor. Mol Ther 5, 770-9 (2002). 
206. Jain, R. K. Vascular and interstitial barriers to delivery of therapeutic agents in tumors. 
Cancer Metastasis Rev 9, 253-66 (1990). 
207. Jain, R. K. Normalization of tumor vasculature: an emerging concept in antiangiogenic 
therapy. Science 307, 58-62 (2005). 
208. di Tomaso, E. et al. Mosaic tumor vessels: cellular basis and ultrastructure of focal 
regions lacking endothelial cell markers. Cancer Res 65, 5740-9 (2005). 
 112 
209. Morikawa, S. et al. Abnormalities in pericytes on blood vessels and endothelial sprouts 
in tumors. Am J Pathol 160, 985-1000 (2002). 
210. Heldin, C. H., Rubin, K., Pietras, K. & Ostman, A. High interstitial fluid pressure - an 
obstacle in cancer therapy. Nat Rev Cancer 4, 806-13 (2004). 
211. Pietras, K. et al. Inhibition of platelet-derived growth factor receptors reduces 
interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61, 
2929-34 (2001). 
212. Brown, D. T., Westphal, M., Burlingham, B. T., Winterhoff, U. & Doerfler, W. 
Structure and composition of the adenovirus type 2 core. J Virol 16, 366-87 (1975). 
213. Eicher, S. A. et al. Evaluation of topical gene therapy for head and neck squamous cell 
carcinoma in an organotypic model. Clin Cancer Res 2, 1659-64 (1996). 
214. Harrison, D. et al. Wild-type adenovirus decreases tumor xenograft growth, but despite 
viral persistence complete tumor responses are rarely achieved--deletion of the viral 
E1b-19-kD gene increases the viral oncolytic effect. Hum Gene Ther 12, 1323-32 (2001). 
215. Hatzivassiliou, G. et al. ATP citrate lyase inhibition can suppress tumor cell growth. 
Cancer Cell 8, 311-21 (2005). 
216. Favier, A. L., Burmeister, W. P. & Chroboczek, J. Unique physicochemical properties 
of human enteric Ad41 responsible for its survival and replication in the 
gastrointestinal tract. Virology 322, 93-104 (2004). 
217. Pereira, H. G. & Wrigley, N. G. In vitro reconstitution, hexon bonding and 
handedness of incomplete adenovirus capsid. J Mol Biol 85, 617-30 (1974). 
218. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF 
system. Nat Med 9, 677-84 (2003). 
219. Shen, B. H. & Hermiston, T. W. Effect of hypoxia on Ad5 infection, transgene 
expression and replication. Gene Ther 12, 902-10 (2005). 
220. Shen, B. H., Bauzon, M. & Hermiston, T. W. The effect of hypoxia on the uptake, 
replication and lytic potential of group B adenovirus type 3 (Ad3) and type 11p 
(Ad11p). Gene Ther (2006). 
221. Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell 
growth. Mol Cell 21, 521-31 (2006). 
222. Harding, H. P., Zhang, Y. & Ron, D. Protein translation and folding are coupled by an 
endoplasmic-reticulum-resident kinase. Nature 397, 271-4 (1999). 
223. O'Malley, R. P., Mariano, T. M., Siekierka, J. & Mathews, M. B. A mechanism for the 
control of protein synthesis by adenovirus VA RNAI. Cell 44, 391-400 (1986). 
224. Brunori, M., Malerba, M., Kashiwazaki, H. & Iggo, R. Replicating adenoviruses that 
target tumors with constitutive activation of the wnt signaling pathway. J Virol 75, 
2857-65 (2001). 
225. Fuerer, C. & Iggo, R. Adenoviruses with Tcf binding sites in multiple early promoters 
show enhanced selectivity for tumour cells with constitutive activation of the wnt 
signalling pathway. Gene Ther 9, 270-81 (2002). 
226. Vigne, E. et al. Genetic manipulations of adenovirus type 5 fiber resulting in liver 
tropism attenuation. Gene Ther 10, 153-62 (2003). 
227. Reynolds, P., Dmitriev, I. & Curiel, D. Insertion of an RGD motif into the HI loop of 
adenovirus fiber protein alters the distribution of transgene expression of the 
systemically administered vector. Gene Ther 6, 1336-9 (1999). 
228. Tao, N. et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear 
dose response of transduction in liver. Mol Ther 3, 28-35 (2001). 
229. Duncan, S. J. et al. Infection of mouse liver by human adenovirus type 5. J Gen Virol 
40, 45-61 (1978). 
230. Wein, L. M., Wu, J. T. & Kirn, D. H. Validation and analysis of a mathematical model 
of a replication-competent oncolytic virus for cancer treatment: implications for virus 
design and delivery. Cancer Res 63, 1317-24 (2003). 
 113 
231. Galanis, E. et al. Phase I-II trial of ONYX-015 in combination with MAP 
chemotherapy in patients with advanced sarcomas. Gene Ther 12, 437-45 (2005). 
232. Stubdal, H. et al. A prodrug strategy using ONYX-015-based replicating adenoviruses 
to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. 
Cancer Res 63, 6900-8 (2003). 
233. Chan, R. & Kerr, D. Hepatic arterial chemotherapy for colorectal cancer liver 
metastases: a review of advances in 2003. Curr Opin Oncol 16, 378-84 (2004). 
234. Pinedo, H. M. & Peters, G. F. Fluorouracil: biochemistry and pharmacology. J Clin 
Oncol 6, 1653-64 (1988). 
235. Rothenberg, M. L. Topoisomerase I inhibitors: review and update. Ann Oncol 8, 837-55 
(1997). 
236. Berlin, J. New directions in the treatment of advanced colorectal cancer. Oncology 
(Williston Park) 15, 27-30 (2001). 
237. Eckardt, J., Eckhardt, G., Villalona-Calero, M., Drengler, R. & Von Hoff, D. New 
anticancer agents in clinical development. Oncology (Williston Park) 9, 1191-9 (1995). 
238. Suomalainen, M. et al. Microtubule-dependent plus- and minus end-directed motilities 
are competing processes for nuclear targeting of adenovirus. J Cell Biol 144, 657-72 
(1999). 
239. Suomalainen, M., Nakano, M. Y., Boucke, K., Keller, S. & Greber, U. F. Adenovirus-
activated PKA and p38/MAPK pathways boost microtubule-mediated nuclear 
targeting of virus. Embo J 20, 1310-9 (2001). 
240. Yu, D. C. et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, 
and paclitaxel and docetaxel. Cancer Res 61, 517-25 (2001). 
241. Boulay, A. et al. Antitumor efficacy of intermittent treatment schedules with the 
rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal 
protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 64, 252-61 
(2004). 
242. Shinohara, E. T. et al. Enhanced radiation damage of tumor vasculature by mTOR 
inhibitors. Oncogene 24, 5414-22 (2005). 
243. Calne, R. Y. et al. Rapamycin for immunosuppression in organ allografting. Lancet 2, 
227 (1989). 
244. Kass-Eisler, A., Leinwand, L., Gall, J., Bloom, B. & Falck-Pedersen, E. Circumventing 
the immune response to adenovirus-mediated gene therapy. Gene Ther 3, 154-62 (1996). 
245. Sarbassov, D. D. et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-
insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 
14, 1296-302 (2004). 
246. Sarbassov dos, D. et al. Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly 
and Akt/PKB. Mol Cell 22, 159-68 (2006). 
247. Chen, Y., Yu, D. C., Charlton, D. & Henderson, D. R. Pre-existent adenovirus 
antibody inhibits systemic toxicity and antitumor activity of CN706 in the nude mouse 
LNCaP xenograft model: implications and proposals for human therapy. Hum Gene 
Ther 11, 1553-67 (2000). 
248. Wu, H. et al. Preclinical evaluation of a class of infectivity-enhanced adenoviral vectors 
in ovarian cancer gene therapy. Gene Ther 11, 874-8 (2004). 
249. Maretto, S. et al. Mapping Wnt/beta-catenin signaling during mouse development and 
in colorectal tumors. Proc Natl Acad Sci U S A 100, 3299-304 (2003). 
250. Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific 
cytolysis and antitumoral efficacy that can be augmented by standard 
chemotherapeutic agents. Nat Med 3, 639-45 (1997). 
251. Nemunaitis, J. et al. Intravenous infusion of a replication-selective adenovirus 
(ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 8, 
746-59 (2001). 
 114 
252. Mamane, Y. et al. eIF4E--from translation to transformation. Oncogene 23, 3172-9 
(2004). 
253. Feigenblum, D. & Schneider, R. J. Cap-binding protein (eukaryotic initiation factor 4E) 
and 4E-inactivating protein BP-1 independently regulate cap-dependent translation. 
Mol Cell Biol 16, 5450-7 (1996). 
254. Xi, Q., Cuesta, R. & Schneider, R. J. Tethering of eIF4G to adenoviral mRNAs by 
viral 100k protein drives ribosome shunting. Genes Dev 18, 1997-2009 (2004). 
255. Yang, Y. et al. Transient subversion of CD40 ligand function diminishes immune 
responses to adenovirus vectors in mouse liver and lung tissues. J Virol 70, 6370-7 
(1996). 
256. Koehl, G. et al. Rapamycin treatment at immunosuppressive doses affects tumor 
blood vessel circulation. Transplant Proc 35, 2135-6 (2003). 
257. Hallden, G. et al. Novel immunocompetent murine tumor models for the assessment 
of replication-competent oncolytic adenovirus efficacy. Mol Ther 8, 412-24 (2003). 
258. Jain, R. K. Physiological barriers to delivery of monoclonal antibodies and other 
macromolecules in tumors. Cancer Res 50, 814s-819s (1990). 
259. Willett, C. G. et al. Direct evidence that the VEGF-specific antibody bevacizumab has 
antivascular effects in human rectal cancer. Nat Med 10, 145-7 (2004). 
260. Winkler, F. et al. Kinetics of vascular normalization by VEGFR2 blockade governs 
brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix 
metalloproteinases. Cancer Cell 6, 553-63 (2004). 
261. Ferrara, N. Role of vascular endothelial growth factor in physiologic and pathologic 
angiogenesis: therapeutic implications. Semin Oncol 29, 10-4 (2002). 
262. Guba, M. et al. Rapamycin inhibits primary and metastatic tumor growth by 
antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8, 128-35 
(2002). 
263. Hardonk, M. J., Dijkhuis, F. W., Hulstaert, C. E. & Koudstaal, J. Heterogeneity of rat 
liver and spleen macrophages in gadolinium chloride-induced elimination and 
repopulation. J Leukoc Biol 52, 296-302 (1992). 
264. Forssen, E. A. & Tokes, Z. A. Use of anionic liposomes for the reduction of chronic 
doxorubicin-induced cardiotoxicity. Proc Natl Acad Sci U S A 78, 1873-7 (1981). 
265. Siris, E. S., Canfield, R. E., Jacobs, T. P. & Baquiran, D. C. Long-term therapy of 
Paget's disease of bone with EHDP. Arthritis Rheum 23, 1177-84 (1980). 
266. Paterson, A. H. et al. Treatment of skeletal disease in breast cancer with clodronate. 
Bone 12 Suppl 1, S25-30 (1991). 
267. Siris, E. S. et al. Effects of dichloromethylene diphosphonate on skeletal mobilization 
of calcium in multiple myeloma. N Engl J Med 302, 310-5 (1980). 
268. Raisz, L. G. New diphosphonates to block bone resorption. N Engl J Med 302, 347-8 
(1980). 
269. Bezzi, M., Hasmim, M., Bieler, G., Dormond, O. & Ruegg, C. Zoledronate sensitizes 
endothelial cells to tumor necrosis factor-induced programmed cell death: evidence for 
the suppression of sustained activation of focal adhesion kinase and protein kinase 
B/Akt. J Biol Chem 278, 43603-14 (2003). 
270. Kuzmin, A. I., Finegold, M. J. & Eisensmith, R. C. Macrophage depletion increases the 
safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 
4, 309-16 (1997). 
271. Ziegler, R. J. et al. Correction of the nonlinear dose response improves the viability of 
adenoviral vectors for gene therapy of Fabry disease. Hum Gene Ther 13, 935-45 (2002). 
272. Bremner, J. C., Bradley, J. K., Stratford, I. J. & Adams, G. E. Magnetic resonance 
spectroscopic studies on 'real-time' changes in RIF-1 tumour metabolism and blood 
flow during and after photodynamic therapy. Br J Cancer 69, 1083-7 (1994). 
273. Muruve, D. A. The innate immune response to adenovirus vectors. Hum Gene Ther 15, 
1157-66 (2004). 
 115 
274. Lyons, M. et al. Adenovirus Type 5 Interactions with Human Blood Cells May 
Compromise Systemic Delivery. Mol Ther (2006). 
275. Chillon, M., Lee, J. H., Fasbender, A. & Welsh, M. J. Adenovirus complexed with 
polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro. 
Gene Ther 5, 995-1002 (1998). 
276. Green, N. K. et al. Extended plasma circulation time and decreased toxicity of 
polymer-coated adenovirus. Gene Ther 11, 1256-63 (2004). 
277. Fisher, K. D. et al. Polymer-coated adenovirus permits efficient retargeting and evades 
neutralising antibodies. Gene Ther 8, 341-8 (2001). 
278. Parker, A. L. et al. Enhanced gene transfer activity of peptide-targeted gene-delivery 
vectors. J Drug Target 13, 39-51 (2005). 
279. Niendorf, H. P., Haustein, J., Cornelius, I., Alhassan, A. & Clauss, W. Safety of 
gadolinium-DTPA: extended clinical experience. Magn Reson Med 22, 222-8; discussion 
229-32 (1991). 
280. Ohno, S., Inagawa, H., Soma, G. & Nagasue, N. Role of tumor-associated macrophage 
in malignant tumors: should the location of the infiltrated macrophages be taken into 
account during evaluation? Anticancer Res 22, 4269-75 (2002). 
281. Nishisho, I. et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer 
patients. Science 253, 665-9 (1991). 
282. de La Coste, A. et al. Somatic mutations of the beta-catenin gene are frequent in 
mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A 95, 8847-51 
(1998). 
283. Tanaka, Y. et al. Frequent beta-catenin mutation and cytoplasmic/nuclear 
accumulation in pancreatic solid-pseudopapillary neoplasm. Cancer Res 61, 8401-4 
(2001). 
284. Saegusa, M. & Okayasu, I. Frequent nuclear beta-catenin accumulation and associated 
mutations in endometrioid-type endometrial and ovarian carcinomas with squamous 
differentiation. J Pathol 194, 59-67 (2001). 
285. Saegusa, M., Hashimura, M., Yoshida, T. & Okayasu, I. beta- Catenin mutations and 
aberrant nuclear expression during endometrial tumorigenesis. Br J Cancer 84, 209-17 
(2001). 
286. Alman, B. A., Li, C., Pajerski, M. E., Diaz-Cano, S. & Wolfe, H. J. Increased beta-
catenin protein and somatic APC mutations in sporadic aggressive fibromatoses 
(desmoid tumors). Am J Pathol 151, 329-34 (1997). 
287. Fallaux, F. J. et al. Characterization of 911: a new helper cell line for the titration and 
propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther 7, 215-22 
(1996). 
288. Malerba, M., Daeffler, L., Rommelaere, J. & Iggo, R. D. Replicating parvoviruses that 
target colon cancer cells. J Virol 77, 6683-91 (2003). 
289. Amalfitano, A., Begy, C. R. & Chamberlain, J. S. Improved adenovirus packaging cell 
lines to support the growth of replication-defective gene-delivery vectors. Proc Natl 
Acad Sci U S A 93, 3352-6 (1996). 
290. Einfeld, D. A. et al. Reducing the native tropism of adenovirus vectors requires 
removal of both CAR and integrin interactions. J Virol 75, 11284-91 (2001). 
291. Sikorski, R. S. & Hieter, P. A system of shuttle vectors and yeast host strains designed 
for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122, 19-27 
(1989). 
292. Gagnebin, J. et al. A photosensitising adenovirus for photodynamic therapy. Gene Ther 
6, 1742-50 (1999). 
293. Pasqualini, R. & Ruoslahti, E. Organ targeting in vivo using phage display peptide 
libraries. Nature 380, 364-6 (1996). 
 116 
294. Pasqualini, R., Koivunen, E. & Ruoslahti, E. A peptide isolated from phage display 
libraries is a structural and functional mimic of an RGD-binding site on integrins. J Cell 
Biol 130, 1189-96 (1995). 
295. Ghosh, D. & Barry, M. A. Selection of muscle-binding peptides from context-specific 
peptide-presenting phage libraries for adenoviral vector targeting. J Virol 79, 13667-72 
(2005). 
296. Fontana, L., Nuzzo, M., Urbanelli, L. & Monaci, P. General strategy for broadening 
adenovirus tropism. J Virol 77, 11094-104 (2003). 
297. Pereboev, A., Pereboeva, L. & Curiel, D. T. Phage display of adenovirus type 5 fiber 
knob as a tool for specific ligand selection and validation. J Virol 75, 7107-13 (2001). 
298. Weinberg, D. H. & Ketner, G. Adenoviral early region 4 is required for efficient viral 
DNA replication and for late gene expression. J Virol 57, 833-8 (1986). 
299. Trinh, K. R. & Morrison, S. L. Site-specific and directional gene replacement mediated 
by Cre recombinase. J Immunol Methods 244, 185-93 (2000). 
300. Zhang, Z. & Lutz, B. Cre recombinase-mediated inversion using lox66 and lox71: 
method to introduce conditional point mutations into the CREB-binding protein. 
Nucleic Acids Res 30, e90 (2002). 
301. Krougliak, V. & Graham, F. L. Development of cell lines capable of complementing 
E1, E4, and protein IX defective adenovirus type 5 mutants. Hum Gene Ther 6, 1575-86 
(1995). 
302. Von Seggern, D. J., Kehler, J., Endo, R. I. & Nemerow, G. R. Complementation of a 
fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 
fibre protein. J Gen Virol 79 ( Pt 6), 1461-8 (1998). 
303. Von Seggern, D. J., Huang, S., Fleck, S. K., Stevenson, S. C. & Nemerow, G. R. 
Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction 
of Epstein-Barr virus-transformed B cells. J Virol 74, 354-62 (2000). 
304. Araki, K., Araki, M. & Yamamura, K. Targeted integration of DNA using mutant lox 
sites in embryonic stem cells. Nucleic Acids Res 25, 868-72 (1997). 
305. Hopwood, D. A. Forty years of genetics with Streptomyces: from in vivo through in 
vitro to in silico. Microbiology 145 ( Pt 9), 2183-202 (1999). 
306. Stark, W. M., Boocock, M. R. & Sherratt, D. J. Catalysis by site-specific recombinases. 
Trends Genet 8, 432-9 (1992). 
307. de Felipe, P. et al. E unum pluribus: multiple proteins from a self-processing 
polyprotein. Trends Biotechnol 24, 68-75 (2006). 
308. Le, L. P., Li, J., Ternovoi, V. V., Siegal, G. P. & Curiel, D. T. Fluorescently tagged 
canine adenovirus via modification with protein IX-enhanced green fluorescent 
protein. J Gen Virol 86, 3201-8 (2005). 
309. Fridman, R., Toth, M., Chvyrkova, I., Meroueh, S. O. & Mobashery, S. Cell surface 
association of matrix metalloproteinase-9 (gelatinase B). Cancer Metastasis Rev 22, 153-66 
(2003). 
310. Bett, A. J., Prevec, L. & Graham, F. L. Packaging capacity and stability of human 
adenovirus type 5 vectors. J Virol 67, 5911-21 (1993). 
311. Kling, J. J., Wright, R. L., Moncrief, J. S. & Wilkins, T. D. Cloning and characterization 
of the gene for the metalloprotease enterotoxin of Bacteroides fragilis. FEMS Microbiol 
Lett 146, 279-84 (1997). 
312. Wu, S., Lim, K. C., Huang, J., Saidi, R. F. & Sears, C. L. Bacteroides fragilis enterotoxin 
cleaves the zonula adherens protein, E-cadherin. Proc Natl Acad Sci U S A 95, 14979-84 
(1998). 
313. Tsuzuki, Y. et al. Vascular endothelial growth factor (VEGF) modulation by targeting 
hypoxia-inducible factor-1alpha--> hypoxia response element--> VEGF cascade 
differentially regulates vascular response and growth rate in tumors. Cancer Res 60, 
6248-52 (2000). 
 
